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GENERAL INTRODUCTION
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GENERAL INTRODUCTION
1. In tro d u c tio n .
Rheumatoid arthritis (RA) is a systemic disease of unknow n etiology, with the main 
manifestation being chronic inflammation in multiple joints. Of high interest, the disease is 
expressed symmetrically in synovial joints with the metacarpophalangeal and the proximal 
interphalangeal joints of the fingers, the wrist and the metacarpophalangeal of the toes as the 
first and m ost severely involved joints. RA affects 1% of the population worldwide, 
predominantly women. In many patients the arthritis is characterized by exacerbations and 
remissions. A hallmark of RA is the progressive destruction of cartilage and bone due to the 
chronic inflammation. Histopathological features include immune complexes in the articular 
cartilage layers and variable amounts of macrophages and T cells in the synovium, accompanied 
by fibrosis and synovial hyperplasia. The disease is often considered as an autoimmune process, 
the articular cartilage being an intriguing component, since it is the victim but also a likely 
trigger of the disease. Arguments for this are based on the observation that destructive forms 
of RA tend to decline when the cartilage is fully destroyed. Moreover, total joint replacement 
often results in a complete remission of arthritis in that particular joint, without the need of 
concomitant synovectomy. This is compatible with cartilage components being joint specific 
autoantigens or cartilage tissue functioning as an avascular reservoir, retaining yet unidentified 
arthritogenic triggers. A major research goal in the field of arthritis is to unravel the 
pathogenesis of chronic arthritis and the concomitant joint destruction. A second, more 
practical goal is to define targeted therapies, selectively inhibiting the progression of destructive 
arthritis, yet leaving host defence mechanisms virtually intact. In the following chapters we 
will discuss, animal models of arthritis, cytokine involvement in arthritis, intervention in RA, 
and the aim of the study.
2. A nim als m odels.
Although animal models are not ideal in terms of precise mimicry of hum an arthritic disease, 
they do reflect key aspects of their hum an counterparts and offer a useful approach to 
understand arthritic processes and to improve therapeutic treatment. Models have been 
developed which have proved the arthritogenic potential of cartilage autoantigens such as 
collagen type II and proteoglycan (1-4). More recently (5-7), arthritogenic potential has been 
demonstrated for novel cartilage components such as collagen types IX and XI, cartilage derived 
oligomeric protein (COMP) and hyaline cartilage glycoprotein 39 (HC gp-39). These models 
all elude to the same principle: arthritis due to the loss of tolerance against a cartilage specific 
autoantigen. Based on the hypothesis that RA is initiated by cross reactivity of T cells to bacterial 
fragments and cartilage components models of experimental arthritis were generated using 
bacteria as antigens. Adjuvant arthritis (AA) and streptococcal cell wall (SCW) induced arthritis 
are the most common models of arthritis, using mycobacterium tuberculosis and group A 
streptococci respectively (8 - 1 1 ).
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2.1 S trep to co cca l cell w all (SCW ) in d u c e d  a r th r it is .
Streptococcal cell wall arthritis is a commonly used arthritis model, induced by injection of 
bacterial fragments, systemically or locally. W hen applied systemically to susceptible rat strains, 
a chronic polyarthritis is induced. The joint inflammation progresses from an acute phase 
through a remission phase followed by a spontaneous reactivation of chronic inflammation. 
Since SCW fragments are poorly degradable in vivo, reactivation of arthritis by this antigen 
leads to chronicity. During the early phase the predom inant infiltrating cells are the 
polymorphonuclear granulocytes and macrophages. These two types of cells migrate into the 
joint in response to chemokines, which are generated by bacterial fragments (12). Once in the 
joint, these fragments stimulate resident lining macrophages to secrete interleukin -1  (IL-1 ), 
tum or necrosis factor alpha (TNFa) and IL-6 . Furthermore, these cytokines stimulate 
chemotaxis and increase expression of adhesion molecules on endothelial cells (13). Using anti- 
T cell treatment it became obvious that T cells play a crucial role in the chronic phase of SCW 
arthritis (14). Predominantly, CD4+ positive T cells expressing IL-2 receptor and interferon 
gamma (IFN-y) were found in late chronic phase. A possible mechanism of chronic phase is 
that during exacerbation of the disease bacterium-specific T cells, which have a cross-reactive 
nature, recognize joint specific antigens and initiate a destructive autoimmune process.
In the mouse, systemic injection does not lead to chronic arthritis. However arthritis can be 
elicited by a single or repeated local injections. One single intraarticular injection of SCW 
fragments induces arthritis in both naive and previously primed mice, indicating that systemic 
immunity to SCW is not obligatory for this type of arthritis (15,16). Reactivation of the arthritis 
in both naive and primed animals can be induced by systemic challenge with SCW. The 
importance of local hypereactivity was demonstrated by the fact that the noninjected knee joint 
remains unaffected after systemic reactivation of the arthritis. Similar to SCW in rats, a strong 
T cell dependence was found in this latter phenomenon. An interesting finding is that non­
related endogenous bacterial fragments can reactivate the SCW-induced arthritis, indicating 
that unnoticed inflammations or lesions of the gut, or short lasting infections of the urinary 
tract might provide bacterial antigens to reactivate and maintain the arthritis. This could explain 
the relation between infection, bowel disease and rheumatoid arthritis.
2.2 C o llagen  ty p e  II  in d u c e d  a r th r i t is  (CIA).
Collagen induced arthritis (CIA) is a widely accepted arthritis model, based on T cell and 
antibody mediated autoimmunereactivity against cartilage collagen type II (CII). The model 
is characterized by severe cartilage and bone erosions. Induction has been demonstrated in 
various strains of rats and mice, susceptibility showing tight genetic restriction. More recently, 
collagen arthritis has been induced in non-hum an primates as well. The model of collagen 
arthritis is highly suited to analyse principles of autoimmune disease expression as well as 
antigen-specific immunosuppression. Moreover, it can be used to study mechanism and 
mediators involved in autoimmune cartilage and bone destruction. The model of CIA was first 
described in 1977 by Trentham and colleagues (1), as a coincidental finding in protocols to 
induce autoantibodies to purified collagen preparations. The initial observations indicated that 
arthritis was confined to sensitization with native collagen type II; denatured CII or native CII 
not showing arthritogenicity. The crucial element in this arthritis is the induction of immunity
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to foreign collagen type II, subsequently cross-reacting w ith hom ologous CII. Plain 
immunization with homologous instead of heterologous CII can also be used, but then much 
stronger immunization regimens are needed to override natural tolerance. Both chicken as 
well as bovine collagen type II preparations are proper heterologous antigens to induce CIA 
in mice. Susceptible strains include DBA/1j mice and B10RIII mice, having the H-2q and H- 
2r haplotype, respectively. Dominant epitopes of the CII molecule are different for DBA/1 and 
B10RIII mice, consistent with the different haplotype (17,18). Male mice show higher 
susceptibility as compared to female mice. In general, DBA/1 male mouse and bovine type II 
collagen are used to induce this model. The model is a mixture of an immune complex disease 
and a delayed type hypersensitivity reaction in the joint. Although anti-CII antibodies alone 
are able to induce arthritis after passive transfer, high concentrations are needed, in particular 
of complement activating subclasses, recognizing multiple epitopes, and even then at best a 
transient arthritis occurs (19). Passive transfer with bulk T cells or T cell clones also yielded 
poor disease expression (20). Probably, antibodies are needed to bind to the cartilage surface, 
herein promoting further release of collagen epitopes upon complement fixation and the 
attraction of leucocytes. Attachment of granulocytes to the cartilage surface is a crucial element 
of CIA. Subsequent influx of anti-CII specific T helper 1 (Th1) cells will than further drive the 
arthritic process. Of interest, the cytokine pattern in the lymphoid organs showed a dominant 
Th1 pattern after immunization with CII in FCA (21). Threatening autoimmune reactivity is 
generated by the immunization protocol, but precipitation of the autoimmune process in the 
joint is facilitated by nonspecific inflammation at such sites or systemic generation of pro- 
inflammatory mediators. It is long recognized that systemic administration of IL-1, shortly 
before onset of the disease, markedly accelerates CIA expression (22). This seems related to 
activation of endothelium, facilitating influx of inflammatory cells. Moreover, IL-1 is a potent 
cartilage destructive mediator, causing loss of cartilage proteoglycans and herein denuding the 
autoimmune target in CIA, collagen type II in the articular cartilage. In addition, it was shown 
that local injection of TN Fa or transforming growth factor beta (TGFP) potentiates CIA 
expression in the injected joint (23,24). TN Fa is a pivotal pro-inflammatory cytokine in 
arthritis and an inducer of IL-1. TGFp, although having immunosuppressive potential, is a 
potent chemoattractant. All of this fits with unmasking of dormant autoimmune reactivity by 
nonspecific attraction of inflammatory cells to the joints, including CII-reactive T cells, and 
amplification of the process by inflammation mediated exposure of autoimmune epitopes.
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3. C y to k in e  in v o lv em en t in  m o d e ls  o f  a r th r it is .
3.1 R ole o f  T N F a  a n d  IL-1.
Tumor necrosis factor alpha (TNFa) and interleukin-1 (IL-1) are considered as key mediators 
in the process of human RA (25). A cascade of TNFa inducing IL-1 production by RA synovium 
is claimed (26). It is demonstrated that both TN Fa and IL-1 are involved in the destruction 
of cartilage and bone (27). Injection of IL-1 into murine knee resulted in inhibition of 
chondrocyte proteoglycan synthesis and cartilage degradation, whereas TN Fa was ineffective
(28). IL-1 and TN Fa can be produced by several cell types, including macrophages, monocytes, 
and fibroblasts. In the first phase of re-challenge SCW arthritis model in rats both TN Fa and 
IL-1 play an im portant role regarding joint swelling. Blocking studies with anti-TNFa
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antibodies revealed that joint swelling was suppressed (29). Neutralization of IL-1a in this 
particular model showed marked suppression of paw swelling. In line with these results, 
administration of IL-1Ra effectively reduced joint swelling (30). In these studies, protective 
effects of TNFa/IL-1 blockade on cartilage or bone destruction was not examined.
In line with a major role of the cytokine TN Fa in hum an RA, the onset of collagen arthritis is 
TN Fa dependent. Studies with neutralizing anti-TNFa antibodies or soluble TNF receptors 
revealed a major suppressive effect, when treatment was started shortly before onset of CIA 
(31,32). W hen the arthritis is fully expressed, subsequent blocking of TN Fa appeared only 
marginally effective, implying that TN Fa is crucial in onset but less so in propagation of 
arthritis. Blocking of IL-1P with neutralizing antibodies markedly reduced severity of the 
arthritis when administered before onset the arthritis (33,34). Moreover, anti-IL-1p treatment 
markedly reduced cartilage damage. Elegant studies in IL-1P deficient mice showed full 
resistance to CIA induction and the critical importance of IL-1 P was also emphasized by greatly 
reduced CIA in IL-1 converting enzyme (ICE)-deficient mice and efficacy of ICE inhibitors 
in CIA in normal mice. Recent studies in TNF-receptor knockout mice revealed a lower 
incidence and a milder form of CIA in the absence of proper TNF-receptor interaction. 
However, once a jo in t was afflicted, the progression of arthritis in that jo in t was 
indistinguishable from that in wild type mice (35), again underlining the limited role of TNF 
in propagation and cartilage destruction. It emphasizes that TN Fa is helpful in acceleration 
of arthritis expression, but that TN Fa independent onset can occur as well. Although it is 
claimed in hum an RA that TN Fa is driving most of the IL-1 production and that TN Fa 
blocking would be sufficient to block the whole arthritic process, this is not found in collagen 
arthritis. These findings imply that anti-TNFa treatment in RA patients would be beneficial 
when the disease is in fact a chronic process, due to repeated flares, with each acute exacerbation 
showing strong TN Fa dependency. Of interest, when expression of collagen arthritis is not 
highly stimulated by additional boosting or synchronizing injections with LPS or additional 
cytokines, onset of arthritis starts only in a small number of joints, with gradual involvement 
of additional joints with time. This creates a seemingly extended period of TN Fa dependency 
of the model, which is lost upon synchronization and speedy propagation to established arthritis 
in most joints.
3.2 In v o lv em en t o f  IL-4 a n d  IL-10.
Apart from a pivotal role of TNF and IL-1 in onset and propagation of CIA, regulation 
of the arthritis can be exerted by the cytokines IL-4 and IL-10. IL-4 and IL-10 are pleiotropic 
cytokines that can exert either suppressive or stimulatory effect on different cell types. IL-4 
and IL-10 were first identified as products of Th2 cells and are part of the cytokines that 
distinguished Th2 cells from other T cells (36). These socalled modulatory cytokines have a 
critical impact on the arthritic process at various levels, including the control of the Th1/Th2 
balance. Both cytokines inhibit the production of pro-inflammatory cytokines, such as IL-1, 
TNFa, IL-6 , IL-8 , IL-12 by monocytes and macrophages (37,38). Furthermore, it has been 
shown that IL-4 and IL-10 upregulate the production of cytokine inhibitors such as IL-1Ra, 
soluble IL-1R type II, and soluble TNF receptor by macrophages and neutrophils (39,40). 
The potential anti-inflammatory capacity of IL-4 or IL-10 has been tested in animal models 
of arthritis. IL-4 suppressed the chronic phase of the polyarthritis SCW model in the rat when
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administered shortly after induction (41). In contrast, anti-IL-4 treatment before reactivation 
of monoarticular SCW model decreased the joint swelling, indicating in this model a pro- 
inflammatory role of IL-4 (42). Data of IL-4 treatment before reactivation of the monoarticular 
SCW arthritis are not available yet.
The role of endogenous IL-10 during reactivation of SCW arthritis seems to be limited, since 
anti-IL-10 exposure was without effect (42). In contrast to this latter model, anti-IL-10 
administration before induction of murine SCW enhanced inflammatory response after 
injection of SCW fragments. In line with these findings, administration of IL-10 during the 
acute phase of SCW arthritis results in suppression of joint swelling and cartilage destruction. 
More therapeutic effect was achieved when IL-10 was combined with IL-4 (43).
It has been reported that the onset of collagen arthritis in under control of endogenous IL-10
(44). High levels of IL-10 are found in the synovial tissue and anti-IL-10 antibodies, given before 
expected onset, enhance disease incidence and severity. In line with these findings, IL-10 
treatment of CIA shows amelioration of the disease activity and reduction of joint pathology
(45). W hether IL-4 is able to suppress established CIA is not investigated yet, but continuous 
IL-4 exposure during the immunization phase revealed that IL-4 clearly suppresses disease 
expression and activity, due to reduced cellular and humoral immunity towards collagen (46).
3.3 IL-12 in v o lv em en t.
An intriguing cytokine deserving major attention is IL-12. This cytokine originates from 
macrophages and is produced after activation with bacterial components. IL-12 is a potent 
inducer of IFN-y and promotes Th1 generation and propagation (47). In general, IL-12 is 
considered to be a principle protective cytokine in bacterial infections, where it bridges innate 
resistance and antigen-specific im munity (48). On the other hand, IL-12 may unmask Th1- 
dependent autoimmune responses and may be a crucial intermediate in the often-suggested 
link between bacterial infections and expression of autoimmune diseases (49). Arthritis has 
been associated with bacterial infections of the throat, the gastrointestinal tract and 
inflammatory bowel disease. On the contrary, IL-12 controls excessive tissue pathology in 
allergy and parasitic infections by suppression of the Th2 response (50). IL-12 is a strong 
inducer of IL-10 production of T cells and macrophages, providing a negative feedback 
mechanism to prevent excessive tissue pathology (51). It has been demonstrated that IL-12, 
when given during the immunization with CII, greatly enhances incidence and severity of CIA 
(52). Furthermore, IL-12 is a powerful inducer of IFN-y, which itself stimulate immune 
reactions. It is likely that IL-12 plays a pro-inflammatory role in bacterial induced arthritis 
models and that blockade of endogenous IL-12 will lead to suppression of arthritis.
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3.4 R ole o f  IL-15, IL-17 a n d  IL-18 in  in flam m atio n .
IL-15 is derived from several cell types, including macrophages and fibroblasts (53,54). IL-15 
induces T cell chemotaxis and activation together with B cell maturation. Furthermore, it 
enhances NK cell cytotoxicity and cytokine production, activates neutrophils and modifies 
monokines secretion (55). IL-15 mediates several diverse effects at multiple stages of the 
immune response. Interestingly, administration of soluble IL-15 receptor a-chain prevents
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the onset of CIA, indicating a role of IL-15 in antigen-induced immunopathology (56).
Two cytokines that were recently discovered are IL-17 and IL-18. IL-17 is a pro-inflammatory 
cytokine, produced by activated CD4+ memory T cells and it induces production of other pro- 
inflammatory cytokines by stromal cells (57). It has been recently described in RA synovium 
and shows similar cellular responses as IL-1 (58). IL-17 induces NFkB activation and IL-1, IL-
6 , IL-8 , G-CSF and T N Fa production in bo th  fibroblasts and macrophages (59,60). 
Interestingly, synergistic effects of IL-17 and IL-1 as well as TN Fa were reported recently 
(61,62). In addition, IL-17 was associated with cartilage destruction and inhibition of 
chondrocyte proteoglycan synthesis due to increased catabolic enzymes and NO production 
(63,64). Furthermore, IL-17 showed to be a potent stimulator of osteoclastic bone resorption 
by enhanced prostaglandin E2  synthesis (65). It would be of high importance to perform 
blocking studies with anti-IL-17 in experimental arthritis models, such as CIA to unravel 
distinct IL-17 activity or its synergy with IL-1. In this particular animal model of arthritis 
marked cartilage and bone destruction is a prime target for study.
IL-18 is a cytokine originally identified as IFN-y inducing factor (IGIF), it is a member of the 
IL-1 family of proteins (6 6 ). As IL-1 P, IL-18 is produced as an inactive precursor and it is cleaved 
by interleukin-1 converting enzyme (ICE) to the biologically active form (67). IL-18 acts 
synergistically with IL-12, IL-2 and antigens to induce the production of IFN-y (6 8 ). The crucial 
role of IL-18 in IFN-y synthesis was demonstrated in IL-18 deficient mice, where the IFN-y 
production was markedly reduced after injection of endotoxin, despite of normal IL-12 
production in these animals (69). IL-18 is produced by hum an articular chondrocytes and it 
induces pro-inflammatory cytokines and catabolic factors like NO, cyclooxygenase and 
stromelysin (70). Recently, IL-18 binding protein (IL-18BP) was isolated and cloned (71). This 
protein blocks the endotoxin induced IFN-y production in mice and belongs to a member of 
novel soluble receptors. Since IL-18 is an early prom otor of Th1 cells, IL-18BP probably plays 
a crucial role in the regulation of immune response. Studies in models of arthritis have to reveal 
the therapeutic value of IL-18BP for treatment of RA.
4. In te rv e n tio n s  in  RA.
There are several levels of intervention possible, including blockade of effector cytokines (IL-1, 
TNFa, IL-12, IL-17, IL-18), downmodulation of Th1 responses by IL-4, IL-10 and TGFP, 
elimination of CD4+T cells, or generation of suppressive Th2/Th3 immune responses by the 
induction of bystander suppression.
4.1 B lockade o f  T N F a, IL-1 o r  IL-12.
At the moment clinical trials in RA patients are performed with anti-TNFa and the first results 
are promising. Both the acute phase proteins and the disease activity rapidly decline after anti- 
T N Fa treatm ent. However, there are no data regarding am elioration of radiological 
progression although the first studies started 5 years ago (72,73). More recently, clinical trials 
with IL-1 receptor antagonist (IL-1Ra) showed that disease activity was not markedly 
suppressed, but X-ray analysis showed a clear ameliorative effect on bone degradation (74,75). 
Studies in RA patients with better IL-1 inhibitors, such as soluble receptors and anti-IL-1
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Figure 1. Cell and cytokine interplay in chronic jo in t inflammation. A scheme of cytokine and cell interactions in 
the synovial tissue. The process is driven by unknow n antigens (X) or bacterial fragments. N ote the various levels of 
possible intervention o f m odulatory cytokines like IL-4 and IL-10. (APC; antigen presenting cell, Th0; naive T cell, 
Th1,2,3; T helper 1,2,3 cell)
antibodies may provide insight whether IL-1 is the key mediator regarding joint destruction. 
Combination studies with both anti-TNFa and IL-1 inhibitors will be performed in the near 
future to establish a rapid anti-inflam m atory and tissue protective therapy. W hether 
neutralization of IL-12 will lead to a protective therapy is at present unknown. At the level of 
IL-12 intervention there are no reports available in human RA at the moment. In other diseases, 
such as cancer and viral infections, IL-12 therapy is under current investigation (76,77).
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4.2 A d m in is tra tio n  o f  IL-4 o r  IL-10.
Apart from intervention on IL-1/TNF level the disease may be regulated by addition of 
immunomodulating cytokines, such as IL-4 and IL-10. In vitro studies showed that production 
of several pro-inflammatory cytokines by hum an RA synovium was suppressed by IL-4. In 
addition, upregulation of cytokine inhibtors was noted after IL-4 exposure (78,79). Since, there 
is hardly any IL-4 found in RA synovium or synovial fluid, treatment of RA patients with IL- 
4 may be effective. The first clinical safety study with rhIL-4 is performed and IL-4 is well- 
tolerated (80). However, a dose-related, decreased lymphocyte and increased platelet counts 
was found after IL-4 treatment. Long-term studies are required to determine IL-4 s potential 
beneficial effects on clinical disease activity. The first clinical trials with IL-10 in hum an RA 
did not show impressive efficacy until now, although IL-10 was found to be anti-inflammatory 
in other diseases (81,82). However, IL-10 is well tolerated and no anti-IL-10 antibodies were
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found during the study (83). Combination of IL-4 and IL-10 showed more therapeutic benefit 
in animal models of RA and it would be worthwhile to investigate whether IL-4/IL-10 treatment 
of RA patients provides a better anti-inflammatory therapy.
4.3 E lim in a tio n  o f  C D 4+  T cells.
It is claimed that RA is driven by CD4+ T cells and that elimination of these T cells would lead 
to downmodulation of the disease (84). In murine SCW arthritis or collagen-induced arthritis 
it was shown that treatment with anti-CD4 antibodies, during the disease induction, abrogated 
the disease onset (15,85). However, when anti-CD4 treatment was started after onset of CIA 
the suppression was limited (8 6 ). Clinical trials are performed with several murine anti-CD4 
antibodies, CD4 depleting and non-depleting antibodies (87,88). In most studies the clinical 
response was variable and hum an anti-mouse response was found in all patients. To avoid the 
latter side effects chimeric anti-CD4 antibodies were constructed (89). The initial results of 
studies with these humanized antibodies are encouraging (90). Treatment with anti-CD4 
induces a state of tolerance in several animal models of autoimmune diseases. Even when anti- 
CD4 was given after onset of the disease tolerance was noted (15,91). If a similar state of 
tolerance can be induced in RA patients is not known at this time point, but this would be a 
great advantage of anti-CD4 treatment of RA.
4.4 In d u c tio n  o f  b y s ta n d e r  su p p re ss io n .
Tolerance induction as a means of therapy is based on the observation that animals fed with 
antigen did not react to this antigen anymore. These animals showed a state of 
hyporesponsiveness towards the fed antigen and this phenomenon is called tolerance induction. 
Three mechanisms for tolerance induction have been proposed: clonal deletion, induction of 
anergy and T cell-mediated suppression (92,93). The dose and route, orally or nasally, of the 
antigen determines the pathway of tolerance induction.
Bystander suppression is a concept that regulatory T cells induced by tolerogenic routes 
suppress immune responses induced by a different antigen (94). Mediators as IL-4, IL-10 and 
TGFP probably play a role in this suppression. Based on this mechanism, clinical trials were 
performed with type II collagen as inducer of bystander suppression. A phase II study with 
280 RA patients with chicken type II collagen (20-2500 |j,g/day) demonstrated positive effects 
in the group treated with the lowest dose (95). Five large studies have been performed with 
oral collagen administration but the results are unclear. Besides collagen other joint related 
proteins are currently under investigation for possible use for treatment of RA, such as cartilage 
derived proteins gp-78 and HC gp-39.
5. A im  o f  th e  p re se n t s tu d y
The aim of this thesis was to investigate several levels of intervention to modulate experimental 
arthritis and concomitant cartilage and bone destruction.
The following major objectives were approached:
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First, we evaluated the role of TN Fa and IL-1 in joint inflammation and whether elimination 
of TN Fa or IL-1 leads to a tissue protective therapy for arthritis. Furthermore we investigated 
whether TN Fa is pivotal for production of IL-1 during arthritic processes. Using IL-10 deficient 
mice and TN Fa deficient mice we clarified the pivotal role of IL-1 P over TN Fa in arthritis. 
Secondly, we investigated the potency of IL-4 and IL-10 to suppress arthritic processes and to 
prevent cartilage and bone destruction. The focus was on regulation of IL-1/TNFa inhibition 
and the upregulation of inhibitors such as IL-1Ra and IL-10. Furthermore, possible synergistic 
effects of IL-4 or IL-10 and low dose steroids were investigated, since it is known that steroids 
inhibit the pro-inflammatory cytokines IL-1/TNFa and the anti-inflammatory cytokines IL- 
4 and IL-10. The anti-inflammatory effect of generation of suppressive mediators IL-4 and IL- 
1 0  was explored by induction of bystander suppression with a possible cartilage derived 
autoantigen of RA, HC gp-39.
Finally, we analyzed whether IL-12 plays a crucial role during the induction phase ofboth SCW 
induced arthritis and collagen-induced arthritis. Furthermore, the role of IL-12 was analyzed 
in established CIA and possible mechanisms of regulation were determined.
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ABSTRACT
We examine the role of TN Fa, IL-1a and IL-10 in collagen-induced arthritis (CIA), 
immediately after onset and during the established phase of the arthritis. Male DBA-1 mice 
with collagen-induced arthritis were treated with antibodies against murine TN Fa and IL-
1 a,P  at different time points of the disease. IL-1Ra was administered using Alzet mini-osmotic 
pumps. The effect of anti-cytokine treatment was monitored by visual scoring. Histology and 
cytokine RT-PCR analysis were performed at the end of the treatment period. Anti-TNFa 
treatment showed efficacy shortly after onset of the disease, but was hardly effective on fully 
established CIA. Histology taken after early treatment revealed that anti-TNFa significantly 
reduced joint pathology, determined on the basis of infiltration of inflammatory cells and 
cartilage damage. Anti-IL-1 a,P  treatment ameliorated both early and full blown CIA. This clear 
suppression of established arthritis was confirmed by administration of high doses of IL-1Ra, 
supplied with osmotic mini-pumps. Dose response experiments showed that a continuous 
supply of 1 mg per day was needed for optimal suppression. Histology showed markedly 
reduced cartilage destruction in both knee and ankle joints. Autoradiography demonstrated 
full recovery of chondrocyte synthetic function of articular cartilage. In addition, we found 
that the IL-1 P isoform plays a dominant role in established CIA. Profound suppression of CIA 
was observed with anti-IL-10, although elimination of both IL-1a and IL-10 still gave better 
protection. Analysis of mRNA with RT-PCR revealed that IL-10 is highly upregulated in 
synovium and cartilage at late stages of CIA, whereas anti-IL-10 treatment markedly reduced 
IL-10 message in the synovium. The present data has identified different TNFa/IL-1 
dependence in various stages of CIA and reveals that blocking of TN Fa does not necessarily 
eliminate IL-1. Continuous, high doses of IL-1Ra are needed to block CIA.
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IN T R O D U C T IO N
Rheumatoid arthritis (RA) is characterized by chronic inflammation in joints and concomitant 
destruction of cartilage and bone. Although the disease is generally considered as an 
autoim m une process, the autoantigen is still unknown, ham pering specific 
im m unomodulation as a straightforward therapeutic approach. In fact, detailed analysis of 
mediator production in the inflamed synovial tissue reveals a relative lack of T cell factors and 
an abundance of cytokines and growth factors, produced by macrophages and synovial 
fibroblasts (1,2). Fortunately, considerable hierarchy seems to exist in this plethora of factors 
and tum or necrosis factor (TNFa) and interleukin-1 (IL-1) seem of pivotal importance in 
arthritis (3-5). It has been claimed that TN Fa is driving most of the IL-1 production in the 
inflamed synovia of RA patients (6 ), making it a prime target for therapy. This is further 
substantiated by the demonstration of arthritis in TNFa-transgenic mice and efficacy of anti- 
TN Fa treatment in collagen arthritis in the mouse (7-9). First clinical trials with neutralizing 
antibodies against TN Fa demonstrated efficacy in hum an RA (10-12). Collagen arthritis is a 
widely used experimental model of polyarthritis. It can be induced in susceptible strains of 
mice and rats by immunization with collagen type II, the major component of articular 
cartilage, and shows histopathological features in common with RA (13-16). Earlier studies 
revealed that the expression of this autoimmune arthritis can be enhanced with passive addition 
of cytokines like TNFa, IL-1 and transforming growth factor beta (TGF0), whereas TGF0 and
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antibodies to TN Fa prevented onset of disease (17-21). Subsequent studies analyzed the effect 
of TN Fa neutralization after onset of CIA, using antibodies and soluble TN Fa receptor fusion 
protein. Significant amelioration was found both macroscopically and histologically (8,9,22). 
However, recent studies, using neutralizing antibodies to IL-1 in CIA, suggest that elimination 
of this cytokine was at least as effective (23,24). Moreover, studies in other arthritis models 
provided evidence that IL-1 is perhaps not always the dominant cytokine in the inflammatory 
process, but is for sure of pivotal importance in cartilage destruction (25,26). In the present 
study we compared the relative efficacy of anti-TNFa and anti-IL-1a,0 treatment in murine 
CIA, using concomitant treatment protocols in large groups of arthritic mice. Moreover, 
treatment was started at different time points after onset of arthritis and besides macroscopic 
arthritic scores we also investigated histopathology in sections of knees and ankle j oints. It was 
found that anti-TNFa was effective at the onset of arthritis but less so at later stages, whereas 
anti-IL-1a,0 was also highly effective in established disease, with a major emphasis on 
reduction of cartilage destruction. We confirmed the importance of IL-1, using IL-1Ra 
treatment. A critical observation in the latter experiments was the need of continuous, high 
concentrations of IL-1Ra, supplied by osmotic minipumps. Finally, we examined the relative 
role of IL-10 and IL-1 a  and analyzed message expression in synovium and cartilage for TNFa, 
IL-10, and IL-1Ra. It is clear from observations in this animal model that IL-1 is a pivotal 
mediator in both early and late disease, whereas blocking of TN Fa does not necessarily 
eliminate IL-1. Given the cartilage destructive character of IL-1, this argues at least for a 
consideration of both TN Fa and IL-1 as therapeutical targets in RA.
MATERIALS a n d  M E T H O D S
Animals
Male DBA-1 Lac/J mice were obtained from The Jackson Laboratories (Bar Harbor, ME). Male 
C57Bl/6 mice, used for induction of SCW-arthritis, were bred in our own facilities. Mice were 
housed in filter top cages, and water and food were provided ad libitum. DBA-1 mice were 
immunized at the age of 9-10 weeks and C57Bl/6 mice were used at the age of 10-12 weeks.
Materials
LPS (E. Coli, 0111:84 ), Ethidiumbromide, hamster Ig’s, rat Ig’s, rabbit Ig’s, and bovine serum 
albumin were purchased from Sigma Chemicals, St Louis, MO. Taq DNA Polymerase, 100 bp 
DNA marker, TRIzol Reagent, and Agarose were obtained from Life Technologies, Breda, The 
Netherlands. GAPDH, 02-microglobulin, IL-10, IL-1Ra, TNFa, and TIMP primers were 
purchased from Pharmacia Biotech, Roosendaal, The Netherlands. Internal DNA construct 
(Pmus) was a kind gift of Dr. D. Shire, Sanofi Recherche, Lab ge, France (27). Complete 
Freund’s adjuvant and Mycobacterium tuberculosis (strain H37Ra) were obtained from Difco 
Laboratories, Detroit, MI. Osmotic m ini-pumps were purchased from Alza, Palo Alto, CA. 
Cells producing rat anti-murine TN Fa IgG1 (V1q) was a kind gift of P.H. Krammer (German 
Cancer Research Centre, Heidelberg, Germany (28)). Rabbit anti-murine IL-1a,0 polyclonal 
antibodies were prepared in our own laboratory by Dr. A.A.J. van de Loo (25,26). Polyclonal 
rabbit anti-murine IL-1a and monoclonal hamster anti-murine IL-10 were generously 
provided by Robert Schreiber (W ashington University Medical School, St Louis), in 
conjunction with Merck Research Laboratories, Rahway NJ. Hum an recombinant IL-1 
receptor antagonist (IL-1Ra) was kindly provided by Synergen, Boulder, CO.
25
TARGETING OF CYTOKINES IN EXPERIMENTAL ARTHRITIS
Collagen preparation
Articular cartilage was obtained from knee j oints of 1-2 years old cows. Bovine type II collagen 
was prepared according to Miller & Rhodes (29). Collagen was resolved in 0.05 M HAc (10 
mg/ml) and stored at -70°C.
Induction o f CIA
Bovine type II collagen was diluted with 0.05 M acetic acid to a concentration of 2 mg/ml and 
was emulsified in an equal volume of complete Freund’s adjuvant (2 mg/ml MT H37Ra). The 
mice were immunized intradermally at the base of the tail with 1 0 0  |jl emulsion ( 1 0 0  |j,g 
collagen). At day 21 the animals were boosted with an i.p. injection of 100 |j,g collagen type II, 
dissolved in phosphate buffered saline. This resulted in onset of arthritis in 20-40 % of the 
mice around day 28. Mice with arthritis are selected at this time point to be used in the studies 
indicated as “classic” CIA.
Acceleration o f CIA
Mice without any macroscopic signs of arthritis at day 28 were used for LPS accelerated CIA. 
Onset of arthritis was initiated by a single i.p. injection of 40 |j,g of LPS (30). This resulted in 
onset of CIA within three days and at day 35 full blown expression of arthritis was noted in 
paws of more than 95% of the animals. Thus anti-cytokine treatments were performed in two 
CIA models, classic and accelerated CIA. The expression of histopathology in knee and ankle 
joints was comparable in accelerated CIA and classic CIA. As described previously, 
administration of 40 ju,g LPS to non-immunized DBA-1 mice did not result in any macroscopic 
or histological abnormalities (31).
Assessment o f CIA
Mice were examined for visual appearance of arthritis in peripheral joints and scores for severity 
were given (macroscopic score) as previously described (24,31). Mice were considered 
arthritic, when significant changes in redness and/or swelling were noted in digits or in other 
parts of at least two paws. At later time points ankylosis was also included in macroscopic 
scoring. Clinical severity of arthritis was graded on a scale of 0 to 2 for each paw, according to 
changes in redness and swelling: 0: no changes; 0.5: significant; 1.0: moderate; 1.5: marked; 
2.0: maximal swelling and redness and lateron ankylosis. Macroscopic score (mean±SD) was 
expressed as cumulative value for all paws, with a maximum of 8 . Assessment of macroscopic 
score was performed by two independent, blinded observers.
Neutralizing anti-cytokine antibodies/IL-1 receptor antagonist
Hybridoma cells (3.106) producing rat anti-murine TN Fa (V1q) were injected in nude Balb/C 
mice and after 3 weeks ascites fluid was collected. Thereafter Ig’s were isolated using a protein- 
G column. This antibody (IgG1) showed efficacy in LPS mediated lethal shock models (28) 
and in the L929 bioassay. The neutralizing capacity of this antibody was 3.5 ng TNFa/|J.g in 
the latter assay. Polyclonal rabbit antibodies were raised against murine recombinant IL-1a 
and IL-10 (25,26). The isotype specific antibodies showed no cross-reactivity against a 
number of other cytokines such as IL-6 , TN Fa or GM-CSF. The antibodies have been 
demonstrated to show neutralizing capacity both in vitro and in vivo. One microgram of 
purified Ig’s neutralized 50-100 pg IL-1 in the NOB-1 bioassay. To confirm the anti IL-1a,0 
treatment results we compared in vivo efficacy of our own anti-IL-1 antibodies with anti-
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IL-1 antibodies from other sources. To this end we used rabbit anti-IL-1a and monoclonal 
hamster anti-IL10 (Robert Schreiber) which neutralized 35 pg IL-1a/|J.g and 175 pg IL-10/^g 
antibody, respectively.
IL-1Ra was administered using mini-osmotic pumps (1007D). Pumps were implanted into 
the peritoneal cavity at day 34 after immunization ( 6  days after acceleration by LPS), and gave 
sustained release of IL-1Ra for the next seven days. All anti-cytokine agents used contained 
no LPS, as measured by the Lumulus assay.
Anti-cytokine treatment o f collagen-induced arthritis
To investigate the effect of anti-IL-1a,0 or anti-TNFa treatment at different phases of classic 
CIA, a single dose of these antibodies was injected i.p. at different time points after onset of 
CIA. We injected 0.6 mg of rabbit anti-IL-1a or 0 polyclonal antibodies or 75 |j,g of rat 
monoclonal anti-TNFa. Dose-response experiments in established CIA were performed with
0.6 mg polyclonal rabbit anti-IL-1a and 0.12 mg monoclonal hamster anti-IL-10 (R. Schreiber) 
as highest dose, which had the same neutralizing capacity as 0.6 mg rabbit anti-IL-1a and 0 
prepared by Dr A.A.J. van de Loo. Daily administrations of anti-TNFa were performed in 
accelerated CIA with a dose of 75 |j,g rat-anti-TN Fa for a period of seven days. As control in 
the anti-IL1/TNFa studies we injected the same amounts of normal rabbit, rat or hamster Ig’s. 
IL-1Ra treatment was started at day 34 after immunization by implantation of osmotic m ini­
pumps which released 0.12 mg upto 1.2 mg IL-1Ra per day. As a control we implanted osmotic 
pumps which released 1.2 mg bovine serum albumin a day. Assessment of arthritis was carried 
out every two days, starting at day 28 after immunization with collagen. Knee and ankle joints 
were isolated and processed for light microscopy at 7 days after start of the anti-cytokine 
treatment, unless stated otherwise. Tissue samples for mRNA measurements were also isolated 
at this time point.
Induction o f endotoxic shock.
Mice, C57Bl/6 were injected i.v. via the tail vein with LPS (100 |j,g) in a saline solution of 200 
|j,l and m onitored for survival for 7 days. All deaths occurred w ithin 3 days of LPS 
administration. Rat anti-murine TN Fa (75 |j,g) was injected i.p. 4h before endotoxic shock 
induction.
SCWpreparation and induction of SCW  arthritis
Streptococcus pyogenes T12 organisms were cultured overnight in Todd-Hewitt broth. Cell walls 
were prepared as described previously (32). The resulting 10.000 x g supernatant was used 
throughout the experiments. These preparations contained 11% muramic acid. Bacteria were 
kindly provided by Dr. M. Hazenberg, Erasmus University, Rotterdam, The Netherlands. 
Unilateral arthritis was induced by intraarticular injection of 25 |j,g SCW (dryweight) in 5 |jl 
phosphate buffered saline (PBS) into the right knee joint of naive mice. As a control, PBS was 
injected into the left knee joint.
Measurement o f SCW  arthritis
SCW arthritis was quantified by the 99mTc-uptake method (33). This method measures by 
external gamma counting the accumulation of a small radioisotope at the site of inflammation 
due to local increased blood flow and tissue swelling. The severity of inflammation is expressed 
as the ratio of the 99mTc-uptake in the right (inflamed) over the left (control) knee joint. All 
values exceeding 1 . 1 0  were assigned as inflammation.
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A nti-TN Fa treatment o f SCW  arthritis
To examine the role of TN Fa during onset of SCW arthritis a single injection of 75 |j,g rat anti- 
TN Fa antibodies was given, one hour before induction of SCW. As control we used 75 |j,g of 
rat Ig’s. Knee joint swelling was measured at days 1, 2 and 4 of the arthritis.
RNA isolation
Mice were sacrificed by cervical dislocation, immediately followed by dissection of the patella 
with adjacent synovium (34). Two synovium biopsies were taken from this specimen, with a 
diameter of 3 mm: one from the lateral and one from the medial side. To this end we used a 
disposable biopsy punch (Stiefel, Wachtersbach, Germany). The synovium samples were 
immediately frozen in liquid nitrogen. Patellae were transferred to a 5% EDTA solution and 
kept on ice for 4h. Thereafter, the cartilage layer was stripped as previously described (35). 
This procedure does not affect mRNA expression. The total RNA of a pool of 10 cartilage 
samples was extracted with 1 ml TRIzol Reagent, an improved single-step RNA isolation 
method based on the method described by Chomczynski and Sacchi (36). Five separate 
synovium samples were grinded to powder using a m icro-dism em brator II (B.Braun, 
Melsungen, Germany). Total RNA was extracted in 1 ml TRIzol reagent in a way similar to 
that used for cartilage samples.
PCR amplification
One microgram of synovial RNA and the total amount of cartilage RNA was used for RT-PCR. 
Messenger RNA was reverse transcribed to cDNA using oligodT primers and 1/20 of the cDNA 
was used in one PCR amplification. PCR was performed according to a standard protocol. 
Message for GAPDH, IL-10, IL-1Ra, and TN Fa was amplified using the primers described in 
references 37-40. Primers for TIMP were designed using Oligo 4.0 or Primer. The results are 
presented as relative increase of the mRNA expression, compared to non-inflamed control 
samples of normal DBA-1 mice. The relative increase in mRNA was calculated as follows: 1.9 
(amplification factor, (41)) to the power of n, where n is the difference in number of cycles 
showing identical staining intensity for experimental and non-inflamed control tissue. IL-10, 
TNFa, IL-1Ra and TIMP mRNA levels were corrected for GAPDH message, if needed. To 
validate the calculated values for mRNA levels, we also performed competitive PCR for 02- 
microglobulin and IL-10 (27). A serial dilution of an internal DNA standard (Pmus) was added 
to a fixed am ount of cDNA (1/20 part of cDNA). The IL-10 mRNA levels were corrected for 
the am ount of 0 2 -microglobulin.
Histology
Mice were sacrificed by ether anaesthesia. Thereafter, ankle and knee joints were removed and 
fixed for 4 days in 4% formaldehhyde. After decalcification in 5% formic acid the specimens 
were processed for paraffin embedding. Tissue sections (7 |j,m) were stained with Haematoxylin 
& Eosin or Safranin O. Histopathological changes were scored using to the following 
parameters. Infiltration of cells was scored on a scale of 0-3, depending on the amount of 
inflammatory cells in the synovial cavity and synovial tissues. Proteoglycan depletion was 
determined using Safranin O staining. The loss of proteoglycans was scored on a scale of 0-3, 
ranging from full stained cartilage to destained cartilage or complete loss of articular cartilage. 
A characteristic parameter in CIA is the progressive loss of articular cartilage. This destruction 
was separately graded on a scale of 0-3, ranging from the appearance of dead chondrocytes
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(empty lacunae) to complete loss of the articular cartilage. Histopathological changes in the 
knee joints were scored in the patella/femur region on 5 semi-serial sections of the joint. For 
the ankle joint we scored in the calcaneus region. Scoring was done in a blinded fashion by 
two observers, as described earlier (24).
Statistical analysis
Differences between experimental groups were tested using the Wilcoxon rank test, unless 
stated otherwise.
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Figure 1. Time-course of TNFa/IL-1 
involvement in classic CIA. A single treatment 
with anti-TNFa or anti-IL-1a,p was given (A, 
B). At time points indicated by arrows separate 
groups were injected with either control Ig’s or 
anti-cytokine. Arthritis was visually scored by 
two independent observers on a scale 0-8 for all 
paws (see materials & methods section). Each 
group consisted of at least 10 mice. This 
experiment was repeated twice, with similar 
outcome and values represent the mean of 3 
experiments. A: ■  = rat anti-TNFa 75 jag, •  = 
control 75^g rat Ig’s. B: ▲ = anti-IL-1a,p 0.6 
mg each, rabbit IgG), •  = control 1,2 mg 
rabbit Ig’s.
RESULTS
Time course o f TNFa/IL-1 involvement in classic CIA
At various time points after the onset of classic collagen-induced arthritis, mice were treated 
with a single i.p. injection of antibodies raised against murine TN Fa or murine IL-1a and IL-
10. When 75 |ag monoclonal anti-TNFa was given just after onset (day 30), a marked reduction 
of arthritis was noted. The effect was less pronounced when treatment was started at day 2 
after onset (day 32), whereas no significant relief was seen any more, when treatment was 
delayed till day 7 after onset (Figure 1A). In contrast, after neutralization of IL-l with a 
combination of antibodies against both isoforms, IL-1a and IL-10, complete prevention of
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Table 1. Histology after anti-cytokine treatment classic of CIA.
Proteo-
Start of Cartilage glycan Day of
Group treatment# Infiltrate& damage depletion killing
Knee joints
Rat Ig’s day 30 1.5±0.6 1.0±0.6 1.9±0.8 day 37
Rabbit Ig’s day 30 1.4±0.7 0.9±0.5 1.8±0.9 day 37
Anti-TNF day 30 0.9±0.3 0.6±0.5 1.1±0.5 day 37
Anti-IL-1 day 30 0.±0. 0.±0. 0.1±0.1* day 37
Rat Ig’s day 32 1.4±0.4 1.1±0.3 2.4±0.6 day 39
Rabbit Ig’s day 32 1.5±0.5 1.0±0.4 2.5±0.3 day 39
Anti-TNF day 32 1.0±0.5 0.7±0.5 1.8±0.6 day 39
Anti-IL-1 day 32 0.±0. 0.1±0.1* 0.±0. day 39
Rat Ig’s day 35 1.3±0.4 1.2±0.3 2.2±0.5 day 42
Rabbit Ig’s day 35 1.4±0.3 1.3±0.4 .40.±2. day 42
Anti-TNF day 35 1.2±0.5 1.0±0.5 2.0±0.6 day 42
Anti-IL-1 day 35 0.6±0.1* 0.5±0.3* 0.9±0.2* day 42
Ankle joints
Rat Ig’s day 30 1.5±0.3 0.9±0.4 1.6±0.4 day 37
Rabbit Ig’s day 30 1.6±0.4 0.8±0.4 1.7±0.5 day 37
Anti-TNF day 30 0.9±0.5 0.6±0.5 ± 7 day 37
Anti-IL-1 day 30 0. ± . * 0.1±0.1* 0.2±0.2* day 37
Rat Ig’s day 32 2.0±0.5 1.0±0.3 2.4±0.3 day 39
Rabbit Ig’s day 32 1.9±0.4 0.9±0.2 2.3±0.4 day 39
Anti-TNF day 32 1.3±0.5 0.7±0.3 1.6±0.8 day 39
Anti-IL-1 day 32 0.2±0.1* 0.±0. 0.2±0.2* day 39
Rat Ig’s day 35 1.9±0.4 .20.± 2.0±0.5 day 42
Rabbit Ig’s day 35 1.8±0.2 1.0±0.3 1.9±0.3 day 42
Anti-TNF day 35 1.7±0.4 1.0±0.3 1.9±0.5 day 42
Anti-IL-1 day 35 0.8±0.2* 0.5±0.2* 1.0±0.2* day 42
#Days after immunization of DBA/1 mice with bovine type II collagen
&Synovial infiltrate, cartilage damage and proteoglycan depletion are scored on a scale of 0-3
*P<0.01 Wilcoxon rank test, compared to control.
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onset was noted upon early treatment. Of interest, a pronounced suppression was still 
observed when treatment was started at day 2 after onset. Unlike the effect of anti-TNFa, anti- 
IL-1 a,P  treatment was also able to significantly suppress established collagen arthritis. Figure 
1B shows a macroscopic arthritis score of 5 at day 35, which slowly increased to 5.5 in the control 
group at day 42, whereas the score was reduced below 2 by treatment at day 35 with anti-IL- 
1a,p. W hen the start of anti-IL-1a,P treatment was delayed till day 56, a phase characterized 
by ankylosis of the j oints, no significant suppression of macroscopic signs was noted any more 
(data not shown).
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In addition to macroscopic scoring we analyzed the histology in both knee and ankle joints at 
day 7 after the start of anti-cytokine treatment. On this parameter, anti-TNFa treatment had 
only a slight effect. Cellular infiltration was marginally reduced, when treatment was started 
early. No effect was seen after late treatment (Table 1). In contrast, anti-IL-1a,P treatment 
highly reduced cellular infiltration, even when treatment was started at day 35. Of importance, 
cartilage proteoglycan depletion and damage to the articular surface was also highly reduced 
by anti-IL-1 (Table 1). This set of data indicates that TN Fa is involved in onset but plays a 
minor role at later stages, whereas IL-1 is a dominant mediator in both onset and established 
collagen arthritis.
Anti-IL-1 and anti-TNFa treatment o f accelerated CIA
In addition, experiments were performed in LPS accelerated CIA. Selected mice, showing no 
clear signs of CIA at day 28, received a single injection of 40 jag LPS i.p. Anti-cytokine treatment 
was started at day 31, when the animals showed definite arthritis. W hen accelerated CIA was 
treated at day 31 with a single dose of 75 |j,g anti-TNFa, some suppression of the arthritis was 
noted. A low dose of 7.5 |j,g was without effect, whereas a higher dose (225 |j,g) did not show 
greater efficacy as compared with 75 |j,g (Figure 2A).
Figure 2. Treatment of accelerated CIA with 
different doses anti-TNFa/anti-IL-1.
A: A single treatment of rat anti-TNFa was 
given just after onset of the disease (day 31),as 
indicated by arrow. Following doses were used: 
7.5 ^g, 75 ^g and 225 ^g anti-TNFa. As 
control 75 ^g rat Ig’s was i.p. injected (•). B: 
Anti-IL-1 a,p  treatment with several doses of 
rabbit anti-IL-1a/monoclonal hamster IL-1p 
(0.6/0.12, 0.2/0.04 and 0.06/0.012 mg) was 
given at day 32, when arthritis was fully 
developed. As control 0.6 mg rabbit Ig’s and 
0.12 mg hamster Ig’s were injected at the same 
time point (•). Similar results were found 
with rabbit anti-IL-1a,p antibodies (♦ 0.6/0.6 
mg) in accelerated CIA as found in classic CIA 
(see Figure 1B). *P<0.01, Wilcoxon rank test 
compared to control group. Data represents 
mean±SD of at least 10 mice per group.
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As found in the classic CIA, treatment of accelerated CIA with anti-IL-1a,P resulted in a 
complete suppression of the arthritis (Figure 2B). To confirm these findings, similar studies 
were done with yet another source of anti-IL-1 antibodies. Rabbit anti-IL-1a combined with 
monoclonal hamster anti-IL-10 showed a dose dependent suppression of CIA. These findings 
were confirmed with histology (Table 2 and Figure 3).
T ab le  2. Histology after anti-cytokine treatment of accelerated CIA.
Start of Infiltrate Cartilage Proteoglycan
Group Treatment Damage Depletion
Knee joints
Rat Ig’s day 31 1.4±0.6 1.2±0.6 2.0±0.9
Anti-TNFa,225 |J,g day 31 0.8±0.7 1.0±0.7 1.7±0.6
Rabbit Ig’s 
Anti-IL-1a,P
day 32 1.4±0.3 1.1±0.6 2.1±0.4
0.06/0.012 mg day 32 0.6±0.5 0.8±0.8 1.3±0.7
0.2/0.04 mg day 32 0.4±0.2* 0.4±0.1* 0.6±0.5*
0.6/0.12 mg day 32 0.2±0.2* 0.5±0.5* 0.4±0.5*
Control# day 34 1.5±0.7 1.7±0.8 2.2±0.8
IL-1Ra, 1.2 mg/day day 34 0.4±0.2* 0.6±0.2* 0.6±0.4*
Ankle joints
Rat Ig’s day 31 1.7±0.5 0.9±0.3 1.8±0.6
Anti-TNFa, 225 |J,g day 31 1.0±0.7 0.6±0.5 1.2±0.6
Rabbit Ig’s 
Anti-IL-1a,P
day 32 1.9±0.5 0.9±0.2 2.2±0.4
0.06/0.012 mg day 32 1.0±0.3* 0.5±0.2* 0.8±0.2*
0.2/0.04 mg day 32 0.8±0.4* 0.4±0.4* 0.7±0.5*
0.6/0.12 mg day 32 0.4±0.2* 0.3±0.2* 0.5±0.5*
Control# day 34 1.9±0.4 1.4±0.3 2.0±0.8
IL-1Ra, 1.2 mg/day day 34 0.7±0.1* 0.5±0.2* 0.5±0.2*
For details see table 1. Histology was performed 7 days after start of anti-cytokine treatment. # As control 1.2 mg
bovine serum albumin was used. *P<0.01 Wilcoxon rank test, compared to control.
Efficacy o f anti-TNF treatment
The studies described above were performed with monoclonal rat anti-TNFa antibodies (V1q). 
To exclude that the apparent inefficacy of anti-TNFa treatment was related to inferior 
pharmacokinetics or inadequate neutralization, a num ber of control experiments were 
performed. Firstly, we tested the capacity of the rat monoclonal anti-murine TN Fa (V1q) in 
LPS induced shock. A single injection of 75 |ag completely prevented lethality when 100 |j,g 
LPS was injected i.v. 4 hours later. Secondly, we performed daily dosing for 7 days in collagen 
arthritis. As can be seen from Figure 4A this did not result in more marked suppression of the
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Figure 3. Frontal sections of knee joints at day 42 of CIA. A: Arthritic knee joint of a mouse treated with control 
IgG at day 30. B: Knee joint of a mouse treated with Rat anti-TNFa (225 |lg) at day 30. C: Knee joint of a mouse 
treated with Rabbit anti-IL-1a,P (0.6 mg each antibody) at day 30. D: Autoradiograph showing 35S-sulfate 
incorporation in an arthritic joint at day 42. E: Autoradiograph of a similar region, after treatment with IL-1Ra (1.2 
mg/day for 7 days, started at day 34). Note the restoration of chondrocyte synthetic function, visualized by distinct 
label. P: patella, F: femur, JS: jointspace, C: cartilage, S: synovium. H&E staining. Magnification 200x.
macroscopic score as compared with the findings in Figure 2A. Finally, we treated SCW arthritis 
with a single injection of 75 |j,g anti-TNFa. As can be seen in Figure 4B, clear suppresion of 
knee joint swelling was measured at days 1, 2 and 4 in this bacterial arthritis model.
Confirmation with IL-1Ra
To further substantiate the im portant role of IL-1, arthritic mice were continuously infused 
with IL-1 receptor antagonist (IL-1Ra) from day 34, using osmotic m ini-pumps. This 
experiment was repeated 3 times with the high dose (1.2 mg IL-1Ra per day), showing a marked 
and consistent decline of the arthritis within a few days after the start of IL-1Ra treatment. 
Moreover, we always noted a slight suppressive effect when control mini-pum ps were 
implanted, probably related to stress effects. In control, arthritic mice the arthritis score slightly 
increased or remained constant from day 34, whereas in mice with control pumps some 
suppression was consistently seen. A typical example of a dose response experiment is shown 
in Figure 5A. It is clear that relatively high doses of IL-1Ra are needed to obtain pronounced
Figure 4. Anti-TNFa treatment of CIA and 
SCW arthritis. (A) Daily dosing (75 ag) for 7 
days was performed in accelerated CIA and 
arthritis scored macroscopically in the paws. (B) 
Unilateral SCW arthritis was treated with a 
single dose of anti-TNFa (75 jag), given i.p. one 
hour before induction. Knee joint swelling was 
determined by 99mTC-uptake method. A ratio 
(R/L) of 1.10 or more indicates knee joint 
inflammation. *P<0.01, Wilcoxon rank test 
compared to control (rat Ig’s, 75 ag).
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Figure 5. IL-1Ra treatment of accelerated 
CIA and classic CIA. (A) At day 6 after 
acceleration of CIA, mice were selected on the 
basis of visual score and divided in 4 separate 
groups with equal levels of arthritic score. 
Osmotic mini-pumps (Alza 1007D) were 
loaded with 100 (1.2 mg/day), 30 or 10 mg 
recombinant human IL-1Ra and were 
implanted i.p. As control we used 100 mg of 
bovine serum albumin (BSA). Thereafter mice 
were scored daily for arthritis severity by two 
independent observers. (B) IL-1Ra treatment 
(1.2 mg/day) of classic CIA was started at day 
34 after immunization by implantation i.p. of 
osmotic pumps. Data represent mean±SD of 10 
mice per group. *P<0.01, Wilcoxon rank test 
compared to control group.
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Figure 6 . Relative role of IL-1 a  and IL-1 p. In 
separate groups of mice with established CIA 
(day 32), we injected anti-IL-1 a  (0.6 mg), anti- 
IL-1p (0.6 mg) or the combination of both 
antisera (1.2 mg). Groups consist of at least 10 
mice, data expressed as mean±SD. *P<0.01, 
Wilcoxon rank test compared to control.
Figure 7. Measurement of mRNA levels in 
synovium of control and anti-IL-1p treated 
mice. A: Treatment of accelerated CIA with 
anti-IL-1 p was started at two different time 
points, day 32 and day 35 as indicated by arrows. 
In separate groups of 10 arthritic mice we 
administered 0.6 mg antibody raised against 
murine IL-1p. The control group received at 
days 32 and 35 0.6 mg control Ig’s. At day 40 
mice were killed and samples of synovium and 
cartilage were isolated for PCR analysis. B: 
Synovium samples of 6 mice per group were 
pooled and RNA was extracted. Quantitative 
PCR was performed as described in M&M 
section. I: arthritic control group, II: mice 
treated at day 32, III: mice treated at day 35. The 
levels for p2-microglobulin (housekeeping 
gene) were 20 femtogram in each group. 
Roughly a 25 fold reduction (500 attogram to 
20 ag) of IL-1p mRNA level was found after 
treatment with rabbit anti-murine IL-1p. * 
Equal levels of DNA construct and cDNA. # 
P<0.05 Wilcoxon rank test compared to 
control.
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suppression. An intermediate dose of 0.4 mg per day still showed significant suppression, but
0.12 mg per day was ineffective. Similar observations were noted in classic CIA (Figure 5B). 
Histology performed in the highest dose group confirmed the pronounced suppression of 
cellular infiltration and cartilage damage (Table 2), as noted with neutralizing anti-IL-1 
antibodies. In addition to histology, we performed autoradiography to get an impression of 
the metabolic activity of the articular chondrocytes. Pronounced suppression of 3 5 S-sulfate 
incorporation, reflecting inhibited proteoglycan synthesis, was noted in the control, arthritic 
mice at day 42. In contrast, the IL-1Ra treated animals showed m arked 3 5 S-sulfate 
incorporation, not different from metabolic activity found in nonarthritic DBA mice (Figure 
3). This indicates that IL-1 is a pivotal mediator in this suppression.
Relative role o f IL-1 a  and IL-1fi
To investigate the relative contribution of IL-1 a  and IL-1 p, we injected mice with either rabbit 
polyclonal anti-IL-1 a  or anti-IL-1 p, starting at day 32. Selective neutralization of IL-1p was 
sufficient to cause marked suppression of arthritis (Figure 6 ). In a repeat experiment (not 
shown) we used hamster monoclonal anti-IL-1 p antibodies, showing roughly similar efficacy. 
In contrast to the pronounced effect of anti-IL-1 p, we did not observe a major suppression 
with selective anti-IL-1 a  treatment. However, it is clear that the most optimal suppression 
was reached with the combination (Figure 6 ).
Cytokine mRNA levels in the arthritic joint
In a repeat experiment groups of mice were treated with anti-IL-1p, either at day 32 or 35 and 
mRNA was extracted from the synovial tissue and patellar cartilage at day 40. The time course 
of the arthritis is shown in Figure 7A, again approving efficacy of anti-IL-1p. Cytokine mRNA 
levels, as approached by PCR analysis are shown in Table 3. In inflamed synovium a marked 
increase, as compared with normal synovium, was found for IL-1p and IL-1Ra, whereas the 
enhancement of TN Fa and TIMP message was less impressive. Treatment with anti-IL-1p 
markedly reduced IL-1 message. This is further illustrated with competitive PCR with an 
internal standard (Figure 7B). Of interest, IL-1Ra message was also markedly reduced upon 
anti-IL-1 p treatment, suggesting tight coupling with IL-1. In contrast, the TIMP levels 
remained constant.
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T ab le  3. Levels of cytokine mRNA in inflamed tissue samples at day 40.
Cytokine Synovium# Cartilage
Anti-IL-1p@ Anti-IL-1p
Control Day 32 Day 35 Control Day 32 Day35
IL-1ß 322& 13 13 13& 13 13
IL-1Ra 322 25 25 47 47 47
TNFa 13 4 4 4 4 4
TIMP 7 7 7 4 4 4
# At day 40 synovium and cartilage samples were isolated as mentioned in M&M section.
@ Start of anti-cytokine treatment. & Relative level of mRNA, compared to control (non-immunized DBA mice) 
synovium or cartilage. A 24 fold decrease of mRNA level for IL-1p was found after treatment with anti-IL-1 p 
antibodies. No differences were found in mRNA on day 40 when treatment was started at either day 32 or day 35. 
The presented data are the mean of three experiments.
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In the arthritic cartilage a similar trend of cytokine expression was observed, although values 
seemed less enhanced as compared with the synovium. Remarkably, anti-IL-1 P treatment did 
not reduce message expression in the chondrocytes.
D ISC U SSIO N
TN Fa is of importance at the onset of collagen arthritis, but appears less dominant at later 
stages. In contrast, IL-1 seems a critical mediator both at the onset and at later stages of this 
experimental arthritis. IL-1 dependence is not noted any more, when the disease enters a 
noninflammatory phase, characterized by total cartilage destruction and onset of ankylosis. 
Of interest, IL-1 p seems the more prom inent IL-1 isotype in this type of experimental arthritis. 
Collagen arthritis is an autoimmune process directed against collagen type II (CII) in the 
articular cartilage and the inflammatory process is a combination of local immune complex 
formation at the articular cartilage surface and an effector T cell reaction to CII. The present 
study confirms earlier studies with neutralizing antibodies or soluble TNF receptor (8,9,22), 
showing that elimination of TN Fa just after onset of arthritis clearly ameliorates joint 
inflammation, but does not fully suppress it. Combination therapy of anti-TNFa and anti- 
CD4 yields more protection in collagen arthritis than either treatment alone (42). Anti-CD5 
therapy also caused significant suppression (43). However, one should be very careful with 
anti-T cell treatment, since at late stages of the disease regulatory T cells are involved as well 
and blocking of T cells may then exacerbate arthritis (44).
The relative role of TN Fa and IL-1 in various stages and forms of chronic arthritis is of 
therapeutic relevance, the more so because the present study clearly shows that anti-IL-1 
treatment is superior above anti-TNFa treatment in this particular model and substantiates 
that inhibition of TN Fa does not necessarily inhibit IL-1 production as well. It must be 
underscored that one should be careful with the overall interpretation of data obtained with 
different antibodies, in view of potential differences in neutralizing capacity and half lives in 
vivo. Moreover, antibodies may significantly differ in effector functions, dependent on the 
isotype. In addition to the data presented in this paper we performed experiments with 
polyclonal anti-TNFa (kindly provided by S. Kunkel and G. Grau) and in fact confirmed the 
slight suppression after treatment of established disease (unpublished observations). Our 
current data with anti-TNFa treatment are in line with earlier findings in collagen arthritis 
(8,9,44). Moreover, our anti-TNFa was sufficiently potent to fully block LPS mediated shock, 
whereas anti-TNFa treatment was also highly suppressive in another murine arthritis model, 
streptococcal cell wall (SCW) arthritis ( Figure 4B, 45). Apparently, bacterial triggers provoke 
a more TNF driven process. Anti-TNFa and anti-IL-1 treatment appeared as effective in 
recurrence of SCW arthritis and the best suppression was obtained with the combination of 
anti-IL-1/anti-TNFa (46).
The importance of IL-1 in fully established collagen arthritis is now further substantiated, 
showing identical suppression with anti-IL-1 antibodies and IL-1Ra. Given the limited half 
life of the receptor antagonist, high pharmacokinetics in mice in general and the need to occupy 
almost all IL-1 receptors to block IL-1 action (47,48), it is conceivable that profound 
suppression of established CIA could only be achieved with high levels of IL-1Ra, supplied 
with osmotic mini-pumps. An earlier study showed efficacy of repeated, systemic dosing of 
IL-1Ra before onset of collagen arthritis (49). However, this treatment clearly suppressed the
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anti-CII antibody levels and probably mainly affected cellular processes in the lymphoid organs 
apart from synovial inflammation, which may ask for different pharmacokinetics.
Further com parison with other arthritis models reveals that IL-1 is not a dom inant 
inflammatory mediator in all forms of arthritis. Neither TN Fa nor IL-1 are of key importance 
in the initiating inflammatory process of antigen induced arthritis (26,49,50). Yet, elimination 
of IL-1 fully normalized chondrocyte proteoglycan synthesis inhibition in the articular 
cartilage, proving that IL-1 is a key mediator in this characteristic, undesired disturbance of 
anabolic processes in arthritic cartilage (26). The general validity of the latter role of IL-1 is 
now established by similar findings in immune complex arthritis and in T cell driven flares of 
antigen induced arthritis (51,52).
IL-1 blockade in CIA also profoundly reduced cartilage destruction, even when treatment was 
started late. Since joint inflammation was markedly suppressed as well it can not be excluded 
that the protective effect on the articular cartilage was indirect, through concomitant reduction 
of destructive mediators other than IL-1. Early anti-TNFa treatment also reduced cartilage 
destruction, in line with its anti-inflammatory effect, but at later stages no protection could 
be seen anymore. This excludes a selective, direct role of TNFa in cartilage destruction. Studies 
with anti-IL-1R antibodies in TNF transgenic mice provided further support for this (53). 
Although TN Fa can be destructive to cartilage in vitro (54), relatively high dosages are needed 
and such a role could not be substantiated by intra-articular injection in knee joints of mice 
and rabbits (25). In the presence of low concentrations of IL-1, TN Fa may however synergize 
with IL-1 (55).
To provoke the expression of slumbering collagen arthritis, addition of extra TN Fa appeared 
as powerful as extra IL-1 (17-20). These cytokines can induce chemotactic factors and the fact 
that TGFp, which is a powerful immunosuppressive but also a potent chemotactic factor, can 
also accelerate CIA expression is in keeping with this reasoning (19,20,56,57). Recently, it was 
shown that expression can also be enhanced by systemic LPS administration (30) or by local 
injection ofZymosan (31). Dependent on the dose, the latter injection caused prime expression 
of CIA in the injected joint, or spill over occurred in the draining limb. The inflammation in 
the draining site, in particular, was sensitive to anti-TNFa treatment. However, at both sites, 
anti-IL-1 treatment was superior in suppression (31). Although, it can not be totally excluded 
that LPS acceleration may shift cytokine balances, our present data show similar efficacy of 
anti-TNFa or anti-IL-1 treatment in spontaneous (classic) CIA as compared with LPS 
accelerated CIA.
Although the severity of CIA is generally scored in the paws, profound expression of joint 
inflammation is also seen in the knee joint, this in contrast to a rather selective paw involvement 
in classic adjuvant and SCW arthritis in Lewis rats (58). A great advantage of analysis in the 
knee joint is the higher degree of standardization of histological sections and the allowance 
for detailed analysis of message expression in defined samples of synovial tissue and cartilage 
strips.
Message expression for IL-1p is highly upregulated in both synovium and cartilage. Anti-IL- 
1p treatment profoundly reduced this message in the synovium but, unexpectedly, the 
message in the cartilage remained high. The process in the articular cartilage probably is 
autocrine or paracrine regulated in that phase of the arthritis. Anti-IL-1p antibodies will not 
enter the cartilage and further analysis of message expression and functional analysis of cartilage 
metabolism after IL-1Ra treatment is warranted. TN Fa expression seemed less enhanced as 
compared with IL-1 p, but was nevertheless clearly higher than control values in both synovium
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and cartilage. TN Fa message was also reduced in the synovium after anti-IL-1p treatment, 
indicating that reduced activation of the cells in the synovium, in general, was achieved with 
such treatment.
The first clinical trials with anti-TNFa antibodies in RA patients show promising symptomatic 
relief and analysis of synovial tissue points to decreased expression of adhesion molecules, 
consistent with reduced cell influx and/or local cell activation (3,10,11,12). Efficacy seems 
related to the subclass of antibodies used. Data on protective effects on cartilage destruction 
are lacking sofar. W hether the process of collagen arthritis is close to the hum an disease is of 
course hard to tell, but if so, it would be tempting to speculate that the chronic phase of the 
hum an disease should in  fact be considered as a repetitive flare, given the TN Fa dependence 
of CIA onset and bacterial flares and the relative insensitivity at later stages. It can not be 
excluded that anti-IL-1 treatment would still be superior over anti-TNFa treatment, in 
particular in terms of protection against cartilage destruction. Unfortunately, good neutralizing 
humanized anti-IL-1 antibodies are not available yet and the recent trials with IL-1Ra have 
not been fully analyzed (3,4). Based on our observations of the need of extremely high IL-1Ra 
dosages to affect cartilage proteoglycan synthesis disturbance in AIA (26), or to suppress CIA, 
underdosing in the present clinical trials may be a serious worry. Although it is difficult to 
extrapolate pharmacokinetic findings in mice to demands in hum ans it is hoped that 
substantially higher doses of IL-1Ra are considered for upcoming trials, when the first results 
are mediocre. Meanwhile, it is tempting to further invest in development of selective IL-1 
production inhibitors or inhibitors of IL-1 converting enzyme (ICE). The present data in CIA 
have identified IL-1p as a relevant therapeutic target in this form of experimental arthritis. 
ICE deficient mice have recently been established (59) and proper analysis of various forms 
of arthritis in these knockout mice seems warranted, to further identify IL-1 p or ICE as a valid 
therapeutic target.
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ABSTRACT
Anti-TNFa treatment of rheumatoid arthritis (RA) patients markedly suppresses inflammatory 
disease activity, but so far no tissue protective effects have been reported. In contrast, blockade 
of IL-1 in RA patients, by an IL-1 receptor antagonist, was only moderately effective in 
suppressing inflammatory symptoms, but appeared to reduce the rate of progression of joint 
destruction. We therefore used an established collagen II murine arthritis model (CIA) to study 
effects on j oint structures of neutralization of either TN Fa or IL-1. Both sTNFbp and anti-IL- 
1 treatment ameliorated disease activity when applied shortly after onset of CIA. Serum analysis 
revealed that early anti-TNFa treatment of CIA did not decrease the process in the cartilage 
as indicated by the elevated COMP levels. In contrast, anti-IL-1 treatment of established CIA 
normalized COMP levels apparently alleviating the process in the tissue. Histology of knee 
and ankle joints corroborated the finding and showed that cartilage and joint destruction was 
significantly decreased after anti-IL-1 treatment, but was hardly affected by anti-TNFa 
treatment. Radiographic analysis of knee and ankle joints revealed that bone erosions were 
prevented by anti-IL-1 treatment, whereas the anti-TNFa treated animals exhibited changes 
comparable to the controls. In line with these findings, metalloproteinase activity, visualized 
by VDIPEN production, was almost absent throughout the cartilage layers in anti-IL-1 treated 
animals, whereas massive VDIPEN appearance was found in control and sTNFbp treated mice. 
These results indicate that blocking of IL-1 is a cartilage and bone protective therapy in 
destructive arthritis, while the TN Fa antagonist has little effect on tissue destruction.
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IN T R O D U C T IO N
Tumour necrosis factor alpha (TNFa) is currently being investigated as a target in the efforts 
to treat rheumatoid arthritis (RA). It has been postulated that TN Fa drives most of the 
interleukin-1 (IL-1) production by synovial tissue in RA. Therefore blocking of TN Fa is 
assumed to sufficiently downregulate all facets of the arthritic process (1,2). Several clinical 
trials using anti-TNFa antibodies or soluble TNF receptors in RA patients showed suppression 
of clinical disease and inflammatory activity (3,4). Although the observed effects are indeed 
encouraging with regard to the acute facets of the disease, there is as yet no information 
regarding protective effects against longer term  bone and cartilage destruction.
The first trials with IL-1 receptor antagonist (IL-1Ra) in RA showed significant, but moderate 
suppression of clinical disease activity. However, a beneficial effect on the rate of joint erosion 
progression was suggested in a 6 -m onth clinical trial (5,6).
Inflammation or clinical disease activity appear not necessarily linked to progression of joint 
destruction (7). Studies of the latter component of the disease is difficult to document in 
patients, short of using extremely long trials. Therefore we turned to animal models to allow 
documentation of all parameters, including the process in the joint structures. Murine 
collagen-induced arthritis (CIA) is a widely used experimental model of arthritis and has 
histopathological features in common with RA. It has been shown that neutralization of TNFa 
ameliorates disease activity when administered before or shortly after onset of the disease 
(8,9,10). However, anti-TNFa treatment did not decrease disease activity when given during 
established CIA. Blocking of IL-1, either after onset or during established CIA effectively 
suppresses the arthritic process, recently demonstrated in several studies (12,13).
CHAPTER 3
We now investigated whether neutralization of the monokines TN Fa or IL-1 during CIA 
influences the development of cartilage and bone destruction. Treatment with either sTNFbp 
or anti-IL-1 a+P  was started shortly after onset of disease and clinical as well as effects on the 
tissues were monitored. Serum COMP levels were analyzed as a marker of cartilage pathological 
turnover and radiography was used to determine bone destruction. Expression of the aggrecan 
neoepitope VDIPEN in the cartilage layers, as marker of metalloproteinase activity, potentially 
a component in the destructive process, was demonstrated by immunohistochemistry. 
Furthermore, histology of knee and ankle j oints was performed to investigate the effect of anti- 
TN Fa or anti-IL-1a+P treatment on the joint tissues.
The findings in this study showed that both anti-TN Fa and anti-IL-1a+P treatm ent 
ameliorates the inflammatory component of the disease but only neutralization of IL-1 a+P  
prevents cartilage and bone destruction in CIA.
MATERIALS and  METHODS
Animals
Male DBA-1 mice were obtained from Bomholdgard, Ry, Denmark. Mice were kept in filter 
top cages and were fed a standard diet and tap water ad libitum. Mice were used at 10 to 12 
weeks of age.
Collagen arthritis induction and anti-cytokine treatment
Mice were immunized with 100 |j,g bovine type II collagen in complete Freunds adjuvant 
enriched with Mycobacterium Tuberculosis H37Ra (4 mg/ml) at the base of the tail. Bovine 
collagen was isolated as described elsewhere (13). The mice were boostered i.p. with 100 |j,g 
collagen dissolved in saline. After disease onset at day 28, mice were selected and divided in 
separate groups of at least 10 mice. The mean arthritis score of the control and anti-cytokine 
groups was comparable at the start of treatment. To neutralize TNFa, mice were injected i.p. 
every other day with 3 mg/kg dimerically linked PEGylated soluble p55 TNFRI receptor 
(Amgen, Boulder, CO, USA). This so called TNFbp showed efficacy in murine streptococcal 
cell wall (SCW) arthritis (14). The ED50 of TNFbp to block the cytotoxic effect of m TN Fa in 
the L929 bioassay was 5 x 10- 9  M. To eliminate IL-1a+P, mice received one single injection 
of purified (IgG fraction) rabbit anti-murine IL-1a and anti-IL1P (1 mg Ig’s each). This dose 
revealed to be sufficient to suppress several murine arthritis models such as antigen-induced 
arthritis, immune complex induced arthritis and collagen-induced arthritis (10,11,15,16). One 
microgram of these anti-IL-1 antibodies neutralized 50-100 pg IL-1 in the NOB-1 bioassay. 
As control we used either bovine serum albumin (3 mg/kg) or normal rabbit Ig’s (2 mg i.p.).
Assessment o f collagen-induced arthritis
Mice were carefully examined three times a week for the visual appearance of arthritis in 
peripheral joints, and scores for disease activity were given as previously described ( 1 0 ,1 1 ). 
The clinical severity of arthritis (arthritis score, Figure 1) was graded on a scale of 0-2 for each 
paw, according to changes in redness and swelling. At later time points, ankylosis was included 
in the macroscopic scoring.
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IL-6 bioassay
IL- 6  activity was determined by a proliferative assay using B9 cells. Briefly, 5 x 103 B9-cells in 
200 |jl 5% FCS-RPMI 1640 m edium per well were plated in a round-bottom  mircotitre plate 
and incubated for 3 days using hum an recombinant IL- 6  (R&D systems, Minneapolis, MN, 
USA) as standards. At the end of the incubation, 0.5 |J,G of 3[H]thymidine (NEN-Dupont, 
Boston, MA, USA) was added per well. Three hours later, cells were harvested and thymidine 
incorporation was determined. Detection limit for the IL- 6  bioassay was 1 pg/ml.
COMP measurements
At the end of the experiments, serum samples were taken and murine COMP levels were 
determined by ELISA using similar conditions as described for the assay for hum an COMP 
(17). The assay was modified by using rat COMP for coating the microtiter plates and for the 
standard curve included in each plate as well as by using a polyclonal antiserum raised against 
rat COMP (18). A high cross-reactivity to murine COMP was shown both by parallel dilution 
curves of murine sera to the standard curve as well as by experiments where a dilution of murine 
serum was added to the standard curve.
Radiology and histology
Knee and ankle joints were removed at the end of the experiments and were fixed and used 
for radiographic analysis as a marker for bone destruction. Radiographs were carefully 
examined by using a stereo microscope. Joint destruction was scored on a scale from 0-5, where
0  denotes no damage, 1 m inor bone destruction observed in one enlightened spot, 2  moderate 
changes, 2-4 spots in one area, 3 marked changes, 2-4 spots in more areas, 4 severe erosions 
afflicting the joint and 5 complete destruction of the joints. Radiographs were scored by two 
observers without knowledge of the experimental group. For histology, j oints were decalcified, 
dehydrated and embedded in paraffin (10). Standard sections of 7 |j,m were made and stained 
with either Haematoxylin & Eosin or Safranin O. Serial sections were scored by 2 observers 
on decoded slides. Inflammation was graded on a scale from 0 (no inflammation) to 3 (severe 
inflamed joint) as influx of inflammatory cells in synovium and joint cavity. Cartilage 
destruction and matrix proteoglycan depletion were scored on a scale from 0-3 ranging from 
no abnormalities to completely destroyed or destained (with Safranin O) cartilage. Bone 
erosions were graded on a scale 0-3, ranging from normal bone appearance to fully eroded 
cortical bone structure in patella and femur head ( 1 0 ,1 1 ).
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Immunohistochemical VDIPEN staining
For immunostaining, sections of knee joints were deparaffinized, rehydrated and digested with 
proteinase-free chondroitinase ABC to remove the side chains of the proteoglycans. 
Subsequently, sections were treated with 1% hydrogen peroxide, 1.5% normal goat serum, 
and affinity purified rabbit anti-VDIPEN IgG (Kindly provided by Dr. I.I. Singer and Dr. E.K. 
Bayne, Merck, Rahway, NJ, USA). This antibody has been characterized before (19,20). 
Thereafter sections were incubated with biotinylated goat anti-rabbit, and avidin-streptavidin- 
peroxidase (Elite kit, Vector Labs, Burlingham, CA, USA) staining was performed. 
Counterstaining was done with orange G.
Statistical methods
The significance of difference between group means was determined by a M ann Whitney 
U-test in the program SigmaStat.
CHAPTER 3
RESULTS
Amelioration o f clinical disease activity by both sTNFbp and anti-IL-1 treatment 
Anti-TNFa treatment by injection of sTNFbp ameliorated clinical expression of CIA when 
started shortly after disease onset (Figure 1A). Significant reduction of joint swelling and 
redness was noted after 4 days of treatment. Blockade of IL-1 during established CIA resulted 
in marked suppression of clinical disease activity as can be seen in Figure 1B. Actually, one 
single injection of anti-IL-1a,p antibodies was sufficient to reduce clinical signs. The anti­
inflammatory effect of both sTNFbp and anti-IL1a+P was further demonstrated by the reduced 
serum IL- 6  levels determined at the end of treatment (Figure 2.). IL- 6  can be viewed as an 
acute phase protein as described previously (21). The strong reduction of serum IL- 6  indicated 
that TN Fa was sufficiently neutralized by sTNFbp treatment
COMP, a circulating marker o f cartilage turnover is decreased by anti-IL-1 treatment 
To obtain further insight into the protection against cartilage destruction, we determined serum 
COMP levels in the various groups. COMP is released from cartilage as a result of increased 
turnover in hum an and experimental arthritis (17,18, 22). Figure 3A shows a strong correlation 
in disease with no intervention between clinical arthritis score and serum COMP levels 
(r=0.94). This is in line with previous findings in collagen-induced and pristane induced 
arthritis in rats (18,23). Although treatment with sTNFbp suppressed clinical disease activity 
of the CIA no reduction was found in serum COMP levels indicating little effect on the process 
in the cartilage (Figure 3B). In contrast, strong reduction of serum COMP levels was seen in 
the anti-IL-1a+P treated animals (6.5±0.9 |lg/ml vs 3.4±0.5 |ig/ml).
Figure 1. Suppression of disease activity of 
collagen-induced arthritis (CIA) by either 
sTNFbp or anti-IL-1a+ß treatment. Mice 
expressing CIA were selected at day 28 after 
immunization of CIA and were divided into 
separate groups of at least 10 mice. Mice were 
injected with 3 mg/kg sTNFbp (A) every other 
day or with one single injection of 1 mg purified 
rabbit anti-IL-1a and anti-IL-1 ß (B). As control 
for sTNFbp, BSA was used. Normal rabbit Ig’s 
control for anti-IL-1a+ß. Disease activity was 
visually scored as described in M&M section. 
Data are expressed as mean±SD. *P<0.01, 
Mann-Whitney U-test, compared to control.
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Figure 2. Serum IL-6 levels after blockade of 
either TNFa or IL-1. IL-6 levels were 
determined at day 36 after treatment with either 
sTNFbp or anti-IL-1 by using B9-cell bioassay. 
For treatment protocol see Figure 1. Data are 
expressed as mean±SD of at least 7 mice 
per group. *P<0.01, Mann-Whitney U-test, 
compared to arthritic vehicle treated animals.
Figure 3. IL-1 neutralization reduced serum 
COMP levels. Serum COMP were determined 
in sera of arthritic mice expressing different 
disease activity at day 36 after immunization 
(A). Strong correlation was found between 
disease activity and circulating COMP levels, 
r=0.94. B, serum COMP levels, determined at 
day 36 after treatment with either sTNFbp or 
anti-IL-1a+ß. For details see Figure 1 and 
M&M section. Dotted line indicates serum 
COMP level in normal DBA-1 mice (4.2±0.6). 
*P<0.001, Mann-Whitney U-test, compared to 
control.
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Prevention o f bone erosions by anti-IL-1 but not by sTNFbp treatment
Radiological analysis, as an indicator of bone erosions of knee and ankle joints, revealed that 
elimination of TN Fa in established CIA did not retard the radiological progression of bone 
destruction (Figure 4). The lack of an effect on bone destruction was further illustrated in Figure
4, which shows erosive processes in knee joints on femur and tibia. In contrast, anti-IL-1a+p 
treatment abolished bone erosions as demonstrated in Figure 4. Figure 5 further emphasizes 
the protective effect of the anti-IL-1 treatment.
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Figure 4. Effect of either anti-TNFa or anti- 
IL-1a+ß treatment on joint destruction. Joints 
were X-rayed on day 36 after induction of CIA. 
Destruction was graded from X-ray 
photography by scoring bone erosions on a 
scale from 0 (no alterations) to 5 (completely 
destroyed joints). For treatment protocol see 
M&M section. Data represent the mean±SD X- 
ray score of at least 20 joints. *P<0.001, M ann­
Whitney U- test compared to control.
Figure 5. IL-1 blockade prevents bone erosions. X-ray photographs taken at day 36 after treatment with either 
sTNFbp or anti-IL-1a+p. A: knee joint of control, rabbit Ig’s treated group, marked zones of bone erosions were 
found in the head of the femur and in the patella (arrows). B: clear protection against joint destruction after blocking 
IL-1a+p during established CIA. C: No improvement of radiological joint destruction after sTNFbp treatment, 
compared to control. No differences in bone erosions were noted between the two control groups.
Effect o f neutralization o f TNFa or IL-1 on joint pathology as demonstrated by histological 
examination
To confirm that IL-1 has a key role in cartilage and bone destruction in j oint disease, we graded 
pathology on sections of whole knee joints. Table 1 shows that sTNFbp treatment reduced the 
inflammatory process, determined as the amount of cells in the synovium and joint cavity, 
but had only marginal effect on cartilage damage, matrix proteoglycan depletion and bone 
erosions. This is further illustrated in Figure 6 . Almost complete prevention of cartilage and 
bone damage was achieved by anti-IL-1 a+P  treatment during established CIA (Table 1, Figure 
6). 49
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Blocking o f IL-1 prevents VDIPEN neoepitope expression
VDIPEN neoepitope is a marker of metalloproteinase (MMP)-mediated cleavage of aggrecan, 
the major proteoglycan of articular cartilage. Previous studies have revealed that VDIPEN 
neoepitope was more abundant at sites and stages of advanced damage (19). To further 
demonstrate the protective effects on cartilage by anti-IL-1  a+P  treatment, sections were stained 
for this neoepitope. As a typical example, VDIPEN was highly expressed throughout the
T ab le  1 . Effect of sTNFbp or anti-IL-1 treatment on cartilage pathology.
Treatment Infiltration of cells Cartilage damage Proteoglycan
Depletion
Bone
Erosions
Control(BSA) 1.5±0.7 1.8±0.6 2.3±0.9 2.2±0.7
STNFbp 0.7±0.6 1.5±0.7 2.0±0.8 1.8±0.5
Control (Ig’s) 1.8±0.6 1.6±0.5 2.1±0.5 2.5±0.9
Anti-IL-1a+ß 0.4±0.3* 0.4±0.3* 0.5±0.4* 0.6±0.3*
Joint pathology was examined after treatment either with 3 mg/kg sTNFbp every other day or with one single 
injection rabbit anti-IL-1 a+ß (1 mg each). Histology was performed on whole knee joints as described in M&M 
section. Scoring was performed by two independent observers on decoded slides. *P<0.001, Mann-Whitney U- 
test, compared to controls.
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Figure 7. Expression of cartilage proteoglycan breakdown neoepitope VDIPEN. Fully affected cartilage in control 
rabbit Ig’s (A) and sTNFbp (B) treated animals. Note the marginal expression of VDIPEN in cartilage of anti-IL- 
1a+p exposed mice (C). VDIPEN expression was determined at day 36. No difference was found in VDIPEN expression 
between the two control groups, BSA and rabbit Ig’s. P=patella, F=femur. Original magnification 100x.
cartilage layers of the patella and femur in sections of vehicle treated animals (Figure 7A). 
Elimination of TN Fa for 8  days, initiated shortly after onset of CIA, did not reduce VDIPEN 
neoepitope expression in cartilage, as can be seen in Figure 7B. In contrast, VDIPEN expression 
was almost absent in cartilage of anti-IL-1a+P treated animals (Figure 7C).
50
Figure 6 . Histopathology at day 36 of knee joints after treatment with either sTNFbp or anti-IL-1a+p. A: Severe 
inflammation and cartilage destruction (arrows) in control, BSA treated animal. B: complete loss of matrix 
proteoglycans, indicated by destained cartilage layers, in control group. C,D: knee joint of an animal treated with 
sTNFbp, although reduced infiltrate no ameliorated cartilage pathology when compared to control. E,F: Almost 
homogeneous Safranin O staining indicated a cartilage protective therapy by anti-IL-1 treatment. Furthermore, 
markedly reduced inflammation by the latter treatment. No difference was seen between the two control groups. A, 
C, E Haematoxilin & Eosin staining. B, D, F Safranin O staining. P=patella, F=femur, C=cartilage, JS=joint space. 
Original magnification 100x.
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D ISC U SSIO N
The onset of clinical symptoms and inflammation in collagen type II arthritis is TNFa 
dependent which is in line with a role of this cytokine also in hum an RA (24). Studies with 
neutralizing anti-TNFa antibodies or soluble TNF receptors have revealed a major suppressive 
effect of the clinical disease activity, when treatment was started directly after onset of CIA 
(8,9). Recently, we showed that when arthritis is fully expressed, subsequent blocking of TNFa 
appeared only marginally effective, implying that TN Fa is crucial in onset but less important 
in propagation of arthritis (10). In contrast, neutralization of IL-1a+P in early and established 
stages of CIA markedly suppressed disease activity (10,11). It has been shown that IL-1P is the 
pivotal cytokine in collagen type II arthritis regarding disease expression by using anti-IL-1p 
antibodies in DBA-1 mice, by studies of CIA in IL-1 P deficient mice and by administration of 
IL-1P-converting enzyme (ICE) inhibitors (10,11,25,26). Furthermore, it was showed that local 
inflammation was impaired in ICE deficient mice (27). In the present study, we investigated 
whether blocking of TN Fa or IL-1 during established CIA would in addition to suppressing 
inflammatory disease activity prevent tissue destruction. As demonstrated previously, anti- 
TN Fa treatment ameliorated CIA when started after onset of disease. In spite of the fact that 
suppression of clinical appearance of CIA and reduced serum IL- 6  levels were found by early 
anti-TNF treatment, serum COMP levels, cartilage damage and bone destruction was not 
affected showing that j oint destruction is progressing. COMP is a major component of articular 
cartilage and serum levels are considered as a marker of generalized cartilage turnover (17,22). 
In joint disease, the contribution from other tissues, e.g. synovia, which has been shown to be 
capable of COMP production (28,29), appears insignificant (Saxne and Heinegard, 
unpublished). Thus, we have found that serum COMP levels were increased after the 
occurrence of cartilage destruction in CIA in both rats and mice, while in early stages of CIA 
with marked inflammation no elevation of serum COMP was found (Saxne and Joosten 
unpublished, Larsson and Saxne unpublished). Corroborating the strong suppression of CIA 
and a cartilage protective effect by anti-IL-1 a+P  treatment, no elevated serum COMP levels 
were found in anti-IL-1treated animals. This was further supported by VDIPEN neoepitope 
appearance in the cartilage layers. Marked presence of this neoepitope was found throughout 
the cartilage in control and sTNFbp treated animals, whereas animals treated with anti-IL- 
1a+P had almost no VDIPEN neoepitope. This neoepitope is formed by proteolytic cleavage 
of aggrecan by metalloproteinases. The fragment remains attached to hyaluronan in the 
cartilage, as an indicator of the proteolytic activity (30). In the model of antigen-induced 
arthritis we noted that VDIPEN expression depended primarily on effects of IL-1 and the 
location correlated with severe cartilage damage (19). More recently, it was demonstrated that 
VDIPEN expression reflects stromelysin (MMP-3) activity, since expression was absent in 
stromelysin deficient mice (31).
Histological analysis of knee and ankle joints revealed that elimination of IL-1 a+P  starting 
after onset of disease, reduced joint inflammation, cartilage damage, loss of matrix proteoglycan 
and bone erosions. The primary effect of treatment by sTNFbp injections was a decreased influx 
of inflammatory cells. Previous studies with anti-TNFa antibodies or sTNF receptor protein 
in CIA reported significant reduction of clinical disease activity, but hardly any measurable 
effect on cartilage or bone destruction (8,9,10). Although anti-TNFa treatment was started 
directly after onset of disease, 75% of the animals developed moderate or severe cartilage 
erosions (8 ).
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IL-1 appears to be an efficient mediator, since in the zymosan-induced experimental arthritis, 
it is clearly demonstrated that IL-1 is responsible for the inhibition of chondrocyte proteoglycan 
synthesis. This suppressive effect appeared mediated by nitric oxide, since NOS2 gene 
knockout mice while having inflammation showed no inhibition of chondrocyte metabolism 
(32). Furthermore, it has been demonstrated that blocking of IL-1 activity prevented cartilage 
proteoglycan depletion in murine antigen-induced arthritis, indicating protection against 
cartilage damage (15). Interestingly, in this latter experimental arthritis anti-IL-1 treatment 
did not ablate joint inflammation.
The first clinical trials with IL-1Ra in hum an RA demonstrated that IL-1Ra has a beneficial 
effect on the rate of progression of joint erosion as well as suppressing inflammatory disease 
activity (5,6). Anti-TNFa treatment on the other hand seems to be somewhat more effective 
in suppressing clinical disease activity, i.e. primarily inflammation. However, there are as yet 
no published data on effects of anti-TNFa treatment on the progression of joint erosions (3,4). 
We have preliminary data showing that in RA patients treated with hum an anti-TNFa (D2E7) 
serum COMP levels were not reduced, although impressive reduction of disease activity was 
seen. Furthermore, IL-1P expression in synvial biopsies were not changed by anti-TNFa 
treatment. This argues against TN Fa dependent IL-1 production in RA synovium (manuscript 
in preparation).
The present study indicates that blocking of IL-1 during arthritis represents therapy that 
protects the cartilage and bone structures. This is demonstrated by reduced serum COMP levels, 
reduced appearance of the VDIPEN neoepitope in cartilage, joint histopathology with 
abolished erosions of the articular cartilage as well as absence of radiographically detectable 
bone erosions.
The effects of IL-1 inhibition, at the same time as TN Fa inhibition has little effects on tissue 
destruction, may appear puzzling. However, it is known that chondrocytes and osteoblasts 
may produce IL-1 (33). It is thus possible that the initial events include setting up a cycle with 
self-activated destruction in cartilage and bone. In view of these findings, although TN Fa 
inhibitors may relieve the actual clinical picture, the long-term outcome with regard to joint 
destruction is likely to have the same bad prognosis. Therefore, to suppress the inflammation 
and offer protection against tissue destruction, combinations of TN Fa and IL-1 inhibition 
should be tested.
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ABSTRACT
In this study two different aspects of tum our necrosis factor a  (TNFa) and interleukin-1 (IL- 
1) in locally induced murine streptococcal cell wall arthritis (SCW) were investigated. First, 
the kinetics and interdependence of TN Fa and IL-1 release; and second, their involvement in 
inflammation and cartilage destruction. Kinetic studies showed that the TN Fa peak level 
preceded the IL-1 peak level. However, in vivo neutralization of TN Fa did not result in 
decreased IL-1 bioactivity or immunoreactivity, suggesting that there is no dominant TNFa 
dependent IL-1 release in this model. Inflammation was studied by measuring knee joint 
swelling and inflam m atory cell influx. Impact on cartilage was studied by measuring 
chondrocyte proteoglycan synthesis and cartilage proteoglycan depletion. The role of TNFa 
in these phenomena was investigated using anti-TNFa antibodies and tum our necrosis factor 
binding protein (TNFbp). Similarly, the role of IL-1 was studied using anti-IL-1 antibodies or 
IL-1 receptor antagonist (IL-1Ra). Anti-TNFa treatment significantly reduced joint swelling, 
whereas this effect was not found using anti-IL-1 or IL-1Ra. In contrast, neutralization of IL-
1, but not TNFa, resulted in a significant decrease of chondrocyte proteoglycan synthesis 
inhibition. Moreover, histology revealed that anti-IL-1 treatm ent reduced cartilage 
proteoglycan depletion and inflam m atory cell influx. Combined anti-TNFa/anti-IL-1 
treatment significantly suppressed both inflammation and cartilage damage. However, the 
impact on these separate parameters did not exceed the effects of either anti-TNFa or anti- 
IL-1. It can be concluded that both TN Fa and IL-1 exert specific activities in SCW arthritis. 
The involvement of TN Fa in this model is limited to joint swelling, whereas IL-1 plays a 
dominant role in cartilage destruction and inflammatory cell influx.
INTRODUCTION
Rheumatoid arthritis (RA) is characterized by chronic inflammation of multiple joints and 
marked destruction of cartilage and bone. The pathogenesis is largely unknown. RA is 
generally considered as an autoimmune disease, with primary or secondary involvement of T 
cells, bu t particular antigens have not been identified yet, thus ham pering specific 
im m unomodulation as a therapeutic approach. On the other hand, evidence is accumulating 
that the inflammatory process in the synovial tissue is dominated by activated monocytes and 
fibroblasts. Cytokines and cytokine inhibitors derived from these cell types can be abundantly 
found and it is now commonly accepted that tum our necrosis factor a  (TNFa) and interleukin- 
1 (IL-1) are pivotal mediators in the RA process (1-5). Clinical trials reveal that TNFa 
neutralization provides substantial relief of RA symptoms, such as pain and number of swollen 
joints (6,7). It is promising to note that the recent trial with IL-1Ra suggests that IL-1 blocking 
results in amelioration of joint erosions (8,9). Further insight in the role of TN Fa and IL-1 in 
inflammation and cartilage destruction has emerged from studies in experimental arthritis. 
In murine models, using zymosan, immune complexes or T cell allergens as arthritogenic 
stimuli, it was shown that cartilage destruction was highly dependent on IL-1, whereas TNFa 
involvement was limited (10,11). In the autoimmune model of murine collagen induced 
arthritis, TN Fa appeared to be im portant at the onset of arthritis but less so in later stages, 
whereas IL-1 plays a pivotal role at both early and late disease (12). Elegant studies in TNF 
receptor knockout mice showed lower incidence and severity of collagen induced arthritis, yet
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full progression to end stage arthritis, once a joint was seriously afflicted (13). This also 
emphasizes that progression to tissue destruction does occur in a TNFa-independent way. In 
the present study we further defined the relative role of TN Fa and IL-1 in a model of murine 
bacterial cell wall arthritis. We selected streptococcal cell wall fragments (SCW) as an 
arthritogenic trigger, related to its potent capacity to induce TNFa production in macrophages. 
Since it is claimed that TN Fa is driving most of the IL-1 production in RA synovial tissue, 
special attention was paid to the putative presence of a TN Fa ^  IL-1 cascade in this arthritis 
model (4). Moreover, we focused on the relative role of TN Fa and IL-1 in joint swelling, cellular 
infiltration and cartilage destruction, using cytokine specific blockers. It was found that TN Fa 
was directly involved in joint swelling, whereas IL-1 was the principle cytokine in cartilage 
destruction. Blocking of TN Fa did not provide full protection, which was in line with the 
absence of a clear TN Fa ^  IL-1 cascade in this model.
MATERIALS and  METHODS
Animals
Female C57B1/6 mice were obtained from Charles River (Germany). Female LPS-non- 
responsive C3H/HeJ mice were obtained from Jackson (Bar Harbor, ME). All mice were fed 
a standard diet and tapwater ad libitum. In all experiments performed mice were 12 to 16 
weeks of age.
Cytokines and neutralizing anti-cytokine factors
Murine recombinant TN Fa (carrier free) was purchased from R&D Systems Ltd (Europe). 
Rat anti-murine TN Fa monoclonal antibodies (Vlq) were isolated from ascites fluid obtained 
from an injection of hybridomas in mice, which were kindly given by P.H. Krammer (German 
Cancer Research Center, Heidelberg, Germany). This antibody showed efficacy in the LPS- 
mediated lethal shock model (36). A dimerically linked, PEGylated p55 STNFRI receptor 
(tum our necrosis factor binding protein, or TNFbp) was synthesized and described elsewhere 
(37,38). Neutralizing capacity was verified in the L929 bioassay for TNF. Both neutralizing 
factors did not interfere with the IL-1 specific NOB-1/CTLL2 proliferation assay. Control rat 
immunoglobulins (RaIg’s) for anti-TNFa were purchased from Sigma (St Louis, MO). Saline, 
containing 40 |j,g bovine serum albumin (BSA), served as control for TNFbp. Purified and 
biologically active murine recombinant IL-1 a  and IL-1P were generously donated by I.G. 
Ottterness (Pfizer Central Research, Groton, CT). Purified hum an recombinant IL-1Ra was 
obtained from Amgen (Boulder, CO) and synthesized as described (39). Polyclonal rabbit 
antibodies directed against each type of m urine recom binant IL-1 were prepared by 
immunization as described elsewhere (10). The IL-1a and IL-1P antibodies showed no 
neutralizing cross-reactivity against each other, nor against IL-2 as tested in the NOB- 
1/CTLL-2 proliferation assay, IL-4 in the CT.4.S proliferation assay and TN Fa in the L929 
cytotoxicity assay. Control rabbit antibodies (RIg’s) for the anti-IL-1 antibodies were purchased 
from Sigma (St Louis, MO).
Preparation o f streptococcal cell walls and induction o f arthritis
The SCW suspension was prepared as described elsewhere (40). Briefly, Streptococcus pyogenes 
T12 organisms were cultured in Todd-Hewitt broth and after 24h the cells were harvested.
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Cells were disrupted with glass beads and sonification. The material was subsequently treated 
with various degrading enzymes and further isolated by differential ultracentrifugation steps 
and the resulting 10.000 x g supernatant was used in all experiments (41,42). The LPS content, 
as tested in the Limulus amebocyte assay, was <30 pg/6 |jl. Streptococcal cell wall arthritis was 
induced by a single i.a. injection of 6  |jl containing 25 |j,g SCW (rhamnose content) in saline 
into the right knee joint (40).
Anti-cytokine treatment o f mice 
Anti-TNFa treatment
Mice were given an intraperitoneal injection of 30 ju,g monoclonal rat antibodies directed against 
murine TN Fa (anti-TNFa) in 200 |jl, 1h before arthritis induction. Control mice were given 
the same amount of normal rat Ig’s. The neutralizing capacity of anti-TNFa used in this study 
was 3,5 ng TN Fa per |j,g anti-TNFa, as tested in the L929 bio-assay.
Treatment with TNFbp
Mice received an intraperitoneal injection of 200 |jl (2 mg/kg) TNFbp 1h prior to arthritis 
induction. Control mice were given 200 |jl, saline supplemented with 40 |j,g BSA. The ED50 
of TNFbp to neutralize the cytotoxic effects of TN Fa in the L929 assay was 5 x 10- 9  M (37). 
Anti-IL-1 (a,P,) antibody treatment
Mice were injected intraperitoneally with a 200 |jl standard dose of 2 mg purified rabbit 
antibodies directed against murine IL-1, 1h before arthritis induction. One microgram of 
purified Ig’s neutralized 50-100 pg IL-1 in the NOB-1 bioassay. Rabbit Ig’s, 2 mg/mouse, served 
as control for the non-specific effects of treatment.
Treatment o f mice with IL-1Ra 
Mini-osmotic pumps (Alzet 1007D, Alza corp., Palo Alto, CA) were implanted into the 
peritoneal cavity two days before arthritis induction, and set to release 50 |j,g of IL-1Ra per 
hour for the next 7 days. Pumps filled with BSA (50 |J.g/h) were used as control.
Combined anti-TNFa and anti-IL-1a,P treatment 
Mice were injected intraperitoneally with 200 |jl saline containing 30 |j,g rat anti-TNFa 
antibodies together with 2  mg rabbit anti-IL-1a,P antibodies 1h prior to arthritis induction. 
Control mice were injected with a total volume of 200 |jl containing 30 |j,g rat Ig’s and 2 mg 
rabbit Ig’s.
Prolonged anti-cytokine treatment
For histological analysis, intraperitoneal injections of anti-TNFa were repeated at days 2, 4 
and 6 .
Cytokine release by synovial tissue
Patellae were dissected with surrounding soft tissue consisting of the tendon, and synovium 
in a standardized manner. Each patella was incubated in 200 |jl serum free RPMI 1640 medium 
(Dutch modification) with Glutamax-1 (Gibco BRL, Life Technologies, Schotland, UK) for 
1h at room  temperature. Dilutions of these washouts were tested for their immunoreactive 
content of TNFa, IL-1 a  and IL-1P as well as for their bioactivity.
Radioimmunoassay for TNFa, IL-1a and IL-1P
T N Fa culture supernatants were m easured in duplicate by a non-equilibrium  
radioim m unoassay (RIA) as described elsewhere (43). Briefly, standards and culture 
supernatants were diluted in a RIA-buffer pH 7.4, 100 fxl polyclonal rabbit anti-murine TNFa,
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IL-1 a  or IL-1 P antiserum dilution in RIA-buffer was added to 100 fxl of samples and standards 
and kept on ice. After vortexing, the tubes were incubated for 24h at 4°C. Subsequently, 100 
|jl of the appropriate 125I-labelled TNFa, IL-1a or IL-1P containing approximately 10.000 
cpm was added to each tube, and incubation was continued for a further 24h at 4°C. To separate 
bound and free tracer, 750 |jl of RIA buffer containing 9% (W/V) polyethylene glycol 6000 
(Merck Diagnostica, Darmstadt, Germany), and 3% (W/V) goat-anti-rabbit serum was 
added. The tubes were incubated for 20 min. at room  temperature and then centrifuged at 
1500g  for 15 min. Supernatants were discarded carefully and quickly drained on adsorbent 
paper. Remaining radioactivity was counted in a gamma counter. The radioactivity in control 
tubes (the non-specific binding activity) was subtracted from samples and standards. The 
detection limit of the assay was 40 pg/ml for TN Fa and 20 pg/ml for IL-1a and IL-1P.
TNF bioassay
Bioactive TNF was measured as the cytotoxic activity against murine L929 fibroblasts as first 
described by Wang et al (44). Briefly, L929 fibroblasts were seeded at 4 x 105/well in a flat- 
bottom  96-well plate, in RPMI 1640 (Dutch modification) with Glutamax-1 supplemented 
with 10% fetal calf serum (FCS), 1% pyruvate and 0.1% gentamycin. The cells were incubated 
for 18h, after which non-adherent cells were removed by washing with RPMI-1640. Samples 
were added in different dilutions after which 1 |J.g/ml actinomycin D was added. After 18h of 
incubation, supernatants were discarded, the monolayer washed with 0.9% saline and the 
adherent cells stained with crystal violet (0.05% in 20% ethanol) for 10 min at RT. Plates were 
washed with tap-water and allowed to dry, after which methanol was added to elute stain from 
cells. Colour intensity was measured with a microtitre plate at a density of 560 nm. Standard 
curves of cell death were determined using murine recombinant TN Fa (R&D systems Ltd, 
Europe); the detection limit of the cytotoxicity assay was approximately 1 pg/ml.
IL-1 bioassay
IL-1 activity was measured in the one-stage bioassay for IL-1 as described by Gearing et al.(45). 
The murine thymoma cell line EL-4 NOB-1 (ECACC, Porton Down, Salisbury, UK) was used 
as an IL-1 specific cell, producing IL-2 in response. This cell line was used in combination with 
the IL-2 sensitive CTLL-2 cell line (ECACC, UK). Samples were added in serial dilutions after 
which the cells were seeded in concentrations of 2.5 x 105/Well NOB-1 cells and 8  x 104/well 
CTLL-2 cells in RPMI 1640 (Dutch modification) supplemented with 5% FCS. After 18h-20h 
of incubation, 0.5 |j,Ci/well of [3H]-Thymidine (specific activity 20 Ci/mmol, Dupont, NEN 
products, Boston, MA) was added. Three hours later, cells were harvested and thymidine 
incorporation (NOB-1 cells are thymidine kinase deficient) was determined. The detection 
limit of the proliferation assay was 0.1 pg/ml murine recombinant IL-1 (46).
Assessment o f joint swelling
Animals were injected subcutaneously in the neck region, with 10 |j,Ci 99mtechnetium 
pertechnetate (99mTc) in 200 |jl saline (47,48). In 15 min., the isotope accumulated in the 
knee due to the increased blood flow and edema, and the am ount of 99mTc was determined 
by external gamma counting. Joint swelling was expressed as the ratio of the 99mTc uptake in 
the inflamed (right) knee joint over its non-inflamed (left) counterpart. A R/L ratio over 1.10 
was indicated as joint swelling.
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Assessment o f chondrocyte proteoglycan synthesis
In vitro 35S incorporation was measured as previously described (49). Briefly, patellae with a 
m inim um  amount of adjoining synovium, tendon and muscle, were separately placed in 2 0 0  
|j,l RPMI 1640/HEPES medium (Life Technologies, Irvine, UK) supplemented with gentamicin 
(50mg/1), L-glutamine (2 mM) and 4 |j,Ci [35S]sulfate. At the end of a 3h incubation period, 
patellae were rinsed with saline, fixed in 10% formalin, decalcified in formic acid (5%), dissected 
and then dissolved in 0.5 ml Lumasolve (Omnilabo, Breda, The Netherlands). The 35S content 
of each patella was measured by liquid scintillation counting. Data are presented as a 
percentage of normal chondrocyte proteoglycan (PG) synthesis.
Histological processing and analysis o f knee joints
Knee joints were dissected, fixed, decalcified, dehydrated and embedded in paraffin (14,50). 
Standard frontal sections of 7 |j,m were prepared and stained with haematoxylin and eosin 
(H&E) for inflammation measurements. They were stained with Safranin O and counter 
stained with fast green for cartilage proteoglycan (PG) measurements. Inflammation was scored 
by influx of inflammatory cells in the joint cavity and in the synovium. They were scored as 0 
when there was no cell influx and 1 to 3 according the the degree of cell influx. Cartilage PG 
depletion scoring was performed on the patella, the patellar side of the femur, the tibial side 
of the femur and the tibia. The mean score of all slides was given. Cartilage PG depletion was 
visualized by diminished staining of the matrix and scored as 0 when normal and 1 to 3 
according to the degree of cartilage PG depletion (loss of staining). Scoring was performed by 
two independent observers on decoded slides.
Statistics
Statistical analysis were performed using the one-tailed Wilcoxon Signed Rank test. A value 
of P< 0.05 was considered as significant.
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RESULTS
Streptococcal cell wall arthritis
A single intra-articular injection of 25 ju,g SCW into the right knee j oint of C57Bl/6 mice resulted 
in an acute joint inflammation. Severe joint swelling was already evident at day 1 after arthritis 
induction, and declined thereafter (Table 1). In the early stages (day 2) macrophage like cells 
and polymorphonuclear cells (PMN’s) infiltrated the synovium (infiltrate) and the joint cavity 
(exudate). At later stages the synovium was dominated by macrophages (day 7). The extent 
of cell infiltrate and exudate was most prominent at day 4 and thus did not parallel j oint swelling 
(Table 1, Figure 1A). At day 2 chondrocyte proteoglycan (PG) synthesis declined to 55% and 
restored gradually thereafter. At day 7 an overshoot of 41 % was seen (Table 1). Severe cartilage 
PG depletion at the patellar, femural and tibial side was observed at days 4 (1.4) and 7 (1.6) 
(Table 1, Figure 1B). Thus, SCW injection in non-immunized mice resulted in a severe but 
transient joint inflammation, resulting in a marked PG depletion. The SCW material was also 
injected into the knee joints of LPS-non-responsive C3H/HeJ mice. The increase in joint 
swelling and the inhibition of chondrocyte PG synthesis during SCW arthritis in LPS-non- 
responsive C3H/HeJ mice was similar to that of C57B1/6 mice (Figure 2). This provides proof 
that the effects found after intra-articular SCW injection were not caused by LPS contamination 
of the SCW material.
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Table 1. SCW-induced joint inflammation and cartilage pathology
Inflammatory cell influx#
Day Joint swelling* Synovium Joint cavity Cartilage PG Chondrocyte&
after (99mTC) (infiltrate) (Infiltrate) depletion@ synthesis
onset ([35S]sulfate)
Day 1 1.8 (0.2) ND ND ND 81 ±4 %
Day 2 1.4 (0 .1) 0.4±0.1 1.1±0.1 0.5±0.1 55±6 %
Day 4 1.2 (0.1) 1.4±0.3 1.2±0.1 1.4±0.1 78±18 %
Day 7 1.1 (0.1) 0.5±0.1 0.2±0.3 1.6±0.4 141±31 %
Time course of arthritis in C57B1/6 mice concerning joint swelling and inflammatory cell influx, after a single 
intra-articular injection of 25 jag SCW into the right knee joint.*Joint swelling as quantified by the 99mTc uptake 
method was expressed as the ratio of the right over the left joint. # Inflammatory cell influx was visualized by 
histology in H&E-stained frontal knee joint sections and scored from 0 (no cells) to 3 (severe influx of cells). 
Scoring was performed in both the synovium and joint cavity. @Histological analysis of cartilage PG depletion 
was performed at the patellar, femural and tibial side. All sides were scored arbitrary from 0 (no depletion = 
strong Safranin 0 staining) to 3 (strong depletion = unstained cartilage). The mean value of all sides is given in 
this table. Scoring was performed by two independent observers on decoded slides. &Chondrocyte PG synthesis 
as measured by 35S-sulfate incorporation was expressed as a percentage of normal chondrocyte PG synthesis. 
The data representing joint swelling and chondrocyte PG synthesis are mean values (± SD) of three experiments, 
each experiment consisted of at least 10 mice/time point. The data representing histology are mean values (± SD) 
of four experiments, each experiment consisted of six mice/time point. ND= not done.
Figure 1. Day 4 of SCW arthritis in C57B1/6 mice.
A. H&E stained frontal knee joint sections. PMN’s and macrophages are infiltrating the synovium and joint cavity.
B. Safranin O stained, fast green counterstained sections. Cartilage PG depletion was visualized by diminished staining 
of the matrix. S = synovium; JC =joint cavity; P = patella; F = femur; C = cartilage. (Original magnification 100x)
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Figure 2. SCW arthritis in C3H/HeJ mice.
SCW 25 |J,g was i.a. injected into the right knee joint of C3H/HeJ 
(open bars) and C57B1/6 (black bars) mice. A. The effects on joint 
swelling were measured at day 1 and 2 of arthritis. B. Proteoglycan 
synthesis inhibition was measured at day 2 of arthritis.
Table 2. Bioactivity of TN Fa and IL-1 expressed as a percentage of the immunoreactive 
amount
Bioactive Immunoreactive %
(pg/ml) (pg/ml)
TNFa (90 min) 43 400 11
TNFa (6h) <1* 250 <1
IL-1 (a+ß) (90 min) 36 405 9
IL-1 (a+ß) (6h) 156 1480 11
Table 2 shows the bioactive fractions of TNFa and IL-1 expressed as a percentage of their respective total amounts 
(as measured using a radioimmunassay). Bioactive TNFa was measured using the L929 cytotoxicity assay. The 
NOB-1/CTLL-2 proliferation assay was used for the detection of bioactive IL-1 (for details see the Materials and 
Methods section). *TNFa, bioactivity was below the detection limit of 1 pg/ml at the 6h time point. The data are 
mean values of 12 sample measurements.
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Local TNFa and IL-1a,ß release in streptococcal cell wall arthritis
To examine the cytokine pattern in SCW arthritis, synovial tissue washouts of the inflamed 
and contralateral joints were assayed for TN Fa and IL-1. A rapid release of TN Fa followed by 
IL-1 was seen, with peak values of TN Fa at 90 min (± 400 pg/ml), IL- l a  at 3h (±500 pg/ml) 
and IL-1 ß at 6 h (±1200 pg/ml) after intra-articular injection of SCW (Figure 3). Comparative 
analysis by RIA and L929 bioassay revealed that approximately 10% of the total am ount of 
TN Fa was biologically active at 90 min (Table 2). At later time points no biologically active
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Figure 3. Synovial cytokine release during the 
SCW arthritis.
C57B1/6 mice received a single i.a. injection of 
25 ^g SCW. At several time points following 
arthritis induction patellae, with adjacent 
synovial tissue, from the inflamed and 
contralateral joints were isolated. The one hour 
washouts of these specimen were tested for 
their immunoreactive TNFa (black bar) 
content (A), as well as their immunoreactive IL- 
1a (open bar) and IL-1p (hatched bar) (B) 
content as measured with a radioimmunoassay. 
For A and B, the 0 hour time point represents 
the amount of TNFa, IL-la or IL-1p found in 
the knee joints of naive mice and the 
contralateral joints of SCW injected mice. Each 
time point represents at least 13 samples.
TN Fa was measurable, indicating that the role of soluble T N Fa was then limited. 
Approximately 10% of the total immunoreactive amount of IL-1 was bioactive at the 90-min 
and the 6 h time point. The proportion bioactive IL-1 to immunoreactive IL-1 did not change, 
indicating that the relationship between IL-1 and its inhibitors does not change during this 
period (Table 2).
TNFa/IL-1 dependence
IL-1 peak levels were preceded by TN Fa peak levels. In order to investigate if TN Fa induced 
IL-1 we neutralized TN Fa and studied the effect on IL-1 release at the 6 h time point. Mice 
were given monoclonal anti-TNFa antibodies (anti-TNFa) 1 h before the SCW preparation 
was administered, and the synovial tissue washouts were collected 6 h thereafter. TN Fa was 
completely blocked at this time point. Instead of a decrease, a significant increase in bioactive 
IL-1 was seen in three out of five experiments (453±173 pg/ml compared to 156±67 pg/ml in 
control mice) (Figure 4), whereas hardly any effect on IL-1 bioactivity was seen in the other 
two experiments (Figure 4). In the latter experiments the total amount of bioactive IL-1 was 
profoundly elevated (approximately 650 pg/ml vs 156 pg/ml in the former experiments). In
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Figure 4. Effect of neutralizing TNFa in SCW 
arthritis on de novo synthesized IL-1.
Mice were pretreated with anti-TNFa or rat Ig’s. 
Six hours after arthritis induction patellae and 
surrounding synovial tissue were isolated. 
Bioactive IL-1 was measured using the NOB-1/ 
CTLL-2 proliferation assay as described in the 
Materials and Methods section. TNFa 
neutralization resulted in a significant increase in 
bioactive IL-1 in three out of five experiments (a) 
but had hardly any effect in the other two 
experiments (b). In the latter (b) experiments the 
mean bioactive IL-1 levels were significantly 
increased as compared to the other experiments 
(a). Values are represented as the mean±SD. Each 
experiment was performed with four mice/group. 
*P<0.01 was considered to be significant as tested 
using the Wilcoxon signed rank test. (black bar), 
control; (open bar), anti-TNFa.
Figure 5. Contribution of TNFa and IL-1 to 
knee joint swelling during SCW arthritis.
A: Mice received a single intraperitoneal injection 
of 30 jig anti-TNFa mAb ( ■  ) or 2 mg anti-IL- 
l(a+ p )  Ig’s ( S  ). Control injections were 
performed with rat Ig’s ( □  ) for anti-TNFa and 
rabbit Ig’s for IL-1 ( £2 ). B: Mice were given 
TNFbp (2 mg/kg) (■ ) by intraperitoneal injection 
or IL-IRa (£2) (50 jitg/h) in mini-osmotic pumps. 
As a control for TNFbp an intraperitoneal 
injection of saline, supplemented with 40 jag BSA 
( □  )> was given and as a control for IL-IRa, 
pumps with BSA were implanted. Effects on joint 
swelling were studied at day 1 and day 2 using the 
99mTc distribution method and expressed as the 
ratio of the 99mTechnetium uptake in the 
inflamed joint over its contralateral counterpart. 
Statistical analysis was performed using the 
Wilcoxon signed rank test. Four experiments were 
performed and mean values±SD are shown. Each 
experiment consisted of at least 10 mice/group. 
*P<0.01.
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contrast to the effects on bioactive IL-1, TN Fa neutralization never affected immunoreactive 
IL-1 a  and IL-1 P in all experiments. Additional studies performed with TNFbp yielded similar 
results. In all experiments performed, TN Fa neutralization never decreased bioactive or 
immunoreactive IL-1. This strongly argues against a dominant TN Fa driven IL-1 production 
in this model. To learn more about the role of TN Fa and IL-1 in SCW arthritis, we tested the 
effect of anti-TNFa and anti-IL-1( a+P) treatment on inflammation and cartilage destruction.
Effect o f anti-cytokine treatment on knee joint swelling
Joint swelling was markedly reduced after TN Fa neutralization. At day 1, the time point where 
swelling was most severe in controls, a significant suppression of 26% was seen in anti-TNFa 
pretreated mice, whereas at day 2 the suppression was even more pronounced: 42% as 
compared to control mice (Figure 5A). Intraperitoneal injections of TNFbp resulted in a similar 
swelling suppression (25% at day 1 and 47% at day 2) as found with the anti-TNFa (Figure 
5B). No effect was seen on knee joint swelling at day 1 or day 2 in anti-IL-1(a+P) treated mice 
(Figure 5A). To confirm the effects found with anti-IL-1(a + P), mini-osmotic pumps 
containing IL-1Ra were implanted prior to arthritis induction. No difference in j oint swelling 
was seen at day 2 in IL-1Ra treated mice compared to controls or mice receiving anti-IL-1(a+P) 
antibodies. The above results show TN Fa to be an im portant factor in joint swelling in murine 
SCW arthritis.
Figure 6 . Contribution of TNFa and IL-1 to 
the inhibition of cartilage proteoglycan 
synthesis during SCW arthritis.
Anti-TNFa mAb, TNFbp or anti-IL-1(a+p) 
Ig’s was administered intraperitoneally 1h 
before SCW arthritis induction. IL-1Ra was 
given in mini-osmotic pumps (for details, see 
the Materials and Methods section). At day 2 
chondrocyte PG synthesis was measured ex vivo 
by incorporation of 35S-sulfate. Chondrocyte 
PG synthesis was expressed as a percentage of 
normal chondrocyte PG synthesis. Three 
experiments were performed and mean 
values±SD are shown. Six mice/group were 
used in each experiment. *P<0.01 was 
considered to be significant as tested in the 
Wilcoxon signed rank test. Rat Ig’s ( □  ); anti- 
TNFa ( ■  ); TNFbp ( ^  ); rabbit Ig’s ( S ) ;  anti- 
IL - la ,P (^ ) ;  IL-R a(H ).
Role o f TNFa and IL-1 in chondrocyte proteoglycan synthesis
TN Fa neutralization with anti-TNFa did not prevent chondrocyte PG synthesis inhibition at 
day 2 (Figure 6 ). In addition to anti-TNFa treatment, mice receiving TNFbp also failed to 
show a diminished chondrocyte PG synthesis inhibition (Figure 6 ). A significant reduction in 
chondrocyte PG synthesis inhibition was seen in mice pretreated with anti-IL-1(a+P). IL-1Ra 
treatment confirmed the anti-IL-1 (a+P) effects, showing that chondrocyte PG synthesis was 
mainly inhibited by the effects of IL-1.
Table 3. Effects of neutralizing antibodies on inflammatory cells in the synovial lining and 
joint cavity.
Day 2 Day 4 Day 7
Infiltrate Exudate Infiltrate Exudate Infiltrate Exudate
Control
anti-TNFa
anti-IL-1(a+P)
anti-TNFa/
anti-IL-1
0.4±0.1 1.1±0.1 1.4±0.3 1.2±0.1 0.5±0.1 0.2±0.3
0.4±0.1 0.9±0.4 1.5±0.3 1.7±0.2* 0.5±0.4 0.2±0.2
0.4±0.2 1.1±0.5 0.8±0.1 0.6±0.1* 0.5±0.4 0.1±0.1
0.4±0.1 0,7±0.3* 1.0±0.3 0.6±0.3* 0.8±0.4 0.1±0.1
Histological analysis of inflammatory cells in the synovium (infiltrate) and joint cavity (exudate) were performed 
at day 2, 4 and 7 after SCW injection using H&E staining. Inflammatory cells in both synovium and joint space 
were scored arbitrary from 0 (no cells) to 3 (severe influx of cells). Scoring was performed by two independent 
observers on decoded slides. The presented data are mean values (±SD) from one representative experiment out 
of four in which six mice/group were used. *P<0.01.
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Figure 7A,B,C,D,E,F. Effects of anti-cytokine treatment on inflammation and cartilage destruction. 
(see page 69 also)
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Figure 7G. Effects of anti-cytokine treatment on inflammation and 
cartilage destruction.
A-C: H&E stained frontal knee joint sections at day 4 of SCW arthritis. 
A: Knee joint section of a mouse treated with 30 |J,g anti-TNFa. B: 
treated with 2 mg anti-IL-1(a+P). C: treated with the combination of 
anti-TNFa and anti-IL-1(a+P). For control knee joint sections, see 
Figure 1A. D-G: Safranin O stained, fast green counterstained knee 
joint sections at day 7 of arthritis. Cartilage PG depletion was visualized 
by diminished staining of the matrix. D: Control knee joint section. E: 
treated with anti-TNFa. F: treated with anti-IL-1(a+P). G: treated with 
the combination of anti-TNFa/anti-IL-1(a+P). S=synovium; JC=joint 
cavity; P = patella; F = femur. (Original magnification 100x)
Table 4. Prevention of cartilage proteoglycan depletion in SCW arthritis by IL-1 
neutralization
Cartilage depletion
Day 2 Day 4 Day 7
Control 0.5±0.1 1.4±0.1 1.6±0.4
anti-TNFa 0.6±0.1 1.5±0.1 1.7±0.5
anti-IL-1(a+ß) 0.5±0.6 1.0±0.1* 1.2±0.6*
anti-IL-1(a+ß)/anti-TNFa 0.3±0.2 1.1±0.3 0.9±0.5*
Mice were treated with either a single intraperitoneal injection of 200 |al/2 mg anti-IL-1 (a+ß) antibodies 1h prior 
to arthritis induction, or received repeated intraperitoneal injections of 200 |jl/30 |J,g anti-TNFa antibodies or a 
combination of both anti-IL-1(a+ß) and anti-TNFa, 1h prior to arthritis induction and at day 2, 4 and 6 of arthritis. 
At day 2, 4 and 7 whole frontal knee joints were isolated and prepared for histology. Histological analysis of 
cartilage PG depletion at the patellar, femural and tibial side was performed by Safranin O staining and fast green 
counterstaining. All sides were scored arbitrary from 0 (no depletion = strong Safranin O staining) to 3 (strong 
depletion unstained cartilage). The mean value (±SD) of all sides is given in this table. Scoring was performed by 
two independent observers on decoded slides. The presented data are from one representative experiment out of 
four in which six mice/group were used. *P= 0.01.
Consequence o f TNFa and IL-1 for joint pathology
For histological analysis at days 4 and 7, repeated anti-TNFa injections were given at days 2, 
4 and 6 . Histology revealed that, in anti-TNFa treated mice no effects were seen on the influx 
of inflammatory cells into the synovium and the joint cavity. There was an exception for day 
4, where an increase of inflammatory cells was found in the joint cavity of anti-TNFa treated 
mice (Table 3). In contrast, IL-1, which was not involved in joint swelling in SCW arthritis,
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played an im portant role in the influx of inflammatory cells. Neutralization of IL-1(a + P) 
resulted in a significant reduction of inflammatory cells (Table 3, Figure 7) both in the synovium 
and the joint cavity which was most pronounced at day 4 of SCW arthritis. Also, in cartilage 
PG depletion a protective effect of anti-IL-1 (a+P) was seen. At days 4 and 7 the progressive 
cartilage PG depletion was significantly reduced, whereas anti-TNFa did not seem to have an 
effect on cartilage PG depletion at all time points measured (Table 4, Figure 7).
Additional effects o f combination therapy
Mice that were treated with both  anti-TN Fa and anti-IL-1(a+P), showed no further 
suppression of joint swelling as compared to the suppression seen with anti-TNFa alone. The 
prevention from  chondrocyte PG synthesis inhibition seen in mice treated w ith the 
combination of anti-TNFa and anti-IL-1(a+P) was comparable to the effect seen in mice 
treated with anti-IL-1(a+P) alone. In addition, histological analysis revealed that also at the 
level of inflammatory cell influx (Table 3) and cartilage PG depletion (Table 4) no other or 
additional effects were seen in mice that received the combined anti-TNFa/anti-IL-1(a+P) 
treatment as compared to mice that were treated with anti-IL-1(a+P) alone. However, the 
benefit of combination treatment over treatment with either anti-TNFa or anti-IL-1(a+P) 
alone was that both inflammation and cartilage destruction were reduced.
D ISC U SSIO N
There is ample evidence that the pro-inflammatory cytokines TN Fa and/or IL-1 are involved 
in animal arthritis (10,14-19). Our objective was to investigate the putative TN Fa —>IL-1 
cascade, the interdependence ofboth cytokines and their effects on joint swelling, inflammatory 
cell influx and cartilage destruction in murine SCW arthritis. The present study demonstrates 
that in SCW arthritis IL-1 release is regulated independently of TN Fa and that IL-1 exerts 
different activities as compared to TNFa. Using TN Fa neutralizing antibodies or TNFbp we 
showed that in this model TN Fa is involved in joint swelling. IL-1, as investigated using IL-1 
neutralizing antibodies or IL-1Ra, is an important regulator of the infiltration of inflammatory 
cells, chondrocyte PG synthesis inhibition and cartilage PG depletion. A single injection of 
SCW elicited an immediate cytokine response, with TN Fa preceding the IL-1 release. This is 
in apparent agreement with a putative TN Fa — IL-1 cascade (6). However, such a cascade 
could not be demonstrated in this arthritis model. Conflicting data emerged from analysis of 
TN Fa dependent IL-1 synthesis after systemic exposure to bacteria or their cell wall products: 
Fong et al.(20) showed a decrease of IL-1 P after TN Fa neutralization in baboons treated with 
live E. coli. On the other hand, no such relation was found by Vasilescue et al.(21) in whole 
blood from normal volunteers receiving endotoxin and by van der Poll et al. (22) in healthy 
volunteers receiving an intravenous injection of TN Fa or Perretti e tal.(23) in rat experimental 
endotoxaemia. The variety of results found under different conditions indicate that, using 
bacterial products, a dominant TN Fa — IL-1 cascade is not a general phenomenon. In vitro 
analysis in cultures of rheumatoid arthritis (RA) synovial cells, demonstrated that ex vivo 
addition of anti-TNFa resulted in a complete inhibition of spontaneous IL-1 production in 
four out of seven patients, suggesting that under these conditions the release of IL-1 depended 
on TN Fa release and that TN Fa was the prime mediator (4). In vivo studies in murine arthritis 
models based on non-bacterial stimuli, such as antigen-induced arthritis (AIA), immune
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complex arthritis (ICA), collagen-induced arthritis (CIA) or zymosan-induced arthritis (ZIA), 
did not provide evidence for substantial TN Fa dependent IL-1 release (10,11,12). In these 
studies the effects of anti-IL-1 treatment on inflammation or cartilage damage could not be 
mimicked by anti-TNFa. Our present study clearly demonstrates that in SCW arthritis IL-1 
release does occur independent of TN Fa and that IL-1 exerts direct effects on cartilage. In 
contrast to an expected TN Fa ^  IL-1 cascade, TN Fa neutralization resulted in some cases in 
an increased IL-1 bioactivity in SCW arthritis. The total amount of immunoreactive IL-1 was 
not altered, suggesting that TN Fa does not affect the IL-1 production, but rather influences 
the IL-1 bioactivity. Possible candidates for this mechanism are IL-1Ra or PGE2 which can 
be induced by both IL-1 and TN Fa (24,25,26). Although the exact mechanism, concerning 
the direct or indirect effect of TN Fa on IL-1 bioactivity, remains unknown, our study shows 
that TN Fa could participate in an IL-1 suppressor system. Another im portant finding from 
our study was the distinct role excerted by TN Fa and IL-1 in SCW arthritis. The dominant 
role of IL-1 over TN Fa in the suppression of chondrocyte proteoglycan (PG) synthesis 
confirmed earlier studies in other murine arthritis models (10,11,12). It appears that the relative 
role of TN Fa and IL-1 in joint swelling depends on the type and stage of arthritis studied. In 
murine T cell mediated arthritis (AIA) and immune complex arthritis (ICA) a role of TN Fa 
in early joint swelling could not be demonstrated, whereas in zymosan arthritis (ZIA) at best 
a minor involvement was seen (10,11). In autoimmune murine collagen induced arthritis 
(CIA), TN Fa appeared to be im portant in early but not in established disease (12,15). Now 
we show that early joint swelling in murine arthritis induced with bacterial cell walls (SCW) 
is also TN Fa dependent and this is in line with observations in acute flares in the ankles and 
knee joints of rats after reactivation of smouldering arthritis with SCW fragments (27,28). With 
regard to IL-1, a major role was found in ICA and CIA, but its involvement in early j oint swelling 
was marginal in AIA or ZIA (10,11,12) and absent in murine SCW arthritis. In all models 
analysed so far, IL-1 is a major player in cartilage destruction and this is now also confirmed 
in the murine SCW arthritis model in which joint swelling was clearly TN Fa dependent. 
However, it cannot be ruled out that the actual role of TN Fa in the arthritic process is more 
embraced, since it has been shown that membrane-bound TNFa. (mTNFa) is responsible for 
at least part of the pathologic activities of TN Fa (29). It has not been studied yet if the anti- 
TN Fa and sTNFbp we used is able to neutralize also the activities of mTNFa. Although TN Fa 
is found in some murine models of arthritis, its role seems to be limited, whereas in a 
reactivation study of SCW arthritis in rats, there was a clear involvement of TN Fa (28). 
Therefore, one could raise the question whether the mouse is an appropriate species to 
investigate TNFa, since hum an studies suggest a much larger involvement of this cytokine in 
RA (6,7) as compared to the murine arthritis models. However, analyses in other models of 
inflammation in mice show that anti-TNFa antibodies are able to significantly reduce 
inflammation (30,31). These observations give confidence in the use of the mouse as a species 
for TN Fa research. An explanation for the differences in the involvement of TN Fa in different 
models of inflammation might be found in the route of administration or site of inflammation. 
For example, sTNFR-Fc treatment, resulted in an inhibition of infiltrating inflammatory cells 
in the lung interstitium, when immunized mice were challenged with Schistosoma mansoni 
eggs (SEA), whereas it showed only a very minor reduction in lung granulomas in systemically 
challenged mice (30,32). This indicates that the route of administration may drive the 
involvement of TN Fa in the inflammatory process. In addition, anti-TNFa treatment in rats 
suffering from immune complex-induced (BSA-anti-BSA) alveolitis or dermal vasculitis
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resulted in a reduced vascular injury in the lung but not in the dermis, showing that there is 
also a clear site specificity (33). Combining the different studies, it becomes obvious that the 
route of antigen administration and the site of inflammation are determining for the 
involvement of TN Fa in inflammation. Although anti-TNFa clearly diminished joint swelling 
in SCW arthritis, it had no reducing effect on cartilage PG depletion. In earlier studies in rabbits, 
where joint swelling was reduced by indomethacin instead of anti-TNFa, cartilage loss was 
even aggravated, also providing evidence that joint swelling and cartilage damage can occur 
as independently regulated processes (34). It was suggested that indomethacin treatment 
enhanced the cytokine levels due to interference with the prostaglandin feedback control. In 
our present study neutralization of TN Fa lead to a diminished j oint swelling but to an increased 
level of bioactive IL-1. However, the increased IL-1 bioactivity did not result in more cartilage 
damage, suggesting that IL-1 already reached a plateau level and further enhancement does 
not have a major contribution. Combined anti-TNFa/anti-IL-1(a+P) treatment further 
improved the outcome of arthritis in such a way that neutralization of both cytokines lead to 
both diminished inflammation and diminished cartilage damage. However, combination 
treatment had no additive effect on the separate parameters of inflammation or cartilage 
damage. This further underlined our finding that TN Fa and IL-1 exert different effects in SCW 
arthritis. The importance of IL-1 in cartilage destruction was also confirmed in studies using 
TNF-transgenic mice (35). Overexpression of TN Fa in these mice leads to chronic arthritis. 
However, when transgenic mice were treated with antibodies to the IL-1 receptor, the arthritic 
process was fully abolished. Intriguingly, TN Fa levels were still high in these animals, which 
excludes a direct action of TNFa. Our study demonstrated that IL-1 and sTNFa can be induced 
independently and mediate different aspects of the disease. It remains to be seen whether IL-
1 can be induced independently of TN Fa in some if not all RA patients. This study strongly 
suggests that in order to improve the outcome of cartilage pathology, blocking of TN Fa alone 
might not be sufficient, warranting combined anti-TNFa/anti-IL-1 therapy as a more 
promising approach in RA patients.
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ABSTRACT
TN Fa is considered as a pivotal cytokine in the inflammatory process in the joint of patients 
with chronic arthritis, but its role in IL-1 production and tissue destruction is still unclear. 
Here we investigated the relative role of TN Fa and IL-1P in joint inflammation and cartilage 
destruction, using the model of Streptococcal cell wall (SCW) induced arthritis in the 
respective cytokine gene knockout mice. After intraarticular injection of SCW fragments into 
the knee j oint, j oint swelling was profoundly reduced in TNF a -/-  mice and was only marginally 
reduced in IL-1P-/- mice. Intriguingly, swelling was as severe, when studies were done in TNFa- 
/- mice, knocked in with membrane bound TN Fa (mTNFa), suggesting that expression of 
m TN Fa is sufficient to drive joint swelling. Cell influx in the synovial membrane was 
markedly reduced in TN Fa-/- mice, but cartilage proteoglycan loss was not diminished. In 
IL-1P-/- mice, cartilage damage was greatly reduced, despite the marginal reduction of joint 
swelling. In line with these findings, IL-1 P levels were still high in synovial washouts of arthritic 
joints of TN Fa-/- mice, implying TN Fa independent IL-1 generation. In addition, cytokine 
dependence was studied in a model of chronic relapsing arthritis, induced by repeated local 
injection of SCW fragments. Swelling remained TNF dependent in each flare. However, 
pronounced cartilage destruction, including erosions at the joint margins, was still seen after 
4 weeks in TN Fa-/- mice. In marked contrast, advanced cartilage destruction was almost fully 
prevented in IL-1P-/- mice. This data provides clear evidence that TN Fa independent 
production of IL-1 P does occur in the inflamed joint. IL-1P is the dominant cytokine in 
propagation of cellular infiltration and cartilage destruction, which should be selectively 
targeted.
INTRODUCTION
TN Fa is considered as a dominant arthritogenic cytokine in rheumatoid arthritis (RA) patients 
(1-3). Its arthritogenic potential is elegantly demonstrated by the occurrence of a chronic, 
destructive joint inflammation in transgenic mice, displaying overexpression of TN Fa (4). 
Moreover, it is shown that TN Fa is produced in considerable quantities by synovial tissue, 
isolated from patients with RA, and it is claimed that blocking of TN Fa also reduces the IL-1 
production in that tissue (5). Treatment of patients with neutralizing antibodies to TN Fa or 
TNF-soluble receptors provided marked relief of inflammatory symptoms, including joint 
swelling and pain (6,7). As yet it remains to be determined whether anti-TNFa treatment also 
reduces joint erosions.
Involvement of cytokines in arthritis has been studied in experimental animal models of 
arthritis. In allergic, T cell driven models such as the autoimmune model of collagen type II 
induced arthritis, blockade of TN Fa with neutralizing antibodies or soluble receptors, 
appeared effective in reduction of joint swelling, in particular when treatment was started 
shortly after onset of arthritis (8 ). Blockade of IL-1 was more effective, even in established 
arthritis, and also reduced cartilage damage (9). Since the direct involvement of T cells in RA 
is much debated, alike studies have been performed in models, initiated with phlogistic stimuli, 
such as streptococcal cell wall fragments. These fragments are potent inducers. It was shown 
that onset of SCW arthritis was TN Fa dependent in rats and mice (10,11,12). However, cartilage 
destruction could be markedly reduced with IL-1 neutralization and not with TN Fa blockade
CHAPTER 5
(12). These observations suggests that TNF independent IL-1 production may occur, but at 
present it can not be excluded that the TN Fa blockade was incomplete, in vivo, in particular 
with regard to membrane bound cytokines.
An elegant approach to circumvent potential differences in in vivo neutralizing capacity of 
blockers is to work with cytokine specific knockout mice. IL-1P-/- mice show no general 
abnormalities in the development of immune responses or generation of inflammatory 
reactions (13). In contrast, TN Fa deficient mice have a disturbed organization of lymphoid 
organs and potential defects in immune responses (14,15). For that reason, we did not consider 
studies in an immune driven model, based on preimmunization of mice, but focused the 
present investigation on analysis of SCW induced arthritis in TNFa-/- and IL-1P-/- mice. Two 
main questions were addressed: Is TN Fa driving most of the IL-1 production and do TN Fa 
and IL-1P have distinct roles in the arthritic process. Since soluble TN Fa is only found in 
considerable quantities in very acute stages of inflammation, and most of it might be present 
as membrane bound forms, we performed additional studies in mice, containing only the 
membrane bound TNFa. This was achieved by m TN Fa knockin in TN Fa-/- mice (16). It was 
found that m TN Fa is a pivotal factor, driving joint swelling. However, TN Fa independent 
generation of IL-P does occur in this model and IL-1P is a crucial cytokine in propagation of 
arthritis and cartilage destruction. This argues that IL-1 P should be a major therapeutic target, 
apart from TNFa.
MATERIALS and METHODS
Animals
TN Fa deficient, membrane TN Fa knockin (mTNFki) mice and control wild type (WT) mice 
were obtained from G. Kollias, Athens Greece. WT type animals were maintained on a mixed 
129sv x C57/Bl6 genetic background. A breeder pair of IL-1P deficient mice were obtained 
from Zheng, Merk, Rahway, NJ, USA (13). As control animals N/N (mixed 129sv x C57Bl/6J 
background) were used. All animals were bred at our university breeding facilities in Nijmegen. 
C57/6 mice were obtained from Charles River, Germany. The mice were housed in filter top 
cages, and water and food were provided ad libitum. The mice were used at the age of 10-12 
weeks. In all studies male mice were used.
Materials
Bovine serum albumin (BSA), purified rabbit immunoglobulins (Ig’s) were purchased from 
Sigma, St-Louis, MO, USA. RPMI 1640 tissue culture medium was obtained from GIBCO- 
BRL Life Technologies, Breda, The Netherlands. Radioactive 35S-sulfate was ordered from 
NEN-Dupont, S’Hertogenbosch, The Netherlands. Lumasolve and Lupoluma was purchased 
from Omnilabo, Breda, The Netherlands.
SCW  preparation and induction o f SCW  arthritis
Streptococcus pyogenes T12 organisms were cultured overnight in Todd-Hewitt broth. Cell walls 
were prepared as described previously (17). The resulting 10.000 x g supernatant was used 
throughout the experiments. These preparations contained 11% muramic acid. Unilateral 
arthritis was induced by intraarticular injection of 25 |j,g SCW (Rhamnose content) in 5 |jl 
phosphate buffered saline (PBS) into the right knee joint of naive mice. As a control, PBS was
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injected into the left knee joint. To induce chronic relapsing SCW arthritis we reactivated SCW 
arthritis at days 7, 14 and 21 by injection of 5 ju,g SCW fragments in the arthritic joint. As control 
we injected 5 |jl PBS.
Anti-cytokine treatment o f chronic relapsing SCW
To eliminate TN Fa or IL-1a+P during reactivation of SCW arthritis we injected 1h prior to 
SCW injection 3 mg/kg sTNFbp (Amgen, CA, USA) or 2 mg/animal purified rabbit anti-murine 
IL-1a+P antibodies (12,18) at days 14 and 2 1 . As control we used 2  mg purified rabbit Ig’s 
and 3 mg/kg bovine serum albumin.
Measurement o f joint inflammation
SCW arthritis was quantified by the 99mTc-uptake method (18). This method measures by 
external gamma counting the accumulation of a small radioisotope at the site of inflammation 
due to local increased blood flow and tissue swelling. The severity of inflammation is expressed 
as the ratio of the 99mTc-uptake in the right (inflamed) over the left (control) knee joint. All 
values exceeding 1 . 1 0  were assigned as inflammation.
In vivo cartilage degradation assay
Patellae cartilage was radiolabeled by injection of 35S-sulphate (74 KBq/g body weight) 
intraperitoneally 24h before induction of SWC arthritis. At days 1 and 2 patellae with minimal 
surrounding tissue were isolated, washed 3 times in saline and fixed in 4% formaldehyde. 
Thereafter, patellae were punched out, dissolved in Lumasolve and the remaining radioactivity 
was counted.
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Determination o f IL-1a and IL-1P
To determine the levels of IL-1 a  or IL-1P in patellae washouts, patellae were isolated from 
inflamed knee j oints as previously described (18). Patellae were cultured in RPMI 1640 medium 
(200 |jl/patella) for 1 hour at RT. Thereafter supernatant was harvested and IL-1a or IL-1P 
levels were measured by radioimmunoassays (RIA). The sensitivity was 20 pg/ml for each IL-
1 isoform.
Histology
Mice were sacrificed by ether anaesthesia. Thereafter, whole knee joints were removed and 
fixed for 4 days in 4% formaldehyde. After decalcification in 5% formic acid the specimens 
were processed for paraffin embedding. Tissue sections (7 |j,m) were stained with Haematoxylin 
& Eosin or Safranin O. Histopathological changes were scored using to the following 
parameters. Infiltration of cells was scored on a scale of 0-3, depending on the amount of 
inflammatory cells in the synovial cavity and synovial tissues. Proteoglycan depletion was 
determined using Safranin O staining. The loss of proteoglycans was scored on a scale of 0-3, 
ranging from full stained cartilage to destained cartilage. Part of the sections were also used 
for computerized scanning of staining intensity, as described (19). In addition, erosion of the 
surface was scored on a scale of 0-3. These histopathological changes in the knee joints were 
scored in the patella/femur region on 5 semi-serial sections of the joint, spaced 70 |xM apart. 
Scoring was performed on decoded slides by two observers, as described earlier (20).
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Statistical analysis
Differences between experimental groups were tested using the Mann-W hitney U-test, unless 
stated otherwise.
Figure 1. A.Joint swelling as measured with 
Technetium uptake of right inflamed over left 
noninflamed knee joint, at various days after 
induction of SCW arthritis. WT = wild type 
control of the TNFa -/- mice. N/N = control 
strain of the IL-1 p-/- mice. Values are the 
mean±SD of 2 repeat experiments consisting of 
5-6 mice per group. Statistical comparison is 
done only between the knockouts and their 
respective control strains.
B. Mean values±SD of 2 separate experiments 
(groups of 5 mice each), comparing the effect 
in TNFa-/- mice and TNFa-/- mice, knocked 
in with membrane-TNFa (mTNFki). *Signifi- 
cant suppression with a P<0.01, compared to 
the control strains. Mann-Whitney U-test.
RESULTS
SCW  arthritis in TNF and IL-1 deficient mice
Arthritis was induced by local injection of SCW fragments into the knee joint of TNFa-/- mice, 
IL-1 P-/- mice and their respective control strains. Joint swelling was measured at days 1 and
2 and appeared profoundly reduced in the absence of TNFa. In fact, swelling was negligible 
at day 2. In marked contrast, swelling was only marginally reduced in IL-1P knockout mice 
(Figure 1A). Of great interest, additional studies were performed in mice, displaying only the 
membane bound form of TN Fa and results compared with normal littermate controls. In 2 
repeat experiments it was shown that swelling was fully restored in the presence of m TN Fa 
(Figure 1B), indicating that soluble TN Fa is not needed and that membrane expression of 
TNF is sufficient to drive joint swelling.
Role o f TNFa and IL-1P in cell infiltration
Mice were sacrificed at various days after SCW injection and the cellular infiltrate in synovial 
tissue and exudate in the j oint space was measured on whole knee j oint sections. Figure 2 shows 
that initial cell influx at day 1 was present in the controls and the respective knockouts. At day 
4 the synovial cell mass was significantly diminished in the TN Fa deficient mice and further
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Figure 2. Synovial infiltration in the knee 
joint at days 1 and 7 after induction of SCW 
arthritis. See also the legends of Figure 1 for the 
code of the different knockout mice. Significant 
suppression (P<0.01) of infiltration is seen at 
day 7 the TNFa-/- compared its proper WT 
control. The infiltrate in the mTNFa knockin 
is not siginificantly reduced compared to WT. 
Significant suppression (P<0.01) is also noted 
in the IL-1 p-/- compared to N/N. Values 
represent mean±SD of groups of at least 9 mice. 
Mann-Whitney U-test.
Figure 3. Histologic sections of the knee joint in WT, TNFa-/- and the mTNFa knockin (mTNFki), at day 4 after 
induction of SCW arthritis. Note the significant reduction of cell influx in TNFa-/- mice, and the normalized 
infiltration in the mTNFki mice. Haematoxilin & Eosin staining, original magnification 200x. P=patella, F=femur, 
JS=joint space, S=synovial tissue.
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reduction was observed at day 7 (Figure 2 and 3). Intriguingly, although joint swelling was not 
reduced in the IL-1 p deficient mice, consistent reduction in cell influx was seen at day 7 (Figure 2). 
Of great interest, m TN Fa is sufficient not only to drive joint swelling, but also to generate 
consistent cellular infiltrate (Figure 2 and 3).
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Role o f TNFa and IL-1P in cartilage proteoglycan depletion
At day 7 after SCW injection knee joint sections were stained with Safranin-O, to detect the 
am ount of proteoglycans in the cartilage matrix. Marked reduction of staining was observed 
in the arthritic controls. In TN Fa deficient mice no significant reduction of proteoglycan loss 
was found, whereas in the IL-1P deficient mice the proteoglycan depletion was marginal, and 
highly reduced compared to that found in the arthritic control. This was seen after 
semiquantitative scoring of staining intensity on sections and confirmed with computerized 
scanning (Figure 4A,B).
In addition, cartilage proteoglycans (PG) were prelabeled in vivo by a single i.p. injection of 
35S-sulfate and loss of 35S-proteoglycans was measured at days 1 and 2 after induction of SCW 
arthritis (Figure 5). The enhanced loss of PG’s due to the inflammatory process was 50 % 
reduced in IL-1 P deficient mice, whereas no significant reduction was seen in the TNFa 
deficient mice. This further underlines the distinct role of IL-1 P in cartilage damage.
Figure 4. A. Loss of proteoglycans from the articular 
cartilage is scored on Safranin O stained knee joint 
sections at days 4 and 7, in a semiquantitative way on a 
scale of 0-3 (see material and methods). Significant 
protection against this loss is seen in the IL-1 P-/- mice 
(*P<0.01). B. Computerized scanning of staining 
intensity in the cartilage surface layer of Safranin O 
stained sections of day 7. Proteoglycan content in normal 
cartilage is posed at 100, completely depleted cartilage 
after sustained enzymatic breakdown gives a background 
value of 40. *P<0.01, comparing IL-1 P-/- with N/N. 
Mann-Whitney U-test.
Figure 5 . Loss of 35S-prelabeled proteoglycan from the 
cartilage of the patella at days 1 and 2 after induction of 
SCW arthritis. Significantly reduced loss of 
proteoglycans in the IL-1 P-/- mice (*P<0.01). Values are 
the mean±SD of two repeat experiments with groups of 
5-6 mice. Mann-Whitney U-test.
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Figure 6 . Cytokine levels were measured with RIA in 
washouts of synovial tissue specimens taken at 3 and 6 
hours after induction of SCW arthritis in WT and TNFa- 
/- mice. Values are the mean±SD of 2 repeat experiments 
with 6 mice each.
IL-1 production independent o f TNFa.
The above data already suggest marked uncoupling of TN Fa and IL-1 production. To verify 
the extent of TN Fa independent IL-1 production in the inflamed joint, we isolated patella 
specimens with surrounding synovial tissue at 3 and 6  hours after induction of arthritis and 
measured IL-1a and IL-1 P in the tissue washout. As can be seen in Figure 6 , there was some 
reduction of IL-1 P levels in the TN Fa knockout mice, in particular at 3 hours, but most of the 
IL-1P production occurred in a TN Fa independent fashion. IL-1a was low and not different 
in the TN Fa deficient mice.
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Figure 7. A. Joint swelling in various groups 
of mice, receiving repeat intraarticular injection 
with SCW fragments at day 7; days 7, 14 and 
days 7, 14, 21, respectively.
B. Mice undergoing the most stringent repeat 
SCW injection protocol (days 7,14 and 21) 
were treated with soluble TNF binding protein 
(sTNFbp) or anti-IL-1a+P antibodies shortly 
(day -1) before the 3th and 4th flare at days 14 
and 21. Animals were killed at day 28 and 
processed for histology (Table 1). Each group 
consists of at least 8 mice. Values are mean±SD. 
*P<0.01 compared to vehicle treated control, 
Mann-Whitney U-test.
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Table 1. Histology at day 28 in chronic relapsing SCW arthritis in anti-cytokine treated 
normal mice and in cytokine deficient mice.
Treatment/Type of 
deficient mice
Number of 
inflammatory cells$
Cartilage damage# Matrix proteoglycan 
depletion&
Vehicle control 1.2±0.3 0.9±0.4 2.5±0.5
STNFbp 1.3±0.4 1.0±0.4 2.7±0.3
Anti-IL-1 0.7±0.2* 0.3±0.2* 1.1±0.4*
C57/Bl6@ 1.4±0.3 0.7±0.2 2.5±0.5
Wild type 1.0±0.3 0.5±0.3 2.3±0.6
TNFa-/- 1.0±0.4 0.5±0.2 1.8±0.7
N/N 0.9±0.3 0.4±0.2 1.9±0.6
IL-1P-/- 0.2±0.1* 0.0±0.0*
@ C57/B16 control strain, as used in routine experiments in our facility 
$ Number of inflammatory cells in the synovial tissue on a scale of 0-3 
# Cartilage damage reflects erosion of the surface on a scale of 0-3 
&Proteoglycan depletion reflects loss of Safranin O staining in the cartilage (scale 0-3)
0.0±0.0*
Values represent the mean±SD of groups of at least 7 mice. * p<0.05 Mann-Whitney U-test.
Chronic relapsing SCW  arthritis
The above studies relate to acute stages of inflammation in the j oint. To investigate the cytokine 
dependence in a chronic stage of arthritis, we first deviced a model of repeated SCW injection 
in the knee joint of normal mice. Figure 7A shows that every repeat injection of SCW fragments 
caused an acute exacerbation of the arthritis and that after 3 to 4 injections acute flares were 
still seen after every renewed injection. The smouldering arthritis remained at a higher level 
after the various repeat injections.
W hen soluble TNF binding proteins (sTNFbp) are given shortly before the 3th or 4th SCW 
injection, marked suppression of joint swelling was still evident in these repeated flares (Figure 
7B). In contrast to findings in acute arthritis (12), anti-IL-1a+P treatment now appeared 
effective in reduction of swelling as well. This indicates that the chronic relapsing arthritis 
becomes more IL-1 dependent. Reduction of the flare at day 22 in the anti-IL-1a+P treated 
mice probably is a mix of reduced reactivation and significantly reduced smouldering 
inflammation at day 21. Histology at day 28 revealed no significant suppression of cellular 
infiltrate with sTNFbp, but some reduction of infiltrate with anti-IL-1a+P and a major 
suppressive effect on cartilage destruction (Table 1).
Relapsing SCW  arthritis in knockout mice
In line with the findings after anti-cytokine treatment, we noted that joint swelling was 
significantly reduced in the IL-1P knockout mice, shortly after the 4th SCW injection (day 
22). Swelling reduction was still significant but not that pronounced in the TN Fa deficient 
mice (Figure 8 ). A day 28 significant swelling was still seen in the two controls and the TN Fa 
deficient mice, but was absent in the IL-1P-/- mice. Cartilage destruction was evaluated at day 
28 in the knockouts and the respective controls. Advanced proteoglycan loss in the cartilage 
matrix and pannus-like overgrowth with underlying cartilage erosion was clearly observed in 
both wild type strains. In the TN Fa knockout mice, cartilage damage was not significantly
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Figure 8 . Joint swelling in the cytokine 
deficient mice and the respective control strains, 
SCW reactivation protocol as in Figure 7. 
*P<0.01, comparison between the knockout 
and the respective control. Values are the 
mean±SD of groups of at least 7 mice. Mann­
Whitney U-test.
Figure 9. Representative histology taken at day 28 of the experiment described in the legend of Figure 8. A. Control; 
note the pronounced loss of proteoglycan staining (Safranin O) in the cartilage layers of the patella and opposite femur. 
B. TNFa-/- mice C. IL-1P-/- mice, showing marked prevention of loss of proteoglycans. For details see Figure 3. 
D,E,F: HE staining of more superficial sections of the knee joint, identifying pannus growth (indicated by arrows). 
Note erosion and tissue overgrowth in control (D) and TNFa-/- (E), but absence of erosion and marked reduction 
in cellular infiltrate in IL-1 P-/- mice (F). See for further scoring of histology Table 1.
reduced, whereas cartilage damage was almost absent in the IL-1p deficient mice. Cellular 
infiltrate in the synovial tissue was also greatly reduced in the IL-1p knockout mice (Table 1, 
Figure 9).
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DISCUSSION
To our knowledge this is the first unequivocal demonstration of the crucial role of IL-1P in 
chronicity and cartilage destruction in experimental arthritis, using IL-1P deficient mice. 
Comparative studies in TN Fa deficient mice made it clear that TN Fa is pivotal in early joint 
swelling and first cell influx in SCW arthritis, but that it has a limited role in propagation of 
cellular infiltration in the synovial tissue and destruction of the cartilage matrix. Intriguingly, 
knockin of membrane bound TN Fa (mTNFa) in TN Fa deficient mice adequately normalizes 
the joint swelling and cellular infiltration, as seen in controls, implying that m TN Fa is sufficient 
to drive these elements of the inflammatory process.
Rheumatoid arthritis is characterized by chronicity of joint inflammation and concomitant 
destruction of cartilage and bone. There is no doubt that TN Fa is a crucial mediator in this 
disease, since clinical trials with neutralizing antibodies or soluble receptors to TN Fa showed 
major improvement of clinical signs, including joint swelling and pain (6,7). Data of potential 
effects on joint destruction are still lacking. The arthritogenic potential of TN Fa was elegantly 
demonstrated by the occurrence of a chronic, destructive polyarthritis in transgenic mice, 
overexpressing T N Fa (4). Intriguingly, the pathology could be totally abolished by 
administration of antibodies to the IL-1 receptor (21), indicating that the arthritic process is 
running through TN Fa mediated induction of IL-1. Moreover, these studies already proved 
the limited destructive role of TN Fa itself. In vitro, TN Fa can exert damaging effects on 
articular cartilage (2 2 ), but its direct potency in vivo appears limited.
Injected TN Fa displays pro-inflammatory activity, but it proved difficult to detect substantial 
quantities of soluble TN Fa at inflamed joints. Along these lines, it makes sense to attribute a 
major role to membrane bound cytokines. Of great interest, arthritis occurred in transgenic 
mice, overexpressing merely membrane TN Fa (23). The present study identifies for the first 
time that this role of m TN Fa not only holds for arthritis induced in a single mediator system, 
but that m TN Fa also has this dominant potential in an arthritis induced with a natural, 
pathogenic trigger. Preliminary studies with selective TNF receptor knockouts suggest that 
the effect on joint swelling runs through the P75 Receptor (manuscript in preparation).
The arthritogenic potential of IL-1 has been convincingly demonstrated by direct injection of 
recombinant IL-1 into knee joints of rodents (24,25). In recent studies this role is further 
substantiated by the induction of chronic erosive arthritis through local overexpression of IL- 
1 with adenoviral gene constructs in the rabbit knee joint (26) and the occurrence of full-blown 
arthritis in transgenic mice, overexpressing IL-1a (27). Apart from the present study, 
suggestive evidence for a role of IL-1 in chronic arthritis and tissue destruction was obtained 
from studies with blocking antibodies. As such IL-1P appeared crucial in the autoimmune 
model of collagen induced arthritis and the late stage of antigen induced arthritis (9,28-30). 
W ith respect to the dominant role of IL-1 in propagation of joint inflammation, it is intriguing 
to note that onset of collagen arthritis is reduced in TNF-receptor deficient mice, but that 
progression of inflammation and j oint destruction occurs unabated in such mice, once a j oint 
gets afflicted with the disease (31). Similar events were recently confirmed in experimental 
encephalomyelitis (32) It fits with the argument that mediators other than IL-1, for instance 
TNFa, can be involved in onset, but that mediators other than TNFa, probably IL-1P, are 
crucial in propagation of a destructive process.
Earlier work in TNF-/- and IL-1-/- mice have identified differential effects, dependent on the 
process studied. Cytokine production induced by LPS appeared essentially intact in TNFa-/-
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mice. However, these mice show little or no initial effect on injection of heat killed 
Corynebacterium Parvum, but then develop a vigorous disorganized inflammatory response, 
suggesting that TNF has an essential homeostatic role in limiting inflammation (33). This fits 
with our observations with SCW fragments, in that we tend to loose TNF dependency on 
repeated flaring. On the other hand, IL-1 seems not required for normal development and 
homeostasis, and reduced inflammatory responses are seen in IL-1P-/- mice, type I receptor 
deficient mice and IL-1P-converting enzyme (ICE) deficient mice (34,35). Remarkably, IL- 
1P seems to control apoptosis of inflammatory neutrophils (36) and this action might 
contribute to the marked reduction of late cellular infiltrate in the joint in our studies.
W ith regard to therapeutic approaches in chronic arthritis, it remains essential to critically 
evaluate a potential cascade of TN Fa ^  IL-1 in arthritis. Although TN Fa is a potent inducer 
of IL-1, the present study in TN Fa deficient mice identifies major IL-1 P production, 
independent of TNFa. Since IL-1P is a direct mediator of chondrocyte mediated cartilage 
destruction and also has a distinct role in propagation of cellular infiltration in the synovial 
tissue, it should be considered to target IL-1P, apart from TNFa. The mechanism underlying 
chronicity and tissue destruction in RA is still unknown. Impaired regulation of TNF 
production proved to cause joint associated immunopathologies (37), and this might be 
operational in RA patients. Further studies on the TN Fa ^  IL-1P interplay should be done 
in RA synovial specimens and old observations suggest a TN Fa ^  IL-1 cascade in cells of RA 
synovial tissue (5). However, these observations have not been confirmed. Our own preliminary 
studies in synovial biopsies taken from RA patients, treated systemically with anti-TNFa 
antibodies, do not identify a reduction in IL-1P in immunostainings (manuscript in 
preparation). Of high interest, these patients do show impressive improvement of clinical signs, 
including a consistent suppression of number and degree of swollen joints, but the synovial 
infiltrate seems hardly affected and cartilage destruction might be ongoing.
The cytokine interplay may be different in acute and advanced arthritis. Repeat injections of 
SCW fragments make the arthritis more chronic and more destructive. As identified in Fig 8 , 
erosive changes occur at the cartilage-synovium interface, and these changes can be profoundly 
prevented in the IL-1P deficient mice. IL-1 P is a powerful stimulant to drive cell-cell interaction 
in the synovial tissue and to stimulate the production of destructive enzymes (38) Also this 
interplay probably occurs at the membrane level. In that sense, it is not unexpected that the 
protection against excessive synovial infiltration and cartilage erosion is more impressive in 
IL-1P deficient mice, as compared to that found in studies with anti-IL-1a+P antibodies in 
normal mice. W ith respect to cartilage damage, IL-1P originating from the synovium, may 
have an impact on chondrocytes in the articular cartilage and this may be blocked rather 
efficiently with the antibodies. The fact that also the cartilage damage is much more protected 
in the IL-1P-/- mice as compared to that in the anti-IL-1a+P treated mice, does suggest that 
local IL-1P production by arthritic chondrocytes contributes to the process. Due to limited 
access of antibodies to the dense cartilage, this latter event is not touched by antibodies but is 
of course fully absent in IL-1P-/- mice. It is promising to see that first clinical studies with IL- 
1Ra (receptor antagonist) identified protection against erosion (39)
The acute model of SCW arthritis is a nonimmune arthritis. The chronic relapsing model with 
the repeated flares is expected to gain T cell involvement, in analogy with earlier studies in 
rats, where it was shown that flares only occurred in Lewis rats, mounting a proper T cell 
immunity against SCW and not in Fisher rats, which were tolerant (40). As such, a suppression 
of the chronic SCW arthritis in TN Fa deficient mice might be expected, since it has been shown
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that these mice have disturbed lymph node organization and potentially display disturbed 
immune responses. We did not identify suppressed chronic inflammation, but in fact noted 
a decline in TN Fa dependence (Table 1). Apparently, no disturbance in im munity is 
operational, or the T cell component is still limited in the relapse model. Recently, we performed 
RT-PCR analysis of the chronic infiltrate after the consecutive flares in this model, identifying 
a consistent increase in IFN-y and IL-12. Further analysis of local T cell immunity and a 
potential role of TNFP is under investigation.
In conclusion, this is the first report showing that m TN Fa is a pivotal cytokine in joint swelling 
and early cell influx. However, TN Fa independent generation of IL-1P does occur in arthritis, 
driven with SCW fragments. Its unequivocal role in cartilage destruction and propagation of 
a chronic infiltrate makes IL-1P a crucial therapeutic target.
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ABSTRACT
We examined the role of endogenous interleukin-4 (IL-4) and interleukin-10 (IL-10) and the 
therapeutic effect of addition of IL-4 and IL-10 in early and established murine collagen 
arthritis. Murine recombinant IL-4, IL-10 or the combination was given intraperitoneally twice 
daily from the day of onset upto 7-10 days of collagen arthritis in DBA 1 mice. Anti-IL-4, anti- 
IL-10 or both antibodies were given i.p. before onset of CIA or after onset of the disease. The 
effect of cytokine or anti-cytokine treatment was monitored visually by macroscopic scoring. 
Histology and reverse transcription polymerase chain reaction (RT-PCR) analyses were 
performed at the end of the treatment period. IL-4 alone did not provoke any effect, IL-10 
slightly suppressed the arthritis, but a more pronounced amelioration was found with the 
combination. This cooperative effect was noted after early treatment but also occurred when 
the start of treatment was delayed untill one week after onset. Apart from suppression of 
macroscopic signs of inflammation the combined treatment with IL-4/IL-10 also reduced 
cellular infiltrate in the synovial tissue and caused pronounced protection against cartilage 
destruction. Moreover, mRNA levels for tum or necrosis factor alpha (TNFa) and interleukin- 
1 (IL-1) were highly suppressed both in the synovial tissue as well as in the articular cartilage. 
In contrast, the interleukin-1 receptor antagonist (IL-1Ra) mRNA levels remained elevated, 
which suggests that the mechanism of protection may be related to suppressed production of 
TN Fa and IL-1, with concomitant upregulation of the IL-1Ra/IL-1 balance. On the contrary, 
accelerated onset of collagen arthritis and increased severity could be achieved with neutralizing 
anti-IL-10 antibodies. This expression could be further optimized with a combination of anti- 
IL-4 and anti-IL-10 antibodies, although anti-IL-4 alone was without effect. Our data are 
consistent with a dominant role of IL-10 in natural suppression of arthritis expression, whereas 
combined treatment with IL-4 and IL-10 appears of potential therapeutic value, not only at 
the onset, but also in established arthritis.
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INTRODUCTION
Interleukin-4 (IL-4) and interleukin-10 (IL-10) are pleiotropic cytokines that can exert either 
suppressive or stimulatory effects on different cell types of the immune system. IL-4 and IL- 
10 were first indentified as products of T-helper 2 (Th2) clones and are part of the cytokines 
that distinguished Th2 cells from other T cells. In addition, IL-4 and IL-10 inhibited 
interleukin-2 (IL-2) and interferon gamma (IFN-y) production by Th1 cells, resulting in 
suppression of macrophage activation (1,2). Recently, it has been demonstrated that IL-4 and 
IL-10 inhibit the production of pro-inflammatory cytokines, such as interleukin-1 (IL-1), 
interleukin - 6  (IL-6 ), interleukin - 8  (IL-8 ) and tum or necrosis factor alpha (TNFa) of 
monocytes and macrophages (3-6). IL-4 and IL-10 suppress cytokine synthesis by different 
mechanisms. IL-4 enhances mRNA degradation, w ithout a decrease in cytokine gene 
transcription, while IL-10 inhibits nuclear factor kappa B (NFfcB) resulting in suppression of 
gene transcription (7). Furthermore, it has been shown that IL-4 and IL-10 stimulate the 
production of cytokine inhibitors such as interleukin-1 receptor antagonist (IL-1Ra), soluble 
interleukin-1 receptor type II (sIL-1RII), and soluble tum or necrosis factor receptor (sTNFR) 
of monocytes/macrophages and neutrophils (8 - 1 1 ).
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by cartilage
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damage and bone destruction. There is increasing evidence that TNFa, and in particular IL-
1 are involved in cartilage damage (12). These pro-inflammatory cytokines are detected in 
synovial fluid of RA patients and production of TN Fa and IL-1 by RA synovial tissue has been 
dem onstrated (13). Recent clinical trials with neutralizing antibodies against T N Fa 
demonstrated efficacy in hum an RA (14,15).
Collagen-induced arthritis (CIA) is a widely used experimental model of polyarthritis. It can 
be induced in susceptible strains of mice and rats by immunization with type II collagen, the 
major component of articular cartilage, and has histopathological features in common with 
RA (16-18). In this animal model of arthritis it is clearly shown that TNF a  and IL-1 are involved 
in onset of the disease (19-20). Furthermore, neutralization of IL-1 with antibodies against 
IL-1 or with IL-1Ra during established CIA completely suppressed the arthritis and prevented 
joint pathology (21-23).
Recently, elevated levels of IL-10 have been found in synovial fluid of RA patients and the 
production of IL-1 and TN Fa of synovium tissue of RA patients can be regulated by IL-4 and 
IL-10 (24-26). In general, attempts to detect IL-4 in RA synovial tissue suggested a relative 
absence of this modulator at the site. This may provide a reason for uncontrolled cytokine 
production in RA and on the other hand, may offer a therapeutic approach. Efficacy of in ­
vivo administration of IL-4 or IL-10 is already shown in TNF/IL-1 dependent animal models, 
such as endotoxin-induced lethality and IgG immune complex-induced lung injury (27-28), 
but data in experimental arthritis is scant. The group of Wahl et al. showed that sustained IL- 
4 treatment suppressed the chronic but not the acute phase of streptococcal cell wall (SCW) 
arthritis in rats and demonstrated upregulated IL-1Ra mRNA levels in monocytes of these 
animals (29). Kunkel et al. (30) showed elevated levels of IL-10 at the onset of collagen arthritis 
and a regulatory role was demonstrated by increased disease activity after neutralization of IL- 
10. Finally, efficacy of IL-10 treatment on progression of murine collagen-induced arthritis 
was recently found by Walmsley et al. (31).
In the present study we have investigated the effect of IL-4 and IL-10, either alone or in 
combination, in the treatment of early and established murine collagen arthritis (CIA). 
Furthermore, we examined the role of endogenous IL-4/IL-10 during both onset and 
established phase of this experimental arthritis model, using neutralizing antibodies in vivo. 
The analysis included histopathology of the joints, with a special emphasis on cartilage 
destruction, and measurement of mRNA levels for cytokines and inhibitors in synovial tissue 
and cartilage by RT-PCR technology. It is demonstrated that expression of CIA is under 
stringent control of endogenous IL-4/IL-10. Treatment with IL-4 alone was not effective but 
IL-4 increased the suppressive action of IL-10 on both joint inflammation and cartilage 
destruction, even in established CIA. Apart from suppression of TNF/IL-1 mRNA levels the 
IL-4/IL-10 treatment resulted in upregulation of the IL-Ra/IL-1 balance. The latter suggests 
that IL-4/IL-10 treatment may offer a valuable alternative therapeutic approach in arthritis, 
apart from TNF/IL-1 inhibitors.
MATERIALS and METHODS
Animals
Male DBA-1 Lac/J mice were obtained from The Jackson Laboratories (Bar Harbor, ME). The 
mice were housed in filter top cages, and water and food were provided ad libitum. The mice 
were immunized at the age of 9-10 weeks.
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Materials
Complete Freund’s adjuvant and Mycobacterium tuberculosis (strain H3Ra) were obtained from 
Difco Laboratories, Detroit, USA. LPS (E. Coli, 0111:84 ), Ethidiumbromide, rat Ig’s, and 
bovine serum albumin were purchased from Sigma Chemicals, St Louis, USA. DMEM 
medium, IMDM medium, Taq DNA Polymerase, 100 bp DNA marker, TRIzol Reagent, and 
Agarose were obtained from Life Technologies, Breda, The Netherlands. GAPDH, IL-10, IL- 
1Ra, TNFa, and TIMP primers were purchased from Pharmacia Biotech, Roosendaal, The 
Netherlands. Recombinant murine IL-3 was obtained from R&D Systems Europe, Abingdon, 
UK. Recombinant murine IL-4 (1 x 107  U/mg) was a kind gift of Immunex (Dr. S. Gilles and 
Dr. M. Widmer), Seattle, USA. Purified recombinant murine IL-10 (2.5 x 105 U/mg) was 
produced by Dr. A Delvaux, Department of Medical Genetics-IRIBHN, Hopital Erasme, 
Universite Libre de Bruxelles, Brussels, Belgium. Murine IL-10 was cloned and expressed as 
previously described (32). The biological activity of IL-10 was verified in a LPS mediated lethal 
shock model (27).
IL-4 and IL-10 bioassays
For IL-4 determination, the IL-4 dependent CT.4S line was used (kindly provided by Dr. W.E. 
Paul (33)). Cells were washed three times and were seeded in duplicate or triplicate 0.1 ml 
cultures at 1 x 104  cells per well in DMEM medium, supplemented with 5% FCS, L-glutamine 
(2 mM), pyruvate (1 mM), 2-ME (0.05 mM) and Gentamicin (50 |J.g/ml) and 100 |jl sample 
or standard was added. After 48h of incubation, 1 |j,Ci 3[H]-thymidine/well was added. 16 
hours later CT.4S cells were harvested and 3[H]-thymidine incorporation was determined. 
The D36 mast cell line was used for IL-10 determination (34). D36 cells were cultured in Iscove’s 
modified Dulbecco’s medium (IMDM) supplemented with 5% FCS, L-glutamine (2mM), 2- 
ME (0.05 mM), Gentamycin (50 |j,g/ml), 10 U/ml rmIL-3 and 8  U/ml rmIL-4. For use as a 
bioassay 2  x 1 0 3 cells were cultured in 0 .1  ml medium with standard cytokine or samples to 
be tested. After 24h 3[H]-thymidine (0.25 |j,Ci/well) was added for an other 24h, whereafter 
the cells were harvested and the incorporated radioactivity was determined by scintillation 
counting. The IL-10 bioassay was performed in the presence of 8  U/ml rmIL-4.
Anti-mIL-4 and anti-mIL-10 antibodies
Hybridoma cells producing rat anti-murine IL-4 antibodies (11B11) or rat anti-murine IL-10 
(JES5-2A5) were obtained from ATCC, Rockville, USA. Hybridoma cells (3 x 106) were injected 
in nude Balb/C mice and after three weeks ascites fluid was collected. Thereafter Ig’s were 
isolated using a protein-G column. Anti-murine IL-4 antibodies (0.75mg, neutralized 1.500 
U mIL-4 in the CT.4S bioassay) and anti-murine IL-10 (0.5 mg, neutralized 25.000 U mIL-10 
in the D36 bioassay) were injected in a volume of 0.2 ml PBS. As previously described, these 
doses revealed to be effective in vivo (35,36). When the mice were treated with the combination 
of both antibodies we injected 0.4 ml PBS containing 1.25 mg Ig’s. As control the same amount 
of normal rat Ig’s was injected.
Collagen preparation
Articular cartilage was obtained from meta-carpophalangeal joints of 1-2 years old cows. Bovine 
type II collagen was prepared according to Miller & Rhodes (37). Collagen was resolved in
0.05 M acetic acid (10 mg/ml) and stored at -70°C.
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Immunization
Bovine type II collagen was diluted with 0.05 M acetic acid to a concentration of 2 mg/ml and 
was emulsified in equal volumes of complete Freund’s adjuvant (2 mg/ml MT H37Ra). The 
mice were immunized intradermally at the base of the tail with 1 0 0  |jl emulsion ( 1 0 0  |j,g 
collagen). At day 21 the animals were boosted with an i.p. injection of 100 |j,g collagen type II, 
dissolved in phosphate buffered saline.
Acceleration o f collagen-induced arthritis
W hen DBA-1 mice were immunized with collagen type II and boosted at day 21 a gradual 
onset of collagen arthritis was noted from day 28. At this time point mice were visually scored 
for having collagen-induced arthritis. In general, spontaneous arthritis incidence ranged from 
10-30 % of the animals. Unless stated otherwise, mice without clear macroscopic signs of 
arthritis were selected at this stage and the onset of arthritis was accelerated by a single i.p. 
injection of 40 |j,g of LPS (21,38). This resulted in onset of CIA within three days and at day 
35 full blown expression of arthritis was noted in paws of more than 95% of the animals. The 
histopathology in knee and ankle joints was comparable in accelerated CIA and classic, 
spontaneous CIA. As described previously, administration of 40 |j,g LPS to non-immunized 
DBA-1 mice, or mice immunized with a non-arthritogenic antigen did not result in any 
macroscopical or histological abnormalities (23).
Assessment o f arthritis
Mice were examined for visual appearance of arthritis in peripheral joints and scores for severity 
were given (macroscopic score) as previously described (21,23). Mice were considered 
arthritic, when significant changes in redness and/or swelling were noted in digits or in other 
parts of the paws. At later time points ankylosis was also included in macroscopic scoring. 
Clinical severity of arthritis was graded on a scale of 0 to 2 for each paw, according to changes 
in redness and swelling: 0: no changes; 0.5: significant; 1.0: moderate; 1.5: marked; 2.0: maximal 
swelling and redness and later on ankylosis. Macroscopic score (mean±SD) was expressed as 
cumulative value for all paws, with a maximum of 8 . Visual score of knee joint inflammation 
was performed, after skin dissection on a scale ranging from non-inflamed/mild, marked or 
severe inflammation. Scoring was done by two independent observers, without knowledge of 
the experimental groups.
Murine IL-4 and mIL-10 treatment o f collagen-induced arthritis
To investigate the effect of mIL-4, mIL-10 or mIL-4/mIL-10 treatment of CIA these cytokines 
were injected twice a day i.p., starting at different time points after onset of CIA. For both mIL- 
4 (29,57) and IL-10 (27) a total dose of 2000 Units a day was injected (0.2 |j,g mIL-4 and 8  |j,g 
mIL-10. As control 8.2 |j,g of bovine serum albumin was used. To determine the effect of IL- 
4 and/or IL-10 on the early phase of CIA, treatment was started directly after onset of arthritis, 
day 29 after immunization. For treatment of established CIA, mice were selected for having 
arthritis and were randomly divided in groups of at least 10 mice. If unwanted skewing of groups 
was apparent after scoring, randomization was repeated. Therefore, each experimental group 
of mice had a similar macroscopic score before starting treatment with mIL-4 or mIL-10. Mice 
were treated for at least 7 days with mIL-4, mIL-10 or with the combination of these cytokines. 
Knee and ankle joints were isolated and processed for light microscopy at the end of anti­
cytokine treatment. Tissue samples for mRNA measurements were also isolated at this time 
point.
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Anti-mIL-4 and anti-mIL-10 treatment before onset o f CIA
At day 29 after immunization with type II collagen, DBA-1 mice without any signs of arthritis 
were selected and divided into 4 groups of 15 animals. These groups were injected with either 
anti-mIL-4 (0.75mg), anti-mIL-10 (0.5 mg), anti-mIL-4/anti-mIL-10 (1.25 mg) or rat Ig’s (1.25 
mg). Injections were repeated at days 32 and 35. Mice were daily assessed for developing CIA 
until day 38. At day 39 mice were killed and sera were collected for antibody subclass 
examination.
Anti-IL-4 and anti-IL-10 treatment o f established CIA
For elimination of endogenous mIL-4 and/or mIL-10 during established CIA, mice were treated 
with antibodies directed against these cytokines at days 32, 35 and 38. Treatment was started 
4 days after LPS acceleration (day 28). In these particular experiments 20 |j,g of LPS was used 
instead of the standard dose of 40 |j,g LPS. This in order to achieve a moderate expression of 
CIA, which would allow for acceleration by treatment with anti-mIL-4 and/or anti-mIL-10. 
The same dosages of antibodies were used in these studies as described in the previous section.
RNA isolation
Mice were killed by cervical dislocation, immediately followed by dissection of the patella with 
adjacent synovium (39). From 6  out of 10 patella specimens synovium biopsies were taken. 
Two biopsies with a diameter of 3 m m  were punched out, using a biopsy punch (Stiefel, 
Wachtersbach, Germany): one from the lateral and one from the medial side. Six patella 
specimens per experimental group were taken and 3 lateral and 3 medial biopsies were pooled, 
to yield 2 samples per group. The synovium samples were immediately frozen into liquid 
nitrogen. Patellae were transferred to a 5% EDTA solution and kept on ice for 4h. Thereafter, 
the cartilage layer was stripped as previously described (21). This procedure does not affect 
mRNA isolation or amplification efficiency. The total RNA of a pool of 10 cartilage samples 
of a particular group was extracted with 1 ml TRIzol Reagent, an improved single-step RNA 
isolation method based on the method described by Chomczynski and Sacchi (40). Synovium 
biopsies were ground to powder using a micro-dismembrator II (B.Braun, Melsungen, 
Germany). Total RNA was extracted in 1 ml TRIzol reagent in a way similar to that used for 
cartilage samples.
PCR amplification
One microgram of synovial RNA and the total amount of cartilage RNA (pool of 10 cartilage 
layers) was used for RT-PCR. Messenger RNA was reverse transcribed to cDNA using oligodT 
primers and 1/20 of the cDNA was used in one PCR amplification. PCR was performed at a 
final concentration of 200 |J,M dNTP’s, 0.1 |J,M of each primer, and 1 unit Taq-polymerase 
(Life-Technologies) in standard PCR buffer. The mixture was overlaid with mineral oil and 
amplified in a thermocycler (Omnigene, Hybaid Ltd, UK). Message for GAPDH, IL-10, IL- 
1Ra, and TN Fa was amplified using the primers described in references 41-44. Primers for 
TIMP were designed using Oligo 4.0 and Primer Software. Samples of 5 |jl were taken from 
the reaction tubes after a certain number of cycles. PCR products were separated on 1.6 % 
agarose and stained with ethidiumbromide. The results are presented as relative increase of 
the mRNA expression, compared to non-inflamed control samples of normal DBA-1 mice. 
The relative increase in mRNA was calculated as follows: 1.9 (amplification factor, (45)) to 
the nth power, in which n is the difference in number of cycles showing identical staining
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intensity for experimental and non-inflamed control tissue. GAPDH levels were very consistent 
in all samples, not warranting any further correction of mRNA values for IL-10, TNFa, IL- 
1Ra and TIMP.
Determination o f anti-collagen antibodies
To investigate whether treatment of CIA with anti-mIL-4 and/or anti-mIL-10 enhanced 
collagen type II specific antibody subtypes, we determined antibodies titres at day 39. 
Antibodies against bovine type II collagen were determ ined with an enzyme-linked 
im munosorbent assay (ELISA). The titres of either total Ig’s, IgG1, IgG2a or IgE were 
measured. Briefly, ELISA plates were coated with 10 |j,g bovine type II collagen. Thereafter, 
non-specific bindings sites were blocked with 1% BSA solution. Serial 1/10 dilutions of the 
immune sera were added followed by an incubation with isotype-specific goat anti-mouse- 
PO (1:1000, Nordic) and substrate (5-aminosalicylicacid). Plates were read at 492 nm.
Histology
Mice were killed by ether anaesthesia. Thereafter, ankle and knee joints were removed and 
fixed for 4 days in 4% formaldehyde. After decalcification in 5% formic acid the specimens 
were processed for paraffin embedding (39). Tissue sections (7 |j,m) were stained with 
Haematoxylin & Eosin or Safranin O. Histopathological changes were scored using to the 
following parameters. Infiltration of cells was scored on a scale of 0-3, depending on the amount 
of inflammatory cells in the synovial cavity and synovial tissues. Proteoglycan depletion was 
determined using Safranin O staining. The loss of proteoglycans was scored on a scale of 0-3, 
ranging from full stained cartilage to destained cartilage or complete loss of articular cartilage. 
A characteristic parameter in CIA is the progressive loss of articular cartilage. This destruction 
was separately graded on a scale of 0-3, ranging from the appearance of dead chondrocytes 
(empty lacunae) to complete loss of the articular cartilage. Histopathological changes in the 
knee joints were scored in the patella/femur region on 5 semi-serial sections of the joint, spaced 
70 |J,M apart. For the ankle joint we scored on semi-serial sections in a standardized region of 
the calcaneus. Scoring was performed on decoded slides by two observers, as described earlier 
(21,23).
Statistical analysis
Differences between experimental groups were tested using the Wilcoxon rank test, unless 
stated otherwise.
RESULTS
Modulation during onset o f CIA with mIL-4, mIL-10 or mIL-4/mIL-10
To investigate the effect of mIL-4, mIL-10 or the combination at the onset of CIA, mice were 
injected i.p. twice daily with a dose of 1000 U of mIL-4, mIL-10 or mIL-4/mIL-10. Treatment 
was started at day 29 after the first immunization and continued, for a period of nine days. 
Murine IL-4 treatment had no effect on the course of the arthritis. Murine IL-10 treatment 
had a slight suppressive effect on the macroscopic arthritis score, not reaching statistical 
significance. However, when the mice were treated with the combination of mIL-4/mIL-10 a 
marked reduction of macroscopic joint score was noted (Figure 1). Enhancement of the doses
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M A CRO SCO PIC  SCORE
DAYS AFTER IMMUNIZATION
Figure 1. Early treatment of accelerated CIA 
with mIL-4, mIL-10 and mIL-4/mIL-10. Mice 
with the first signs of CIA (day 29) were divided 
in four separate groups of at least 10 mice. 
Treatment with cytokines was started the same 
day. Murine IL-4, mIL-10 and mIL-4/mIL-10 
were injected i.p. twice a day with a dose of 1000 
Units. Mice were treated for a period of 9 days. 
*P<0.05, Wilcoxon rank test compared to 
control, which received bovine serum albumin.
Table 1. Histology after mIL-4/mIL-10 treatment during onset of CIA 
Knee joints
Group Start
of treatment#
Infiltrate & Cartilage
damage
Proteoglycan
depletion
Day of 
sacrifice
Control@ day 29 1.0 ± 0.4 0.8 ± 0.4 2.0 ± 0.6 day 38
mIL-4 day 29 1.2 ± 0.5 0.7 ± 0.5 1.8 ± 0.5 day 38
mIL-10 day 29 1.4 ± 0.6 .50.±.70. 2.1 ± 0.6 day 38
mIL-4/mIL-10 day 29 .70.±.80. 0.±.20. 1.2 ± 0.7* day 38
Ankle joints
Group Start
of treatment#
Infiltrate & Cartilage
damage
Proteoglycan
depletion
Day of 
sacrifice
Control@ day 29 1.4 ± 0.4 0.4 ± 0.2 1.2 ± 0.8 day 38
mIL-4 day 29 1.2 ± 0.6 0.5 ± 0.3 1.3 ± 0.8 day 38
mIL-10 day 29 1.5 ± 0.5 0.4 ± 0.2 1.4 ± 0.7 day 38
mIL-4/mIL-10 day 29 0.7 ± 0.4 0.1 ± 0.1* 0.3 ± 0.4* day 38
# Days after immunization of DBA/1 mice with bovine type II collagen, LPS i.p. at day 28.
& Synovial infiltrate, cartilage damage and proteoglycan depletion are scored on a scale of 0-3.
@ Control group treated with bovine serum albumin. Data represent the mean±SD of two experiments and each 
experimental group consists at least 10 mice. *P<0.01 wilcoxon rank test, compared to control.
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of mIL-4 and mIL-lO in this combined therapy (up to a concentration of 5000 U/day) did not 
further enhance efficacy. When these higher dosages where given separately, mIL-4 remained 
without effect, whereas m IL-l0 alone became suppressive as well. Moreover, we recently 
mimicked our IL-l0 results with a highly purified m IL-l0 preparation (Schering-Plough, 
Kenilworth, NJ, 6  x l0 7  U/mg, data not shown).
In addition to visual scoring we analyzed the histology in both knee and ankle joints at day 9
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after the start of cytokine treatment. On this parameter, only the combination of mIL-4/mIL- 
10 showed reduction of joint pathology (Table 1). Of importance, apart from reduction of the 
amount of inflammatory cells also a significant decrease of cartilage damage and proteoglycan 
depletion was seen.
MACROSCOPIC SCORE MACROSCOPIC  SCORE
DAYS AFTER IMMUNIZATION DAYS AFTER IMMUNIZATION
Figure 2. Effect of mIL-4, mIL-10 and mIL-4/mIL-10 treatment on established, accelerated CIA 
In separate experiments the effect of mIL-4 (A), mIL-10 (B) or both mIL-4 and mIL-10 (C) treatment of establish­
ed CIA was investigated. In (D) treatment was delayed till day 35. The cytokines were applied i.p., twice a day in a 
dose of 1000 Units per injection. As control, bovine serum albumin was used. Start cytokine treatment was indica­
ted by an arrow and the mice were treated for a period of 7 days. The data represents the mean±SD macroscopic 
score of three experiments. Macroscopic scoring was performed daily by two independent observers, without 
knowledge of treatment. The groups in each experiment consist of at least 10 mice. At the end of the experiment 
knee and ankle joints were dissected for histological examination (Table 2). * P < 0.05 compared to control group, 
by Wilcoxon rank test. 101
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Table 2. Histology after mIL-4/mIL-10 treatment of established CIA
Knee joints
Group Start of 
treatment#
Infiltrate & Cartilage
damage
Proteoglycan Day of 
depletion sacrifice
Control@ day 32 1.5 ± 0.3 1.0 ± 0.4 2.5 ± 0.3 day 39
mIL-4 day 32 1.4 ± 0.3 1.2 ± 0.5 2.3 ± 0.6 day 39
Control day 32 1.3 ± 0.3 1.1 ± 0.4 2.5 ± 0.3 day 39
mIL-10 day 32 1.2 ± 0.3 0.8 ± 0.5 1.9 ± 0.5 day 39
Control day 32 1.2 ± 0.3 1.1 ± 0.3 2.4 ± 0.4 day 39
mIL-4/mIL-10 day 32 0.6 ± 0.3 0.5 ± 0.3* 1.3 ± 0.5* day 39
Ankle joints
Group Start of 
treatment#
Infiltrate & Cartilage
damage
Proteoglycan Day of 
depletion sacrifice
Control@ day 32 1.5 ± 0.4 0.8 ± 0.3 1.5 ± 0.2 day 39
mIL-4 day 32 1.3 ± 0.5 0.7 ± 0.3 1.6 ± 0.4 day 39
Control day 32 1.6 ± 0.4 0.7 ± 0.2 1.3 ± 0.6 day 39
mIL-10 day 32 1.3 ± 0.3 0.6 ± 0.1 1.4 ± 0.5 day 39
Control day 32 1.3 ± 0.5 0.9 ± 0.3 1.4 ± 0.5 day 39
mIL-4/mIL-10 day 32 0.6 ± 0.4 0.4 ± 0.2* 0.7 ± 0.3* day 39
# Days after immunization of DBA/1 mice with bovine type II collagen, LPS i.p. at day 28.
& Synovial infiltrate cartilage damage and proteoglycan depletion are scored on a scale of 0-3. @ Control group 
treated with bovine serum albumin. Data represent the mean±SD of three experiments with at least 10 mice 
per group. *P<0.01 wilcoxon ranktest, compared to control.
Modulation o f established CIA by mIL-4, mIL-10 or mIL-4/mIL-10
To extend the potential therapeutic effect to the later stages of the arthritis the start of treatment 
was delayed to day 32 or day 35 respectively. Mice with marked arthritis at day 32 after 
immunization were treated with mIL-4, mIL-10 or mIL-4/mIL-10. Cytokines were injected
i.p. twice a day in a concentration of 1000 U per injection and this was continued for 7 days. 
Treatment of established CIA with mIL-4 did not improve the arthritis score, as can be seen 
in Figure 2A. In contrast, mIL-10 treatment of CIA resulted in a significant suppression of 
macroscopic arthritis scoring (Figure 2B). Interestingly, treatment of established CIA with the 
combination of mIL-4 and mIL-10 markedly ameliorated further expression of collagen 
arthritis (Figure 2C). Of importance, from a therapeutic point of view, treatment of mice with 
full blown arthritis at day 35 with both mIL-4 and mIL-10 resulted in a significant suppression 
of the macroscopic score of CIA (Figure 2D).
Histology, taken at day 39 (after a period of 7 days treatment), revealed that the combination 
of both mIL-4 and mIL-10 protected against cartilage destruction in knee joints as well as in 
the ankle joints (see Table 2, Figure 3). Both parameters, cartilage damage and proteoglycan 
depletion were significantly reduced after treatment with mIL-4/mIL-10 for 7 days. Although 
mIL-10 suppressed the m acroscopic score, no significant effect was found on joint 
histopathology. Murine IL-4 administration had no effect on the histological parameters,
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Figure 3. Effect of late mIL-4/mIL-10 treatment on cartilage destruction. A, Arthritic knee joint (day 39) of a mouse 
treated with bovine serum albumin, twice a day for 7 days. B, Knee joint of a mouse treated with mIL-4/mIL-10 for 
the last 7 days. Note enhanced infiltrate, severe cartilage surface disruption and bone erosion in A (arrows). P= patella; 
F= femur; JS= joint space; C= cartilage; S= synovium. Original magnification x 200.
Table 3. Levels of cytokine mRNA in inflamed tissue samples at day 39.
Relative cytokine mRNA levels
Treatment Tissue# IL-1P IL-1Ra IL-1Ra/IL-ip ratio TNFa TIMP-1
Control@ Synovium 322& 322 1 18 7
mIL-4/mIL-10 Synovium 25 322 13 6 7
Control cartilage 25 47 2 4 4
mIL-4/mIL-10 cartilage 4 47 12 1 4
# On day 39 synovium and cartilage samples were isolated as described in Materials and Methods. 
Values are the relative level of messenger RNA (mRNA), compared with norm al (nonimmunized 
DBA-1 mice) synovium or cartilage. @Arthritic control group.
&Values represent the mean o f 3 repeat studies o f IL-4/IL-10 treatm ent in groups with CIA and 
the PCR measurements on a particular mRNA sample were routinely repeated 3 times. The 
variation in the 3 repeat experiments never exceeded more than 2 cycles.
IL-1P= interleukin-1 beta; IL-1Ra= interleukin-1 receptor antagonist; TN Fa= tum or necrosis 
factor alpha; TIMP= tissue inhibitor o f metalloproteinases. 103
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Figure 4. PCR analysis of cartilage samples. Patellar cartilage samples of 5 
mice were pooled (10 samples) and RNA was extracted. PCR was performed as 
described in Materials and Methods. This experiment was repeated twice, with 
similar outcome.
I, mRNA expression of GAPDH, IL-1, IL-IRa, TNFa and TIMP of arthritic 
control cartilage at day 39. II, mRNA expression in cartilage from mice treated 
from day 32 for 7 days with mIL-4/mIL-10 (2000 U/day).
cellular influx, cartilage damage and proteoglycan depletion. This is in line with the 
macroscopic findings after mIL-4 treatment of CIA.
In a repeat experiment mice were treated for 7 days, started at day 32 with the combination 
of mIL-4/mIL-10. Marked suppression was again found, confirming the above studies. At day 
39 the mice were killed and mRNA was extracted from the synovial tissue and patellar cartilage 
of the knee. Cytokine mRNA levels, determined by RT-PCR analysis are shown in Table 3. In 
inflamed synovium and patellar cartilage a marked increase was found for IL-1 P and IL-1Ra 
message, compared to normal synovium and cartilage. Enhancement of mRNA for TN Fa and 
TIMP was less impressive. Treatment with mIL-4/mIL-10 clearly reduced the message for IL- 
10 and TN Fa in both synovium and cartilage. Although IL-1Ra levels were not upregulated, 
the balance of IL-1Ra/IL-10 improved markedly after treatment with mIL-4/mIL-10, rising 
from 1 to 13. The same effect on the IL-1Ra/IL-10 balance was found in cartilage. This is further 
illustrated in Figure 4. Remarkably, TIMP levels remained similar in the arthritic control, and 
the mIL-4/ mIL-10 treated group and this was found both in synovial tissue as well as in patellar 
cartilage.
Involvement o f mIL-4 and/or mIL-10 during onset o f CIA
To investigate whether endogeneous mIL-4 and/or mIL-10 controlled the onset of CIA we 
neutralized mIL-4 and/or mIL-10 in mice which did not yet develop CIA at day 29 after 
immunization. Groups of mice not showing first signs of arthritis at day 29 were selected and 
divided in 4 groups of 15 mice. Groups then received either control rat Ig’s, anti-mIL-4, anti­
mIL-10 or the combination (anti-mIL-4/anti-mIL-10) by i.p. injection. This treatment was 
repeated at days 32 and 35. Figure 5 shows a poor onset of arthritis in the selected control group. 
Treatment of such animals with anti-mIL-4 antibodies did not alter the course of the disease. 
However, elimination of mIL-10 during this phase markedly accelerated the expression of the 
disease, determined as incidence of arthritis as well as macroscopic severity (Figure 5A,B). This 
indicated that mIL-10 is involved in suppressing disease expression of CIA. Neutralization of 
both mIL-4 and mIL-10 further accelerated the expression of type II collagen-induced 
arthritis. These findings indicate that the onset of CIA is under control of IL-4 as well as IL-
10. This pro-inflammatory effect of both anti-mIL-4 and anti-mIL-10 is further demonstrated 
in Table 4. Both visual score of knee joint inflammation after skin removal and histology are 
increased after elimination of endogenous mIL-4 and mIL-10. Anti-mIL-4 and/or anti-mIL- 
10 treatment before onset of CIA did not induce a shift in collagen type II specific isotype titres
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DISEASE INCIDENCE MACROSCOPIC SCORE
DAYS AFTER IMMUNIZATION DAYS AFTER IMMUNIZATION
Figure 5. Acceleration of CIA with anti-mIL-4/anti-mIL-10 antibodies. To examine the effect of elimination of 
mIL-4/mIL-10 separate groups of mice were treated with either anti-mIL-4 (0.75 mg), anti-mIL-10 (0.5 mg) or both 
antibodies before onset (day 29) of CIA. As control 1.25 mg rat Ig’s was injected. Administration of antibodies was 
repeated at days 32 and 35. Mice were assessed for having arthritis daily. Mice were noted as arthritic when one or 
more digit was inflamed. Data are expressed as incidence (A) and macroscopic score (B). The data represent the mean 
of two experiments, 15 mice per group in the first and 10 mice per group in the second experiment. Findings were 
consistent in the 2 experiments. After killing the mice at day 38, knee joints were examined for joint inflammation 
by visual scoring (Table 4).
Table 4. Effect of anti-mIL-4, anti-mIL-10 or anti-mIL-4/mIL-10 on the expression of 
CIA in knee joints.
Macroscopic Score knee joints.
Visual score# 
None/mild 
Marked 
Severe
Rat Ig s@ 
28*
1
1
Anti-mIL-4
28
1
1
Anti-mIL-10
23
3
4
Anti-mIL-4/mIL-10
15
8
7
Histopathology knee j oints
Rat Ig s@ Anti-mIL-4 Anti-mIL-10
Arthritic joints 17%$ 20% 37%
Infiltration of cells& 0.1 ± 0.2 0.2 ± 0.5 0.6 ± 0.4
Cartilage destruction 0.1 ± 0.3 0.2 ± 0.3 0.2 ± 0.3
Proteoglycan depletion 0.1 ± 0.4 0.2 ± 0.5 0.7 ± 0.4
Anti-mIL-4/mIL-10
70%
1.1 ± 0.5 
0.6 ± 0.3 
1.4 ± 0.4
Effect of neutralization of mIL-4 and/or mIL-10 during onset of CIA. @Each group consists of 15 mice which 
had no signs of arthritis when the first anti-cytokine treatment was given at day 29, as indicated by arrows in 
Figure 5. #Visual arthritis score of knee joints was assessed at day 39 by two independent observers, after the 
skin was removed. This was on a scale ranging from none/mild to severe joint inflammation. *A total of 30 
knee joints per group were scored for having arthritis. $Percentage indicates the arthritic joints as scored by 
histology (score above 0.25 considered arthritic). &Infiltration of inflammatory cells, cartilage destruction and 
proteoglycan depletion was scored on a scale from 0 to 3. Data expressed as mean±SD of all joints (n=30).
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in sera of arthritic mice. Antibody titres of total Ig’s (1/1280), IgG1 (1/640), IgG2a (1/640) and 
IgE (1/320) were found in rat Ig’s treated control mice and in anti-mIL-4, anti-mIL-10 and 
anti-mIL-4/mIL-10 treated mice.
Involvement o f mIL-4 and/or mIL-10 in established CIA
To examine whether endogenous IL-4 and/or IL-10 also has a controlling role in already 
established arthritis, the expression of arthritis was first accelerated in a synchronized way with 
a moderate dose of LPS (20 p,g) at day 28. Separate groups of arthritic mice were then treated 
at days 32, 35 and 38 with either control rat Ig’s, anti-mIL-4, anti-mIL-10 or with the 
combination. Neither treatment enhanced the expression of CIA, as compared to control Ig’s 
(Figure 6 .).
Figure 6 . Effect of neutralization of 
endogenous mIL-4 and/or mIL-10 during 
established CIA. Mice without signs of type II 
collagen arthritis at day 28 were injected with 
20 ^g LPS. This to accelerate the expression of 
CIA. Control rat Ig’s, anti-mIL-4, and/or anti­
mIL-10 treatment was given at days 32, 35 and 
38. Mice were scored daily for having arthritis. 
Data represent the mean of two experiments 
with 10 mice per group for each experiment. 
For details see Figure 5.
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DISCUSSION
Collagen arthritis is a widely accepted model of rheumatoid arthritis and understanding of 
regulation of expression of this form of experimental arthritis as well as insight in cytokine 
manipulations to suppress established disease may provide better therapeutic approaches in 
patients. The critical role of TNFa and IL-1 in this model has been confirmed using neutralizing 
antibodies and IL-1Ra (21,22). In the present study it is clearly demonstrated that therapeutic 
benefit can also be achieved with the combined treatment with IL-4 and IL-10, apparently by 
suppression of TNF/IL-1 production and concomitant shift in the IL-1Ra/IL-1 balance. It is 
furthermore shown that IL-10, and to a lesser extent IL-4 are endogenous mediators in 
prevention of disease expression.
There is ample evidence that IL-10 is an im portant downregulator of a number of macrophage 
functions, including the production of TN Fa and IL-10. IL-10 is abundantly present in joints 
with active RA (24) and in vitro studies with isolated synovial tissue revealed that TNF/IL-1 
production was markedly enhanced after anti-IL-10 treatment, whereas additional, exogenous
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IL-10 was still able to further suppress this cytokine production (25). IL-4, but not IL-10 
enhanced the production of IL-1Ra by RA synovial cells (26). The current findings made it 
clear that systemically administered IL-10, in cooperation with IL-4, markedly suppressed 
established collagen arthritis. Although the effects were impressive, the degree of suppression 
was less than was achieved with anti-IL-1a,0 antibodies or IL-1Ra (21,22). This probably 
indicates that the suppression of IL-1 production with IL-4/IL-10 is not complete, which is 
also suggested by the mRNA data of the cytokine in the synovial tissue. Earlier studies from 
our group revealed that TNF is of importance at onset of collagen arthritis, whereas IL-1 is a 
pivotal cytokine at both onset and later stages of the disease (21,22). The critical dependence 
of IL-1 is recently confirmed by the total absence of onset of collagen arthritis in IL-10 knockout 
mice (46), although these animals showed normal reactions to a large range of inflammatory 
stimuli, including an undisturbed delayed hypersensitivity reaction (47).
There is suggestive evidence from in vitro studies that IL-4 and IL-10 have overlapping, but 
also distinct activities. IL-4, but not IL-10 was shown to inhibit the production of leukemia 
inhibitory factor (LIF) by rheumatoid synoviocytes (48).
Moreover, upregulation of IL-1Ra production has been found for both IL-4 as well as IL-10 
with isolated monocytes (10). However, variable effects have been seen with synovial fluid 
macrophages, intact pieces of synovial tissue and isolated synovial cells, referring to selective 
effects on IL-1Ra production as well as relative potency differences to suppress IL-1 and TNF 
production (26,49,50). Regulation is probably complicated by cytokine interplay between 
various cell types in  inflamed tissue and may also depend on maturation stage of cells. In 
addition, it is now clear that IL-4 and IL-10 exert their suppressive effect on TNF/IL-1 
production through different mechanisms, i.e. by inhibited transcription and enhanced 
mRNA degradation, respectively (7). This fits with the cooperative effect of IL-4 and IL-10 to 
suppress cytokine production by synovial cells (50). Our study is the first to show that IL-4 
and IL-10 exert a clear cooperative effect in an arthritis model in vivo, and this appears to hold 
for both the early and the established phase of collagen arthritis.
Apart from suppression of macroscopic signs of inflammation, combined IL-4/IL-10 treatment 
also markedly reduced histologic scores, including the im portant parameter of cartilage 
destruction. Collagen arthritis is an aggressive form of arthritis showing rapid depletion of 
proteoglycans from the cartilage matrix, as well as surface disruption. Both parameters 
markedly improved (Tables 1 and 2) after combined treatment with IL-4 and IL-10, but not 
with IL-4 or IL-10 alone, at the dose o f2000 Units/day. We have done a few studies with higher 
dosages of IL-10, revealing more marked suppression of macroscopic swelling and synovial 
infiltrate with 5000 Units as compared to 2000 Units. This is in accordance with a recent study 
of Walmsley (31), showing a clear dose dependency of the IL-10 effect and marked suppression 
with a dose of 5 |j,g (5000 U) of IL-10 per day, starting directly after onset of arthritis. In our 
hands, cartilage protection remained limited with IL-10 alone and never reached the marked 
effect noted with the combination.
Of interest, IL-4 may exert a direct protective effect on cartilage destruction in vitro, exceeding 
the level of inhibition of TNF/IL-1 production. IL-4 significantly reduced cartilage proteoglycan 
depletion induced by TNF, IL-1 or LPS (51). Stromelysin levels were enhanced after IL-1, TNF 
and LPS treatment, but IL-4 had no measurable effect on this parameter, leaving the 
mechanism of cartilage protection to be identified. Our analysis of mRNA levels of cartilage 
after IL-4/IL-10 treatment in vivo showed reduced levels of TNF/IL-1 on the one hand and 
similar levels of IL-1Ra/ TIMP (tissue inhibitor of metalloprotease) on the other hand (Table
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3), revealing a protective shift in balance of control of destructive cytokines as well as 
degrading enzymes. The beneficial effect of IL-4/IL-10, directly on the chondrocyte, may 
provide additional therapeutic value of such a treatment, above therapy directed at elimination 
or blocking of TNF/IL-1.
IL-4 is known as a potent mediator to shift the balance of Th1/Th2 cells and to skew the 
production of antibody subtypes. W ith the dosage used in  the present study, we have seen a 
marked shift in the production of anti-lysozyme antibodies in earlier studies in Lysozyme 
arthritis (35). The current findings did not show a change in the subtypes of anti-collagen 
antibodies, probably due to the fact that IL-4/IL-10 treatment was given late (day 29) after a 
first immunization and a booster at day 21. Antibody levels are already very high at that stage 
and the observation period is too short to expect a notable deviation. It further suggests that 
the effects of IL-4/IL-10 treatment on the arthritis were not related to major changes in anti­
collagen antibodies, although it can not be excluded that crossreactive T cell responses to 
murine collagen type II are m ounted at the destructive stage of the disease and may be skewed 
by IL-4.
IL-10 appears to be a natural suppressant of a num ber of inflammatory responses. IL-10 
knockout mice show normal immune responses and hematopoietic development at early age, 
but older animals were afflicted with chronic enterocolitis (52). Endotoxic shock and cutaneous 
inflammatory responses were enhanced in IL-10 knockouts (53,54). Likewise, blocking of 
endogenous IL-10 with neutralizing antibodies enhanced endotoxic shock, IgG immune 
complex-induced lung injury and severity of collagen arthritis (27,28,30). The latter study of 
the group of Kunkel showed an increase in IL-10 at mRNA and protein level in joint tissues 
from the onset of arthritis and accelerated expression of CIA was noted when anti-IL-10 
treatment was started at day 24. This coincided with enhanced expression of the macrophage 
chemokines M IP-1a and MIP-2. We confirmed the anti-IL-10 effect, but in addition showed 
that the highest incidence and most severe arthritis was achieved after elimination of both IL- 
10 and IL-4, although blocking of IL-4 alone did not influence arthritis expression. These 
observations are compatible with an im portant role of IL-4 and IL-10, in particular in control 
of arthritis expression, presumably by suppression of excessive TN Fa and IL-1 production. 
The latter would fit with the earlier observations that a single dose of TN Fa or IL-1, given 
shortly before spontaneous onset of collagen arthritis, caused immediate expression of joint 
inflammation. Along the same line, our current findings indicated that antibodies against IL-
4 and IL-10 did not further enhance collagen arthritis, which was already accelerated with LPS, 
probably due to the fact that these mice already display high levels of LPS induced TN Fa and 
IL-1.
In contrast to the protective role played by IL-10 and IL-4 in collagen arthritis, these cytokines 
may have an opposite role in Th2 dependent processes. IL-10 was shown to exacerbate lupus­
like autoimmunity in NZB x NZW mice and pulmonary histopathology, induced with a 
pneumonia virus could be abrogated by depletion of IL-4 and IL-10 (36,55). Moreover, IL-4 
was recently shown to play an essential role in contact sensitivity skin reactions, transfer of 
delayed hypersensitivity by T cell lines and T cell mediated flares of lysozyme arthritis 
(56,57,35). In addition, it was suggested that IL-10 may have a pathogenic role in rheumatoid 
factor production in RA synovial tissue (24). Finally, in a model of LPS induced uveitis, either 
suppressive or stimulating effects of IL-10 were found, dependent on the dose of IL-10 applied 
(58). These observations underline the different roles in various disease processes and will 
complicate the therapeutic potential in diseases which are not fully understood. Since
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rheumatoid arthritis is considered a Th1 disease, with a dominant involvement of macrophage 
activation and excessive cytokine production, it seems likely that IL-4/IL-10 treatment may 
be of benefit in this disease and clinical trials are warranted.
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ABSTRACT
We investigated potential synergy of low dosages glucocorticosteroids (GC’s) and interleukin- 
10 (IL-10), using established murine collagen-induced arthritis (CIA) as a model. DBA-1J/Bom 
mice were immunized with bovine type II collagen and boosted at day 21. Mice with 
established CIA were selected and treated for at least 7 days with either prednisolone (0.05-5 
mg/kg), IL-10 (0.1-5 |j,g/day) or the combination of prednisolone/IL-10 (0.05/1 and 0.05/5). 
Arthritis score was monitored visually, and joint pathology was examined by histology, and 
serum cartilage oligomeric matrix protein (COMP) measured. Amelioration of CIA was found 
with dosages of 1 and 5 mg/kg prednisolone, while a dose of 0.05 mg/kg prednisolone was 
ineffective. Treatment of CIA with 5 |j,g/day IL-10 resulted in a mild, but significant suppression. 
Synergistic effects were seen with the combination of low dose prednisolone and IL-10 (0.05 
mg/kg, 1 |j,g/day). Both arthritis score and joint pathology were significantly reduced. 
Moreover, COMP levels were significantly decreased after IL-10/prednisolone treatment, 
confirming decreased cartilage involvement. O f great interest, treatm ent of CIA with 
prednisolone/IL-10 markedly reduced IL-10 and enhanced IL-10 production by synovial tissue. 
In addition, synovial mRNA levels for IL-10 were decreased, while mRNA levels for IL-10 and 
IL-1Ra were upregulated by combined treatment. This study demonstrates synergistic effects 
of combined treatment with prednisolone and IL-10 on suppressing disease activity of CIA as 
well as reducing cartilage destruction.
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INTRODUCTION
Interleukin-10 (IL-10) is a pleiotropic cytokine that can exert either suppressive or stimulatory 
effects on different cell types. It was discovered as a factor produced by mouse Th2-cells that 
inhibits cytokine production by Th1 cells. IL-10 stimulates the proliferation and cytolytic 
activity of CD8 + T-cells and activates NK cells (1,2). IL-10 is also known as a potent anti­
inflammatory cytokine which acts by inhibiting the synthesis of pro-inflammatory cytokines 
such as interleukin-1 (IL-1), tum or necrosis factor alpha (TNFa), interleukin - 6  (IL-6 ) and 
interleukin - 8  (IL-8 ) by macrophages and monocytes (3,4). Furthermore, IL-10 inhibits 
metalloproteinases and stimulates TIMP-1 production in hum an mononuclear phagocytes 
indicating a protective effect of IL-10 towards extracellular matrix degradation (5). 
Glucocorticoids (GC’s) are potent and commonly used anti-inflammatory agents for human 
RA. Treatment of RA for a long period with these drugs results in  a num ber of side effects 
including osteoporosis and reduced adrenal function. GC’s action on osteoblast function and 
renal calcium uptake leads to general bone loss. It is known that GC’s downregulate pro- 
inflammatory cytokine production, such as IL-1 and TNFa, by macrophages and monocytes. 
This inhibition is due to enhanced IKBa protein synthesis, with trapping of NF-kB in inactive 
cytoplasmic complexes (6,7). NF-kB activates many immunoregulatory genes in response to 
pro-inflammatory cytokines.
Rheumatoid arthritis (RA) is associated with an increased production of a range of cytokines 
including TN Fa and IL-1, which display potent pro-inflam m atory actions thought to 
contribute to the pathogenesis of RA (8,9). The first clinical trials in RA patients with 
neutralizing agents against TN Fa revealed effective suppression of disease activity (10,11). 
W hether neutralization of TN Fa also results in protection against the ongoing cartilage 
destruction remains unknown.
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A novel therapeutic approach focuses on downregulation of the expression or action of IL-1 
and TNFa, by modulatory cytokines such as interleukin-4 (IL-4) and IL-10. IL-4 and IL-10 
can suppress the production of IL-1 and TN Fa by monocytes/ macrophages and upregulate 
the natural inhibitors of these cytokines, soluble TNF receptor (sTNFR) and interleukin-1 
receptor antagonist (IL-1Ra). Furthermore, ex vivo production of IL-1 and TN Fa by synovial 
tissue from RA patients is suppressed by IL-4 and IL-10 (12,13,14). At the mom ent the first 
clinical trials with IL-10 are performed in inflammatory disorders such as Crohn’s disease and 
RA.
Murine collagen-induced arthritis (CIA) is a widely used experimental model of arthritis. 
Neutralization of the monokines IL-1 and TN Fa before or during onset of arthritis arrested 
the development of CIA. Furthermore, elimination of IL-1 by antibodies or IL-1Ra treatment 
can even suppress fully established arthritis and ameliorate cartilage pathology, whereas TNFa 
neutralization is less effective at this late stage (15,16). Expression of CIA is under stringent 
control of IL-4 and IL-10, in particular. Treatment with anti-IL-4/anti-IL-10 shortly before 
onset accelerated the disease expression. Moreover, IL-4/IL-10 treatment of establised CIA 
results in suppression and prevents cartilage destruction (17).
In the present study, we have investigated the potential synergy of combined low dose of 
prednisolone and IL-10 in the treatment of established CIA. The analysis included visual 
arthritis score and histopathology of the joints, with emphasis on cartilage destruction. 
Furthermore, serum COMP levels were evaluated, as a marker of generalized cartilage 
turnover (18). Finally, synovial IL-10 and IL-10 production and mRNA expression for IL-10, 
IL-1Ra and IL-10 were assessed, to obtain an insight into the mechanism of action. The findings 
suggest that combined IL-10/steroid treatment may provide a safe, cartilage protective therapy 
in inflammatory arthritides, including hum an rheumatoid arthritis.
MATERIALS & METHODS
Animals
Male DBA-1/Bom mice were purchased from Bomholdgard, Denmark. The mice were housed 
in filter top cages, and water and food were provided ad libitum. The mice were immunized 
at the age of 1 0 - 1 2  weeks.
Materials
Complete Freund’s adjuvant and Mycobacterium tuberculosis (strain H37Ra) were obtained 
from Difco Laboratories, Detroit, USA. Bovine serum albumin (BSA), prednisolone 21-sodium 
succinate (P-4153) and OPD (P-3888) were purchased from Sigma Chemicals, St Louis, USA. 
Taq polymerase, TRIzol reagent, and agarose were purchased from Life Technologies, Breda, 
Netherlands. All primers were from Eurogentec, Seraing, Belgium. Anti-murine IL-10 
antibodies (capture PM-425B, detection MM-425B-B) were obtained from  Endogen, 
Cambridge, MA, USA. Anti-murine IL-10 antibodies (capture 18151D, detection 18152D) were 
purchased from Pharmingen, San Diego, CA, USA. PolyHRP-streptavidine (M2032) and 
Casei'ne colloid buffer (M2052) was ordered from  CLB, Amsterdam, Netherlands. 
Recombinant murine IL-10 was generously provided by Dr I. Otterness, Pfizer, Groton, CT, 
USA. Recombinant murine IL-10 (6.5 x 107 U/mg) was kindly provided by Dr. S. Smith, 
Schering-Plough, Kenilworth, NJ, USA.
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Collagen preparation
Articular cartilage was obtained from meta-carpophalangeal joints of 1-2 years old cows. Bovine 
type II collagen was prepared according to Miller & Rhodes (19). Collagen was resolved in 
0.05 M acetic acid (5 mg/ml) and stored at -70°C.
Immunization
Bovine type II collagen was diluted with 0.05 M acetic acid to a concentration of 2 mg/ml and 
was emulsified in equal volumes of complete Freund’s adjuvant (2 mg/ml MT H37Ra). The 
mice were immunized intradermally at the base of the tail with 1 0 0  |jl emulsion ( 1 0 0  |j,g 
collagen). At day 21 the animals were boosted with an i.p. injection of 100 |j,g collagen type II, 
dissolved in phosphate buffered saline (pH 7.4).
Assessment o f arthritis
Mice were examined for visual appearance of arthritis in peripheral joints and scores for severity 
were given (arthritis score) as previously described (16,17). Mice were considered arthritic when 
significant changes in redness and/or swelling were noted in digits or in other parts of the paws. 
At later time points ankylosis was also included in the arthritis score. Clinical severity of arthritis 
was graded on a scale of 0  to 2  for each paw, according to changes in redness and swelling; 0 : 
no changes; 0.5: significant; 1.0: moderate; 1.5: marked; 2.0: maximal swelling and redness 
and later on ankylosis. Arthritis score (mean±SD) was expressed as cumulative value for all 
paws, with a maximum of 8 . Arthritis score was expressed as percentage of the initial arthritis 
score at the beginning of treatment.
Treatment o f CIA with IL-10, prednisolone or IL-10/prednisolone
To evaluate the effect of IL-10, prednisolone or the combination IL-10/prednisolone on 
established CIA, mice with CIA were selected at day 28 and divided into groups of at least 10 
mice with similar arthritis scores. Thereafter, mice were treated twice a day i.p. with IL-10 (1,
5 |j,g/day), prednisolone (0.05 upto 5 mg/kg/day) or with IL-10/prednisolone (1 |j,g or 5 |j,g 
mIL-10 combined with 0.05mg/kg prednisolone) for several days as indicated in the results.
Cytokines in tissues
To examine cytokine levels in patella washouts, patellae were isolated from inflamed knee joints 
as previously described (20). Patellae were incubated in RPMI 1640 medium completed with
0.1% BSA (200 |jl/patella) for 1h at room  temperature. IL-10 and IL-10 levels were measured 
in these washouts by ELISA. The sensitivity of these ELISA’s were respectively 20 and 40 pg/ml.
Determination o f cytokine levels
IL-10 and IL-10 were measured by ELISA. Briefly, Nunc Maxisorb ELISA plates were coated 
with capture antibodies (5 |J.g/ml, carbonate buffer, pH 9.6, 24h at 4 C) thereafter non-specific 
binding sites were blocked with 1% BSA/PBS-Tween. Standards and unknown samples were 
diluted in 0.5% BSA/ PBS-Tween and incubated for 3h at room  temperature. Biotinylated 
detection antibodies were added at concentrations of 0.2-0.4 |J.g/ml in 0.5% BSA in PBS-Tween 
for 1.5h at room temperature. Thereafter plates were incubated with PolyHRP (0.1 |J.g/ml in 
1% caseïne colloïd buffer) for 45 minutes and OPD (0.8 mg/ml) was used as substrate. Plates 
were read at 495 nm.
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COMP measurement
At the end of the experiments, serum samples were taken and murine COMP levels were 
determinated by ELISA using similar conditions as described for the assay for hum an COMP 
(18). The assay was modified by using rat COMP for coating the microtiter plates, the standard 
curve included in each plate and by using the polyclonal antiserum raised against rat COMP 
to detect the antibody (21,22). A high cross reactivity was found to murine COMP. This was 
shown both by parallel dilution curves of murine sera to the standard curve prepared with rat 
COMP as well as in experiments where a dilution of murine serum was added to the standard 
curve.
RNA isolation
Mice were killed by cervical dislocation, immediately followed by dissection of the patella with 
adjacent synovium (23,16,17). Two biopsies with a diameter of 3 m m  were punched out of 
each patella, using a biopsy punch (Stiefel, Wachtersbach, Germany): one from the lateral and 
one from the medial side. Six patella specimens per experimental group were taken and 3 lateral 
and 3 medial biopsies were pooled, to yield 2 samples per group. The synovium samples were 
immediately frozen in liquid nitrogen. Synovium biopsies were ground to powder using a 
micro-dismembrator II (B.Braun, Melsungen, Germany). Total RNA was extracted in 1 ml 
TRIzol reagent, an improved single-step RNA isolation method based on the method described 
by Chomczynski and Sacchi (24).
PCR amplification
One microgram of synovial RNA was used for RT-PCR. Messenger RNA was reverse 
transcribed to cDNA using oligodT primers and 1/20 of the cDNA was used in one PCR 
amplification. PCR was performed at a final concentration of 200 |J,M dNTP’s, 0.1 |J,M of each 
primer, and 1 unit Taq-polymerase (Life-Technologies) in standard PCR buffer. The mixture 
was overlaid with mineral oil and amplified in a thermocycler (Omnigene, Hybaid Ltd, UK). 
Message for GAPDH, IL-10, IL-1Ra, and IL-10 was amplified using primers described 
elsewhere [25]. Samples of 5 |jl were taken from the reaction tubes after a certain number of 
cycles. PCR products were separated on 1.6 % agarose and stained with ethidiumbromide. 
GAPDH levels were very consistent in all samples, not warranting any further correction of 
mRNA values for the cytokine of interest.
Histology
Mice were killed by ether anaesthesia. Thereafter, knee joints were removed and fixed for 4 
days in 4% formaldehyde. After decalcification in 5% formic acid the specimens were 
processed for paraffin embedding (26,27,16,17). Tissue sections (7 |j,m) were stained with 
Haematoxylin & Eosin or Safranin O. Histopathological changes were scored using the 
following parameters. Infiltration of cells was scored on a scale of 0-3, depending on the amount 
of inflammatory cells in the synovial tissues. Inflammatory cells in the joint cavity were graded 
on scale of 0-3 and expressed as exudate. Proteoglycan depletion was determined using Safranin
O staining. The loss of proteoglycans was scored on a scale of 0-3, ranging from full stained 
cartilage to destained cartilage or complete loss of articular cartilage. A characteristic parameter 
in CIA is the progressive loss of articular cartilage. This destruction was separately graded on 
a scale of 0-3, ranging from the appearance of dead chondrocytes (empty lacunae) to complete 
loss of the articular cartilage. Histopathological changes in the knee joints were scored in the 
patella/femur region on 5 semi-serial sections of the joint, spaced 70 |J,M apart. Scoring was 
performed on decoded slides by two observers, as described earlier (26,27,16,17).
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Statistical analysis
Differences between experimental groups were tested using the Student t-test, unless stated 
otherwise.
Figure 1. Dose dependent suppression of 
disease activity of CIA by IL-10, prednisolone 
or combination IL-10/prednisolone. A, Mice 
with established CIA were divided into separate 
groups of at least 10 mice. Groups were treated 
i.p. twice a day with either vehicle, 0.1, 1 or 5 
ag/day rmIL-10 for 9 consecutive days. Initial 
arthritis scores at day 28 were respectively: 
vehicle 2.3±0.9, IL-10 0.1 jag, 2.0±0.7, IL-10 1 
ag 2,6±0.6, and IL-10 5 ¡ag 2.5±0.8. B, Mice with 
CIA were treated with either vehicle, 0.05, 0.1, 
1 or 5 mg/kg/day prednisolone. Arthritis score 
at day 28 were respectively; vehicle 1.8±0.5, 
prednisolone 0.05 mg/kg 1.6±0.7, 0.1 mg/kg 
1.9±0.5, 1 mg/kg 1.7±0.4, and 5 mg/kg 1.8±0.7.
C, Mice with CIA were treated with either 
vehicle or combined IL-10/prednisolone at 1 
ag/0.1 mg, 1 ag/0.05 mg or 5 ag/0.05 mg per 
day. Arthritis scores of the groups at day 28 were 
respectively; vehicle 2.2±0.7, IL- 
10/prednisolone 1 |ag/0.1 mg 2.0±0.5, 1 ¡ag/0.05 
mg 2.5±0.7, and 5 ¡ag/0.05 mg 2.3±0.6. The data 
represent the mean arthritis score, expressed as 
percentage of initial value at day 28. 
Experiments were repeated once with roughly 
the same outcome. *P<0.05, Wilcoxon rank­
test compared to vehicle.
RESULTS
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Modulation o f CIA by in vivo treatment o f mIL-10, prednisolone or combination o f mIL-10 and 
prednisolone
To investigate possible synergistic effects of in vivo treatment of CIA with mIL-10 and 
prednisolone, we first performed dose-finding studies with IL-10 and prednisolone. Mice 
expressing CIA at day 28 were injected i.p. with either vehicle, 0.1, 1 or 5 |ig mIL-10 a day. 
Figure 1A shows a dose-dependent suppression of CIA by mIL-10. A dose of 5 |ig mIL-10 results
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Table 1. Effect o f IL-10/prednisolone treatment on the joint pathology o f CIA mice
Treatment Dose# Infiltrate Exudate Cartilage PG
Destruction loss
Vehicle - 1.6±1.0 1.1±0.7 1.5±1.1 2.3±1.2
IL-10/Pred 1/0.1 0.9±0.8 0.6±0.7 1.0±0.9 1.5±1.1*
IL-10/Pred 1/0.05 0.7±0.7 0.6±0.5 0.9±0.9 1.2±1.0*
IL-10/Pred 5/0.05 1.0±0.8 0.6±0.6 0.8±0.7* 1.0±1.1*
Histopathology of arthritic knee joints after treatment with vehicle or the combination of IL-10 and prednisolone. 
Mice were sacrified and both knee joints were used for histology.
#Mice were treated twice a day i.p. with 1 or 5 ^g/day rmIL-10 combined with 0.1 or 0.05 mg/kg prednisolone. 
Each group consist of at least 20 knee joints. *P<0.05 Student t-test, compared to vehicle.
Figure 2. Therapeutic effect of combined IL- 
10/prednisolone treatment on joint pathology 
during establised CIA. A, arthritic knee of the vehicle 
treated group. Note the severe joint inflammation 
and marked loss of proteoglycan staining in 
superficial cartilage. Empty lacunae reflects 
chondrocyte death as marker of cartilage 
destruction, indicated by arrows. B, Knee joint of 
mouse treated with IL-10/prednisolone, 5 ag/0.05 
mg for 9 consecutive days. Note the reduced 
cartilage destruction. P, patella; F, femur; JS, joint 
space; C, cartilage; S, synovium. Safranin O staining 
was used. Original magnification, x200.
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in significant amelioration of CIA, in line with previous results (17), but lower dosages were 
w ithout effect. In addition, mice were treated with a range of prednisolone, 0.05 up to 5 mg/kg 
a day. A significant suppressive effect was noted at doses of 1 and 5 mg/kg (Figure 1B). 
Treatment with doses of 0.1 and 0.05 mg/kg did not result in significant suppression of arthritis. 
We then examined synergistic effects of mIL-10 and prednisolone, using low dose prednisolone 
(0.05 or 0.1 mg/kg) and 1 or 5 ^g mIL-10. Treatment of CIA with mIL-10/prednisolone 
completely arrested the development of CIA (Figure 1C). All the combinations tested revealed 
full suppression of disease progression. The anti-inflammatory effect of mIL-10/prednisolone 
treatment was further supported by joint histology. Table 1 shows that influx of inflammatory 
cells in both synovial tissues and joint cavity was decreased. Moreover, cartilage destruction 
determ ined as chondrocyte death and erosions was suppressed. Furtherm ore, IL- 
10/prednisolone treatm ent of CIA resulted in a significantly reduced loss of m atrix 
proteoglycans as examined by Safranin O staining. Although the amount of inflammatory cells 
in the knee joints was not significantly decreased by IL-10/prednisolone treatment, still a 
cartilage protective effect was seen. Figure 2 depicts the protective effect of mIL-10/prednisolone 
treatment on cartilage joint pathology. In contrast, no reduction in joint pathology was found 
with either mIL-10 (1 or 5 ^g/day) or prednisolone (0.1, 0.05 or 1 mg/kg) treatment alone 
(data not shown). Treatment with high dose of prednisolone (5 mg/kg) significantly reduced 
joint pathology determined as cell influx and cartilage destruction (data not shown).
COMP levels in CIA after treatment with mIL-10, prednisolone or mIL-10/prednisolone 
To obtain further insight into the protection against general cartilage destruction, we 
determined serum COMP levels in the various groups. COMP can be viewed as a marker of
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Figure 3. Serum COMP levels as a marker of 
cartilage turnover. A, COMP level was 
determined in sera of arthritic mice expressing 
different disease activity at day of sacrificing 
(day 36). B, Synergistic suppression of serum 
COMP was found after treatment with IL- 
10/prednisolone Both doses, 1 ag/0.05 mg and
5 ag/0.05 mg per day, reduced serum COMP 
levels to basic levels as found in nonimmunized 
animals (4.2±0.2 ag/ml, dotted line). The data 
represent the mean±SD COMP level of at least
6 sera per group. *P<0.01, student t-test 
compared to vehicle.
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cartilage turnover during experimental arthritis (21,22). Figure 3A shows a strong correlation 
between visual arthritis score and serum COMP levels (r=0.94). This is in line with previous 
findings in collagen-induced and pristane induced arthritis in rats (21,22). Figure 3B shows 
that in non-immunized animals a concentration of 4.6±0.2 |lg/ml COMP is found. Immunized 
DBA-1 mice without signs of collagen arthritis had almost normal COMP levels (data not 
shown). In mice with fully established CIA, serum COMP levels were increased to 8.4±1.3 |ig/ml 
(vehicle group). Treatment of CIA with high dose of prednisolone (5 mg/kg) reduced COMP 
levels to physiological levels, while a dose of 1 mg/kg prednisolone did not decrease COMP 
levels in arthritic animals (data not shown). In line with the histopathological findings after 
mIL-10/prednisolone (5 |lg/0.05 mg) treatm ent of CIA, serum COMP levels were significantly 
reduced compared to vehicle treated CIA (5.2±1.2 versus 8.4±1.3 |ig/ml). Suppression of serum 
COMP levels in CIA was not found after treatm ent with either mIL-10 or low doses 
prednisolone alone.
Figure 4. Synovial tissue levels of IL-1P and IL-10 after 
treatment with either vehicle, IL-10, prednisolone and IL- 
10/prednisolone. Patellae were isolated as described in 
materials and methods section and cultured for 1h at 37°C 
in RPMI 1640 medium. Thereafter IL-1P and IL-10 were 
determined by ELISA. The data are the mean±SD of six 
patellae washouts. This experiment was repeated once with 
roughly the same outcome. *P<0.05, student t-test compared 
to vehicle.
Modulation o f local cytokine levels by mIL-10, prednisolone or mIL-W/prednisolone treatment 
To examine the effect of mIL-10, prednisolone or mIL-10/prednisolone treatment on local 
cytokine production, we analyzed synovial IL-1 P and IL-10 production by arthritic knee joints. 
After 4 or 8  days of treatment with low dose prednisolone (0.05 mg/kg), synovial IL-10 levels 
were decreased compared to a vehicle treated group. In contrast, synovial IL-10 levels of the 
mIL-10/prednisolone treated group were enhanced (Figure 4A). Remarkably, IL-1 P levels were 
unaffected by low dose prednisolone treatment and decreased by IL-10/prednisolone treatment 
(Figure 4B). This was found at days 4 and 8  after treatment. Synovial IL-10 and IL-1P levels 
were not affected by IL-10 treatment compared to the vehicle treated group. These findings
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Figure 5. RT-PCR analysis of synovial tissue mRNA levels for 
IL-ip (A), IL-10 (B) and IL-1Ra (C) after treatment with vehicle, 
prednisolone and IL-10/prednisolone. Synovium biopies of six 
mice per group were pooled and RNA was extracted. Mice were 
treated twice a day i.p. with vehicle, prednisolone (0.05 mg/kg) 
or IL-10/prednisolone (5 |ag/0.05 mg) for 4 or 8 consecutive days. 
Expressed is the number of PCR cycles in which gene product of 
interest was first detectable compared with normal synovium. 
Values are the mean of two experiments in groups with CIA. The 
PCR measurements of a particular cytokine was routinely repeated 
three times. The variations never exceeded more than two cycles.
were further supported by local gene expression of IL-1P, IL-10 and IL-1Ra. Synovial IL-10 
and IL-1Ra mRNA levels of arthritic animals were upregulated after exposure to mIL- 
10/prednisolone for 4 or 8  days (Figure 5). Messenger RNA levels for IL-1 P were decreased 
compared to vehicle treated group. This suppression was more pronounced at day 8  after 
treatment with mIL-10/prednisolone. Of interest, low dose of prednisolone downregulated 
synovial gene expression of IL-10 and IL-1Ra, whereas this is not shown for the combination.
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DISCUSSION
The present study demonstrates clear synergy between low dose prednisolone and IL-10. At 
doses of prednisolone which on their own are ineffective, the combination therapy provided 
marked protection against ongoing arthritis as well as cartilage destruction. This might offer 
an attractive alternative to the use of high dose prednisolone, since it can circumvent the 
unwanted side effects of the drug, including steroid induced osteoporosis.
In earlier studies of murine collagen arthritis it is shown that TN Fa is im portant at onset of 
the disease, whereas IL-1 is the dominant cytokine, not only at the onset but also in the 
progression of the arthritis and the concomitant cartilage destruction (16). Further support
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for the critical role of IL-1 is provided by the absence of collagen arthritis in IL-10 deficient 
mice and the marked reduction of this arthritis in ICE deficient mice as well as normal mice, 
treated with ICE inhibitors (28). Moreover, reduced onset of arthritis was noted in TNF- 
Receptor deficient mice, but once a joint was afflicted the arthritis progressed to full blown 
expression and cartilage destruction, again underlining that TNF is im portant in onset but 
not the dominant cytokine in progression and tissue destruction (29).
Steroids are potent and commonly accepted anti-inflammatory agents, but the major drawback 
on continued usage in arthritis is the severe negative effect on the bone. More recent studies 
into the mechanism of action revealed strong downregulation of macrophage production of 
the pro-inflam m atory cytokines T N Fa and IL-1, related to enhanced IKBa synthesis. 
Intriguingly, over a large dose range the steroids not only inhibit TNF and IL-1, but also reduce 
the production of IL-1RA and regulatory cytokines such as IL-4 and IL-10 (30,31). This suggests 
that the net effect in joint inflammation is flawed by the lack of the protective cytokines IL- 
4/IL-10, which not only inhibit TNF/IL-1 production but are also potent upregulators of 
scavengers such as soluble receptors for TNF and IL-1 as well as IL-1Ra (12,13,14). Moreover, 
IL-4 powerfully reduces iNOS expression, herein counteracting the suppressive effect of IL-1 
on chrondrocyte proteoglycan synthesis, which is mainly NO mediated. Evidence for the latter 
was provided in in vitro studies with NO inhibitors, an observation extended to the in vivo 
situation by our recent finding of lack of IL-1 induced PG synthesis inhibition in iNOS deficient 
mice (32).
Our present data clearly demonstrates the synergistic effect of combination therapy with low 
dose prednisolone and IL-10. IL-10 alone was marginally effective on the arthritis at a dose of 
1-5 ug/day, in line with previous observations in our and other groups (17,33). However, when 
combined with doses of prednisolone as low as 0.05 mg/kg, the development of the arthritis 
was arrested and cartilage destruction was profoundly inhibited. The much improved efficacy 
of the combination was reflected by the desired reduction of IL-1 levels and increased IL-10 
levels in synovial wash-outs. In accordance, synovial IL-10 and IL-1Ra mRNA levels were 
upregulated, and IL-10 mRNA was reduced.
Of interest, we recently showed that the progression of collagen arthritis can be controlled with 
late treatment with recombinant IL-12. W hen mice with established collagen arthritis were 
given a daily dose of 100 ng IL-12, the arthritis was significantly suppressed and the most 
impressive impact on cytokine levels was the marked enhancement of IL-10 in the circulation
(34). In vitro studies already demonstrated the potential of IL-12 to induce considerable levels 
of IL-10 in activated macrophages (35), apparently as a negative feedback control to 
ameliorate/counteract excessive Th1 activation by IL-12. Although we could demonstrate in 
the in vivo study that the suppressive effect on continued IL-12 administration could be blocked 
with anti-IL-10 (34), it remained unlikely that the suppression was solely attributable to 
upregulation of IL-10. Recently, we also analysed the serum samples of these IL-12 treated 
mice on steroid levels, and noted a significant increase in corticosterone levels (244 nmol/l to 
647 nmol/l). In line with the present data, it is tempting to speculate that the observed IL-12 
mediated suppression of collagen arthritis was due to IL-10/steroid synergy.
Since it is documented that high dose steroids not only induce osteoporosis, but also negatively 
affect chondrocyte proteoglycan synthesis (36), we concentrated on the net effect on cartilage 
destruction. Apart from the histology, COMP levels were assessed in the serum of the mice at 
the end of the experiments. This molecule is a major component of articular cartilage and serum 
levels are considered as a marker of generalized cartilage turnover (19,37). More recent studies
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also demonstrated the production of COMP by activated synovial cells (38). Although the 
relative contribution to serum levels is not firmly established im portant information has been 
obtained from studies of collagen arthritis in rats. Thus, increased serum COMP levels are seen 
at time points when erosive changes appear in cartilage while in early stages with marked 
inflammation in the synovium no increased COMP levels are seen (21,22, Larsson and Saxne 
unpublished). In support, the correlation observed in the present study between altered 
cartilage histopathology and serum COMP suggests that altered levels of circulating COMP 
reflects changes in the cartilage. In untreated, arthritic mice, an impressive correlation was 
noted between serum COMP levels and arthritis score (Figure 3). Moreover, COMP levels are 
low in the combination IL-10/prednisolone groups and this reduction is not noted in the 
IL-10 treatment groups. This set of data is fully in line with the lack of consistent reduction of 
histologic cartilage destruction parameters after mere IL-10 treatment and the cartilage 
protective effect in the combination groups.
In conclusion, IL-10 might offer an alternative therapy apart from TNF/IL-1 inhibitors, but 
its limited effect on cartilage destruction warrants combination with other therapeutic 
modalities. The present data suggests that combination with prednisolone at, low dosages 
provides an intriguing option. In line with earlier observations of IL-4/IL-10 synergy (17), it 
must be considered that such a cocktail, together with low dose steroid, might be even more 
efficacious. IL-4 levels are virtually non-detectable in arthritic tissue of RA patients and IL-4 
is expected to contribute also at the level of downregulation of Th1 reactivity.
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ABSTRACT
We investigated the tissue protective effect of systemic interleukin-4 (IL-4) treatment using 
established murine collagen-induced arthritis (CIA) as a model. Potential synergy of low 
dosages glucocorticosteroids (GC’s) and IL-4. DBA-lJ/Bom mice were immunized with bovine 
type II collagen and boosted at day 21. Mice with established CIA were selected at day 28 after 
immunization and treated for at least 7 days with either IL-4, prednisolone, or combinations 
of prednisolone/IL-4. Arthritis score was monitored visually. Joint pathology was evaluated 
by histology, radiology and serum cartilage oligomeric matrix protein (COMP). In addition, 
serum IL-1Ra and anti-collagen antibodies were determined. Treatment of established CIA 
with 1 |j,g/day IL-4 resulted in suppression of disease activity. Of great interest, although IL-4 
had a moderate effect on disease activity, it strongly reduced cartilage pathology, as determined 
by histological examination. Moreover, serum COMP levels were significantly reduced, 
confirming decreased cartilage involvement. In addition, radiological analysis revealed that 
bone destruction was also prevented. Systemic IL-4 administration increased serum IL-1Ra 
levels and reduced anti-CII antibody levels. Treatment with low dose IL-4 (0.1|j,g) was 
ineffective. However, synergistic suppression of both CIA and COMP levels was noted when 
IL-4 was combined with low dose prednisolone, which in itself was not effective. This study 
demonstrates that systemic IL-4 treatment ameliorates disease activity of CIA and protects 
against cartilage and bone destruction. Improved anti-inflammatory effect was achieved with 
IL-4/prednisolone treatment. This indicates that systemic IL-4/prednisolone treatment may 
provide a cartilage and bone protective therapy for hum an rheumatoid arthritis.
INTRODUCTION
Interleukin-4 (IL-4) is a pleiotropic T-cell derived cytokine that can exert either suppressive 
or stimulatory effects on different cell types. It was originally identified as a B-cell growth factor 
and regulator of humoral immune pathways (1,2). IL-4 is produced by activated CD4+ T-cells 
and it promotes the maturation of Th2 cells. IL-4 inhibits the differentiation of naive T-cells 
to Th1 and cytokine production by Th1 cells, such as IL-2, and IFN-y (3). IL-4 stimulates 
proliferation, differentiation or activation of several cell types, including fibroblasts, 
endothelium cells, and epithelium cells (4). IL-4 is also known as a potent anti-inflammatory 
cytokine which acts by inhibiting the synthesis of pro-inflammatory cytokines such as IL-1, 
tum or necrosis factor alpha (TNFa), IL-6, IL-8, and IL-12 by macrophages and monocytes 
(5,6,7). Moreover, IL-4 stimulates the synthesis of several cytokine inhibitors such as IL-1Ra, 
IL-1-RII and TNF receptors (8-10). IL-4 suppresses metalloproteinases production and 
stimulates TIMP-1 production in hum an mononuclear phagocytes and cartilage explants, 
indicating a protective effect of IL-4 towards extracellular matrix degradation (11,12). 
Furthermore, IL-4 inhibits both osteoclast activity and survival and thereby blocks bone 
resorption in vitro (13,14).
Rheumatoid arthritis (RA) is associated with an increased production of a range of cytokines 
including TN Fa and IL-1, which display potent pro-inflam m atory actions thought to 
contribute to the pathogenesis of RA (15,16). While TN Fa seems to be the major cytokine in 
the inflammatory process, IL-1 is the key mediator regarding cartilage and bone destruction 
(17,18). Beside direct blockade of IL-1/TNF, regulation can be exerted at the level of
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modulatory cytokines such as IL-4 and IL-10. Of great importance, IL-4 could not be detected 
in both synovial fluid and tissues and this lack of IL-4 is likely to contribute to the uneven 
Th1/Th2 balance in chronic RA (19,20).
Although having a number of side effects, including osteoporosis and reduced adrenal 
function, glucocorticoids (GC’s) are potent and commonly used anti-inflammatory agents for 
hum an RA. GC’s downregulate pro-inflammatory cytokine production, such as IL-1 and 
TNFa, by macrophages and monocytes through enhanced IKBa protein synthesis. IKBa forms 
inactive cytoplasmic complexes with NF-kB which it self activates many immunoregulatory 
genes in response to pro-inflammatory cytokines (2 1 ,2 2 ).
Murine collagen-induced arthritis (CIA) is a widely used experimental model of arthritis. 
Neutralization of the monokines IL-1 and TN Fa before or during onset of arthritis arrested 
the development of CIA (23,24). Expression of CIA is under stringent control of IL-4 and IL-
10, in particular. Treatment with anti-IL-4/anti-IL-10 shortly before onset accelerated the 
disease expression (25). Furthermore, it was demonstrated that IL-12 plays a crucial role in 
the development of CIA, since blockade of endogenous IL-12 completely prevented onset of 
the disease (26). In line with these findings, during onset of CIA predominantly Th1 responses 
towards CII were found (27,28). It is claimed that IL-4 exposure could induce immune 
deviation by enhanced development of Th2-like primary CD4 effector cells (29,30). Several 
animal studies indicated that IL-4 administration, starting just after immunization with the 
disease inducing agent, ameliorated Th1 mediated models of autoimmune diseases such as 
diabetes in nonobese diabetic (NOD) mice and experimental arthritis (31-33). This is the first 
study in fully established CIA with systemic IL-4 treatment. Here we investigated the protective 
effect of IL-4 alone or in combination with prednisolone on disease activity, cartilage and bone 
destruction. In addition, serum COMP levels were evaluated, as a marker of severe cartilage 
destruction. Anti-CII specific antibodies and serum IL-1Ra levels were assessed, to obtain an 
insight into the mechanism of action. The findings suggest that IL-4 treatment protects against 
cartilage and bone destruction and that combined IL-4/steroid treatment may provide a safe, 
anti-inflammatory and anti-destructive therapy in hum an rheumatoid arthritis.
MATERIALS and METHODS
Animals
Male DBA-1/Bom mice were purchased from Bomholdgard, Denmark. The mice were housed 
in filter top cages, and water and food were provided ad libitum. The mice were immunized 
at the age of 1 0 - 1 2  weeks.
Materials
Complete Freund’s adjuvant and Mycobacterium tuberculosis (strain H37Ra) were obtained 
from Difco Laboratories, Detroit, USA. Bovine serum albumin (BSA), prednisolone 21-sodium 
succinate (P-4153) were purchased from Sigma Chemicals, St Louis, USA. Anti-murine IL- 
1Ra antibodies (capture MAP-480, detection BAF-480) were obtained from R&D systems, 
Minneapolis, MN, USA. PolyHRP-streptavidine (M2032) and Caseïne colloïd buffer (M2052) 
was ordered from CLB, Amsterdam, Netherlands. Recombinant murine IL-1Ra was purchased 
from R&D systems, Minneapolis, MN, USA. Recombinant murine IL-4 (6.5 x 107  U/mg) was 
kindly provided by Dr. S. Smith, Schering-Plough, Kenilworth, NJ, USA.
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Collagen preparation
Articular cartilage was obtained from meta-carpophalangeal joints of 1-2 years old cows. Bovine 
type II collagen was prepared according to Miller & Rhodes (34). Collagen was resolved in 
0.05 M acetic acid (5 mg/ml) and stored at -70°C.
Immunization
Bovine type II collagen was diluted with 0.05 M acetic acid to a concentration of 2 mg/ml and 
was emulsified in equal volumes of complete Freund’s adjuvant (2 mg/ml MT H37Ra). The 
mice were immunized intradermally at the base of the tail with 1 0 0  |jl emulsion ( 1 0 0  |j,g 
collagen). At day 21 the animals were boosted with an i.p. injection of 100 |j,g collagen type II, 
dissolved in phosphate buffered saline (pH 7.4).
Assessment o f arthritis
Mice were examined for visual appearance of arthritis in peripheral joints and scores for severity 
were given (arthritis score) as previously described (17,18,24,25,26). Mice were considered 
arthritic when significant changes in redness and/or swelling were noted in digits or in other 
parts of the paws. At later time points ankylosis was also included in the arthritis score. Clinical 
severity of arthritis was graded on a scale of 0  to 2  for each paw, according to changes in redness 
and swelling; 0: no changes; 0.5: significant; 1.0: moderate; 1.5: marked; 2.0: maximal swelling 
and redness and later on ankylosis. Arthritis score (mean±SD) was expressed as cumulative 
value for all paws, with a maximum of 8 . Arthritis score was expressed as percentage of the 
initial arthritis score at the beginning of treatment.
Treatment o f CIA with IL-4, prednisolone or IL-4/prednisolone
To evaluate the effect of IL-4, prednisolone or the combination IL-4/prednisolone on 
established CIA, mice with CIA were selected at day 28 and divided into groups of at least 10 
mice with similar arthritis scores. Thereafter, mice were treated twice a day i.p. with IL-4 (0.1,
1 |j,g/day), prednisolone (0.05 kg/day) or with IL-4/prednisolone (0.1 |j,g or 1 |j,g IL-4 
combined with 0.05 mg/kg prednisolone) for several days as indicated in the results.
Determination o f IL-1Ra levels
IL-1Ra was measured by ELISA. Briefly, Nunc Maxisorb ELISA plates were coated with capture 
antibodies (5 |J.g/ml, carbonate buffer, pH 9.6, 24h at 4°C) thereafter nonspecific binding sites 
were blocked with 1% BSA/PBS-Tween. Standards and unknown samples were diluted in 
normal DBA-1 serum and incubated for 3h at room  temperature. Biotinylated detection 
antibodies were added at concentrations of 0.2-0.4 |J.g/ml in 0.5% BSA in PBS-Tween for 1.5 
h at room  temperature. Thereafter plates were incubated with PolyHRP (0.1 |J.g/ml in 1% 
caseïne colloïd buffer) for 45 minutes and OPD (0.8 mg/ml) was used as substrate. Plates were 
read at 495 nm.
COMP measurement
At the end of the experiments, serum samples were taken and murine COMP levels were 
determinated by ELISA using similar conditions as described for the assay for hum an COMP
(35). The assay was modified by using rat COMP for coating the microtiter plates, the standard 
curve included in each plate and by using the polyclonal antiserum raised against rat COMP 
to detect the antibody (36,37). A high cross reactivity was found to murine COMP (38). This 
was shown both by parallel dilution curves of murine sera to the standard curve prepared with
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rat COMP as well as in experiments where a dilution of murine serum was added to the standard 
curve.
Determination o f anti-collagen antibodies
Antibodies against bovine type II collagen were examined by using an enzyme-linked 
immunosorbent assay (ELISA). Titers of total IgG, IgG1 and IgG2a were measured. Briefly, 
plates were coated with 10 |j,g of bovine type II and thereafter nonspecific bindings sites were 
blocked with 0.1 M ethanolamin (Sigma). Serial 1:2 dilutions of the sera were added followed 
by incubation with isotypes specific goat anti-mouse peroxidase (Southern Biotechnology 
Associates, Birmingham, AL, USA) and substrate (5-aminosalicyclic acid, Sigma). Plates were 
read at 492 nm. Titres were expressed as mean±SD dilution which gives the half maximal value.
Radiological analysis o f bone destruction
At the end of the experiments, knee joints were removed and used for radiological analysis as 
a marker for bone destruction. X-ray photographs were carefully examined using a stereo 
microscope and joint destruction was graded on a scale from 0-5, ranging from no damage, 
m inor bone destruction observed as one enlightened spot, moderate changes, 2-4 spots 
observed in one area, marked changes, 2-4 spots observed in more areas, severe erosions 
afflicting the joint, complete destruction of joint and/or new bone formations. Bone destruction 
was scored on femur head, tibia and patella as described previously (17).
Histology
Mice were killed by ether anaesthesia. Thereafter, knee joints were removed and fixed for 4 
days in 4% formaldehyde. After decalcification in 5% formic acid the specimens were 
processed for paraffin embedding (17,18,24,25,26). Tissue sections (7 |j,m) were stained with 
Haematoxylin & Eosin or Safranin O. Histopathological changes were scored using the 
following parameters. Infiltration of cells was scored on a scale of 0-3, depending on the amount 
of inflammatory cells in the synovial tissues. Inflammatory cells in the joint cavity were graded 
on scale of 0-3 and expressed as exudate. Proteoglycan depletion was determined using Safranin 
O staining. The loss of proteoglycans was scored on a scale of 0-3, ranging from full stained 
cartilage to destained cartilage or complete loss of articular cartilage. A characteristic parameter 
in CIA is the progressive loss of articular cartilage. This destruction was separately graded on 
a scale of 0-3, ranging from the appearance of dead chondrocytes (empty lacunae) to complete 
loss of the articular cartilage. Bone erosion was scored on a scale ranging from 0-3, ranging 
from no abnormalities to complete loss cortical and trabecular bone of femur and patella. 
Histopathological changes in the knee j oints were scored in the patella/femur region on 5 semi­
serial sections of the joint, spaced 70 |xM apart. Scoring was performed on decoded slides by 
two observers, as described earlier (17,18,24,25,26).
Statistical analysis. Differences between experimental groups were tested using the M ann­
W hitney U-test, unless stated otherwise.
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Figure 1. Dose dependent suppression of 
disease activity of CIA by IL-4 and the 
combination of IL-4/prednisolone. Mice with 
established CIA were divided into separate 
groups of at least 10 mice. Groups were treated 
i.p. twice a day with either vehicle, IL-4, 
prednisolone, or with combined IL- 
4/prednisolone for 8 consecutive days. The data 
represent the mean arthritis score, expressed as 
percentage of initial value at day 28. 
Experiments were repeated once with roughly 
the same outcome. *P<0.05, Mann-Whitney 
U-test, compared to vehicle.
Figure 2. Dose-dependent arrestment of 
disease activity by treatment with IL-4 and IL- 
4/prednisolone. The enhancement of disease 
activity between days 28 and 35 of each 
individual mouse is expressed as delta disease 
activity. For treatment protocol see figure 1. 
*P<0.05, Mann-Whitney U- test, compared to 
vehicle.
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RESULTS
Amelioration o f CIA by in vivo treatment o f IL-4
To investigate effects of in vivo treatment of established CIA with IL-4, mice expressing CIA 
at day 28 after immunization were injected i.p. with either vehicle, 0.1, or 1 ^g IL-4 per day. 
Figure 1 shows that administration 1 ^g/day IL-4 results in significant amelioration of CIA, 
but a lower dosage of 0.1 |ig IL-4 was w ithout effect. The anti-inflammatory effect of 1 |ig IL- 
4 was further identified in Figure 2. Herein we expressed the disease progression as delta disease 
activity of all individual mice. Clear increased severity of CIA can be seen in animals treated 
either with vehicle or 0.1 ^g IL-4, whereas significantly decreased disease activity was noted 
after treatm ent with 1 ^g IL-4. Histology revealed that no effect was found on the influx of 
inflammatory cells in joint tissues of IL-4 treated animals when compared to the vehicle treated 
animals (Table 1).
IL-4 protects against cartilage destruction
Systemic treatm ent with high dose of IL-4 (1 ^g/day) significantly decreased cartilage 
destruction, determined as chondrocyte death and cartilage erosions (Figure. 3, Table I). 
However, it did not result in a significantly reduced loss of matrix proteoglycans as examined 
by Safranin O staining (Figure 4, Table 1). It has been demonstrated previously that there is a 
strong correlation between severe cartilage damage and serum COMP levels during murine 
CIA. In naive DBA-1 mice, serum COMP levels are approximately 4.0 |ig/ml and COMP levels 
increased up to 8-12 |ig/ml in mice with fully established CIA (data not shown). Serum COMP 
levels were determined in the various groups to identify the protection against severe cartilage
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Figure 3. IL-4 treatment reduced cartilage destruction, whereas IL-4/prednisolone treatment additionally decreased 
cell influx. A, knee joint of vehicle treated mouse. Severe cartilage destruction can be seen. Empty lacunae reflects 
chondrocyte death as marker of cartilage destruction, indicated by arrows. B, Knee joint of a mouse treated with IL-4, 
1 jig for 8 consecutive days. Note the reduced cartilage destruction and chondrocyte death. C, Knee joint of vehicle treated 
animal. Note the severe cell influx in synovial tissues and joint cavity. D, Knee joint of a mouse treated with IL- 
4/prednisolone (1 |ig/0.05 mg/kg). Note the marked reduction of cell influx. P, patella; F, femur; JS, joint space; C, cartilage; 
S, synovium. Haematoxylin & Eosin staining was used. Original magnification, x200 (A, B) and x100 (C, D). 133
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Table 1. Effect o f prednisolone, IL-4 or IL-4/prednisolone treatment on the joint pathology o f 
CIA mice.
Treatment # Dose Infiltrate Cartilage PG Bone #
destruction loss erosion
Vehicle - 2.3±0.9 2.2±0.9 2.7±1.0 1.9±0.9 20
Prednisolone 0.05
000.+1 2. ± 2 2.6±0.6 1.7±1.1 20
IL-4 0.1 2.5±0.7 2.5±0.8 2.9±0.3 2.0±0.8 10
IL-4 1 2.0±1.0 1.2±0.8* 2.0±0.7 0.6±0.6* 20
IL-4/pred 0.1/0.05 2.1±0.4 1.6±0.7 2.5±0.8 .60.±2. 10
IL-4/pred 1/0.05 1.2±0.5* 1.1±0.9* 1.4±0.7* 0.4±0.5* 10
Histopathology of arthritic knee joints after treatment with vehicle, IL-4, prednisolone or the combination of IL- 
4/prednisolone. Mice were sacrified and knee joints were used for histology. Histology was scored as indicated in 
M&M section. #, Mice were treated twice a day i.p. with either 0.05 mg/kg prednisolone, 0.1 or 1 jag/day IL-4, IL- 
4 or combined with 0.05 mg/kg prednisolone. #number of knee joints per group. *P<0.05 Mann-Whitney 
U-test, compared to vehicle.
Figure 4. Effect of IL-4 or IL-4/prednisolone treatment on matrix proteoglycan loss. A, Knee joint of a control naive 
mouse. The fully stained cartilage layers indicate no loss of proteoglycans. B, Knee joint of an arthritic mouse treated 
with vehicle. Note the severe joint inflammation and complete loss of Safranin O staining of the cartilage layers 
(indicated by arrows). C, Mouse treated with IL-4 (1 ^g/day). Still loss of matrix proteoglycan can be seen. D, Knee 
joint of a mouse treated with IL-4/prednisolone (1 jag/0.05 mg/kg). Marked reduction of matrix proteoglycan depletion 
after combined treatment. For details see Figure 3. Safranin O staining, original magnification x100.
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destruction by IL-4. Figure 5 shows that elevated COMP in CIA were not reduced by treatment 
with low dose IL-4. Of high interest, treatment with high dose IL-4 (1 jag) significantly reduced 
serum COMP levels to values found in non-arthritic control animals.
Figure 5. Serum COMP levels as a marker of 
cartilage turnover. Suppression of serum COMP was 
found after treatment with IL-4 and IL- 
4/prednisolone. IL-4 (1 ag/day) and both doses, 0.1 
ag/0.05 mg and 1 ag/0.05 mg per day, of IL- 
4/prednisolone reduced serum COMP levels to basic 
levels as found in nonimmunized animals (4.2±0.2 
ag/ml). The data represent the mean±SD COMP 
level of at least 6 sera per group. *P<0.01, Mann­
Whitney U-test, compared to vehicle.
Figure 6 . Protection of IL-4 and IL- 
4/prednisolone treatment on bone destruction. 
Knee joints were isolated at day 35 and bone 
destruction was examined by X-ray analysis. For 
treatment scheme see figure 1. Erosions were scored 
on a scale ranging from 0 to 5 on the femur head, 
tibia and patella. Each group consists of at least 9 
knee joints per group. *P<0.01, Mann-Whitney U- 
test, compared to vehicle.
IL-4 protects against bone destruction
Bone destruction, which is a common feature of murine collagen arthritis, was examined by 
radiological analysis. X-rays of knee j oints were taken at the end of the treatment period. Figure 
6  showed that treatment with 1 |ag IL-4 was sufficient to prevent bone destruction, determined 
as bone erosions on the head of the femur, the patella and the tibia. No effect was noted after 
treatment with low dose IL-4. Histological analysis of knee joints corroborated the protective 
effect of IL-4 (Table 1). Figure 7A/C depicts degradation of patellar and femoral cortical bone 
by osteoclasts in the vehicle treated group, whereas almost no osteoclasts were seen in the IL- 
4 treated group (Figure 7D).
Combined IL-4/prednisolone treatment
We examined potential synergistic effects of IL-4 and prednisolone, using low dose 
prednisolone (0.05 mg/kg) and 0.1 or 1 |j,g IL-4. Treatment of CIA with IL-4/prednisolone 
completely arrested the development of CIA (Figure 1 and 2). Both combinations tested 
revealed full suppression of disease progression. In line with previous observations, mice treated 
with 0.05 mg/kg prednisolone alone did not result in significant suppression of arthritis. 
Histology taken after 7 days treatment showed that depletion of matrix proteoglycans, as 
reflected by loss of Safranin O staining, was only reduced in IL-4/prednisolone (1/0.05) treated 
animals (Table 1, Figure 4D). This was in line with the marked reduction of joint inflammation 
as can be seen in Figure 3D. Both combinations of IL-4 and prednisolone reduced serum COMP 
to values found in naive DBA-1 mice. Interestingly, synergistic suppression of serum COMP
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Figure 7. Bone destruction is prevented by IL-4 and IL-4/prednisolone treatment. A, Severe bone destruction in 
patella and femur in knee joint of vehicle treated animal. B, Almost no bone degradation was noted after treatment 
with IL-4/prednisolone (1 ^g/0.05 mg/kg). C, Bone destruction in femur of a vehicle treated animal at higher 
magnification. Osteoclasts, large multinuclear cells, located at the site of bone destruction (arrows). D, No osteoclast 
like cells were found in IL-4 (1 ^g/day) treated animals. For treatment details see Figure 3. S = synovium, B= bone, 
BM = bone marrow. Original magnification, A/B x200, C/D x400.
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was noted after exposure of low dose IL-4 and prednisolone (Figure 5). In contrast to serum 
COMP levels, combined IL-4/prednisolone treatment did not result in synergistic protection 
against bone destruction. High dose IL-4 alone was already highly effective and the combination 
of IL-4 /prednisolone did not further improve the pattern, nor was an adverse effect of 
prednisolone noted (Table 1, Figure 6 , 7B). As found after treatment of CIA with 1 ^g IL-4 
alone, combined IL-4/prednisolone treatment for 7 days caused similar reduction in osteoclast 
numbers (data not shown).
Table 2. Serum IL-IRa levels after treatment with either IL-4, prednisolone, or IL-4/
prednisolone.
Treatment# Dose IL-1Ra (pg/ml)
Vehicle - 414±155
IL-4 0.1 386±213
IL-4 1 838±187*
Prednisolone 0.05 326±165
Prednisolone/IL-4 0.05/0.1 422±129
Prednisolone/IL-4 0.05/1 499±187
Serum IL-1Ra was determined using ELISA at day 35 after immunization. #, Mice were treated as indicated in 
table 1. The data represent the mean±SD of at least 8 mice per group. The sensitivity of the IL-1Ra assay was 160 
pg/ml. *P<0.05, Mann-whitney U-test, compared to vehicle treated animals.
Figure 8 . IL-4 or IL-4/prednisolone treatment is 
associated with reduced anti-CII antibody levels. 
Treatment with 1 jig/day IL-4 resulted in lower anti- 
CII antibodies. Total Ig’s, IgG1 and IgG2a levels were 
reduced. Similar effects were found after treatment 
with IL-4/ prednisolone (1 |lg/0.05 mg/kg). Anti-CII 
levels were determined in at least 6 mice per group. 
Data are expressed as mean±SD dilution which gives 
the half maximal value.
Effect o f IL-4, or IL-4/prednisolone treatment on IL-IRa and anti-collagen antibody levels 
Serum IL-1Ra levels were determined at the end of the experiments and Table 2 shows a 2 fold 
increase after IL-4 treatm ent (1 ^g dose). Treatment with 0.1 ^g IL-4 was without effect on 
serum IL-1Ra levels. Prednisolone reduced IL-1Ra levels, when compared to vehicle treated 
animals. In line with these findings, combined IL-4/prednisolone (1/0.05) treatment resulted 
in lower IL-1Ra levels than found with IL-4.
In addition, anti-collagen antibodies were assayed at the end of treatment period at day 35. 
Collagen specific antibody levels increased rapidly following clinical expression of CIA around 
day 28 after immunization. After IL-4 (1 ^g) exposure for 7 days total IgG’s levels as well as 
IgG1 and IgG2a anti-CII Ab levels were lower compared with vehicle treated animals (Figure 
8 ). Although all anti-CII antibodies were reduced, IgG2a levels showed the most reduction,
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indicating an effect on the Th1 rather that on the Th2 immune response. No decreased anti- 
CII antibody levels were found after treatment with low dose IL-4. The high dose IL- 
4/prednisolone reduced anti-CII antibody levels in the order that was found after treatment 
with 1 |j,g IL-4.
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The present study demonstrates clear tissue protective effect of IL-4, although IL-4 treatment 
did not reveal to be a very potent anti-inflammatory cytokine. Both cartilage and bone erosion 
were prevented by IL-4 treatment of established CIA. Combination with low dose prednisolone 
enhanced the anti-inflammatory capacity of IL-4. This might offer an attractive alternative to 
the use of high dose prednisolone, since it can circumvent the unwanted side effects of the 
drug, including steroid induced osteoporosis.
In previous studies of murine collagen arthritis it is shown that TN Fa is im portant at onset 
of the disease, whereas IL-1 is the dominant cytokine, not only at the onset but also in the 
progression of the arthritis and the concomitant cartilage destruction (17,18,24). Further 
support for the critical role of IL-1 is provided by the absence of collagen arthritis in IL-10 
deficient mice and the marked reduction of this arthritis in ICE deficient mice as well as normal 
mice, treated with ICE inhibitors (39,40). Moreover, reduced onset of arthritis was noted in 
TNF-Receptor deficient mice, but once a joint was afflicted the arthritis progressed to full blown 
expression and cartilage destruction, again underlining that TNF is im portant in onset but 
not the dominant cytokine in progression and tissue destruction (41).
In recent studies, it was clearly demonstrated that onset of CIA is under stringent control of 
IL-4 and IL-10 since blockade of both IL-4 and IL-10, by the use of antibodies accelerated disease 
onset. Furthermore, it was showed that treatment of established murine CIA with low dose of 
IL-4 was without suppressive effect on disease activity and joint pathology. Interestingly, 
combination of low dose IL-4 and IL-10 showed to be more potent anti-inflammatory and 
thereby resulted in protection against cartilage pathology (25). Systemic treatment of murine 
CIA with high dose of IL-4 (3 |j,g/day) during the immunization stage revealed to suppress 
onset and severity. However, when IL-4 administration was terminated disease expression and 
activity rapidly accelerated to values found in the vehicle treated control group (33). Systemic 
IL-4 exposure of streptococcal cell wall (SCW) arthritis in rats resulted in suppression of the 
disease activity and ameliorated the chronic destructive lesions (32). This was associated with 
enhanced levels of IL-1Ra, the natural inhibitor of IL-1. This is in line with the present study 
and with studies in humans, systemically treated with IL-4 (42). However, it is not likely that 
the 2 fold increasement of serum IL-1Ra levels, found after IL-4 exposure is sufficient to 
suppress CIA. As previously mentioned, blockade of IL-1 by anti-IL-1 antibodies or very high 
dose IL-1Ra completely suppressed CIA and leads to full protection against joint pathology 
(17,18,24).
IL-4 levels are virtually non-detectable in arthritic tissue of RA patients, suggesting that the 
disease is either a selective Th1 process or is not driven at all by T cells. An alternative 
explanation could be the fact that IL-1 a  and IL-10 specifically inhibited IL-4 synthesis by T 
cells (43). Other pro-inflammatory cytokines, such as TNFa, IL-6  and IL-12 did not decrease 
IL-4 production, indicating the pivotal role of IL-1 in RA. It is known that IL-4 has a suppressive 
effect on Th1 activity and is a crucial factor in differentiation of naive T cells into the Th2
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phenotype. It is claimed that this suppression is due to the inhibitory effect of IL-4 on IL-12 
generation by APC’s and macrophages (7). IL-12 itself is a potent stimulator of the generation 
of Th1 cells. Analysis of anti-CII antibodies revealed that systemic IL-4 treatment did not alter 
the balance of IgG2a/IgG1 antibodies, indicating no suppressive effect on the Th1 immune 
response. Total anti-CII antibody levels were lower in both IL-4 (1 |j,g/day) and IL- 
4/prednisolone treated animals when compared to vehicle group. We found earlier that anti- 
CII antibody levels rapidly increased after onset of the disease and reached the highest levels 
at day 7 after onset of CIA (Joosten, unpublished data). IL-4 treatm ent arrested the 
development of high anti-CII antibody levels after onset and did not alter IgG2a/IgG1 balance. 
Apart from the histology, COMP levels were assessed in the serum of the mice at the end of 
the experiments. This molecule is a major component of articular cartilage and serum levels 
are considered as a marker of generalized cartilage turnover (43,44). More recent studies also 
demonstrated the production of COMP by activated synovial cells (45). Although the relative 
contribution to serum levels is not firmly established important information has been obtained 
from studies of collagen arthritis in rats. Thus, increased serum COMP levels are seen at time 
points when erosive changes appear in cartilage while in early stages with marked inflammation 
in the synovium no increased COMP levels are seen (36,37, Larsson and Saxne unpublished). 
In line with these findings, low dose IL-4/prednisolone treatment did not suppress disease 
activity but clearly reduced serum COMP levels. Histology revealed that serum COMP levels 
correlated more with cartilage erosions than with loss of matrix proteoglycans, which is a 
reversible process. Recently, it was shown that expression of neo-epitope VDIPEN correlated 
with marked cartilage erosions during experimental arthritis. This neoepitope is formed by 
proteolytic cleavage of aggrecan by metalloproteinases (MMP). VDIPEN expression reflects 
MMP-3 (e.g. stromelysin) activity and it co-localized with collagen breakdown epitopes, 
indicating severe cartilage damage by M M P’s (46,47). It was demonstrated that IL-4 down- 
regulates both stromelysin and collagenase synthesis and thereby contributed to inhibition of 
cartilage destruction (11,12,48). Thus, reduction of cartilage destruction found after IL-4 
treatment may well be due to inhibition of MMP activity.
To control the bone destruction is the most difficult target in the treatment of RA. In areas of 
tumor-like synovial tissue, erosion of subchondral and cortical bone is common, leading to 
the characteristic erosions seen on X-rays in this disease. Osteoclasts, can be seen in the areas 
of bone destruction during CIA. It has been reported that IL-4 inhibits bone resorption by 
inhibition of osteoclasts development and activity in vitro (13,14). Here we reported for the 
first time that systemic IL-4 treatment of established CIA markedly reduced bone erosions, 
examined by radiographic analysis and histopathology. Both bone destruction and osteoclasts 
were not noted in arthritic knee joints of animals treated with high dose IL-4, indicating 
decreased formation of these latter cells. IL-4 also downregulates IL-1, IL-6 , TN Fa and 
prostaglandin E2 production in several cell types, which can play a role in the resorption process 
of the bone. Interestingly, blocking studies with neutralizing antibodies directed against IL-4 
in CIA indicated that endogenous IL-4 inhibited bone destruction. In animals treated with 
anti-IL-4 bone destruction determined by X-ray analysis was aggravated compared to vehicle 
treated animals (data not shown).
Steroids are potent and commonly accepted anti-inflammatory agents, but the major drawback 
on continued usage in arthritis is the severe negative effect on the bone. More recent studies 
into the mechanism of action revealed strong downregulation of macrophage production of 
the pro-inflam m atory cytokines T N Fa and IL-1, related to enhanced IKBa synthesis.
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Intriguingly, over a large dose range the steroids not only inhibit TNF and IL-1, but also reduce 
the production of IL-1Ra and regulatory cytokines such as IL-4 and IL-10 (49). This suggests 
that the net effect in joint inflammation is flawed by the lack of the protective cytokines, which 
not only inhibit TNF/IL-1 production but are also potent upregulators of scavengers such as 
soluble receptors for TNF and IL-1 as well as IL-1Ra (8,9,50). Moreover, IL-4 powerfully 
reduces iNOS expression, herein counteracting the suppressive effect of IL-1 on chondrocyte 
proteoglycan synthesis, which is mainly NO mediated. Evidence for the latter was provided in 
in vitro studies with NO inhibitors, an observation extended to the in vivo situation by our 
recent finding of lack of IL-1 induced PG synthesis inhibition in iNOS deficient mice (51). 
Our present data clearly demonstrates the synergistic effect of combination therapy of low dose 
prednisolone and IL-4. Low dose IL-4 was without suppressive effect on disease activity, which 
is in line with previous studies (38). However, when combined with prednisolone the 
progression of CIA was completely arrested. Furthermore, synergistic suppression was found 
on serum COMP levels, which was reflected also by reduced cartilage destruction. Only 
combined therapy with high dose IL-4 and prednisolone was able to suppress the influx of 
inflammatory cells in joint tissues and reduced the loss of matrix proteoglycans.
In conclusion, IL-4 might offer an alternative cartilage and bone protective therapy apart from 
TNF/IL-1 inhibitors, but its limited effect on the inflammatory process warrants combination 
with other therapeutic modalities. The present data suggests that com bination with 
prednisolone at low dosages provides an intriguing option. In line with earlier observations 
ofboth IL-10/prednisolone and IL-4/IL-10 synergy (38,25), it must be considered that a cocktail 
of IL-4, IL-10 together with low dose steroid, might be even more efficacious therapy for human 
rheumatoid arthritis.
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ABSTRACT
Human cartilage gp-39 (HC gp-39) was recently identified as a candidate autoantigen in the 
pathogenesis of rheumatoid arthritis (RA). Here we investigated the capacity of HC gp-39 to 
interfere in clinical disease induced by a non-related auto-antigen, collagen type II (CII), by 
the induction of cross tolerance. DBA-1J/Bom mice were immunized with bovine CII/FCA 
and were boosted i.p. on day 21 with CII. Tolerance was induced via the intranasal pathway 
with either the disease-inducing antigen (CII), a control antigen (ovalbumin) and HC gp-39 
before priming with CII or around the day of boosting. Arthritis was monitored visually and 
joint pathology was examined by histology and radiology. In addition, CII antibody levels in 
serum were analyzed by ELISA. In contrast to treatment before priming, intranasal application 
of HC gp-39 after immunization markedly suppressed disease activity and prevented joint 
destruction, whereas application of ovalbumin or CII was ineffective. Evidence of HC gp-39 
interfering with the im m une response to CII was demonstrated by decreased anti-CII 
antibody-levels. The combined data indicate that intranasal treatment with HC gp-39 may 
trigger modulatory or regulatory mechanisms that interfere with expression of disease in 
murine collagen-induced arthritis. HC gp-39 is the first cross-tolerance inducing protein in 
arthritis downmodulating a spectrum of disease parameters when given in a semi-therapeutic 
protocol.
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IN T R O D U C T IO N
Rheumatoid arthritis (RA) is characterized by a chronic inflammatory infiltration of the 
synovial membrane which is associated with destruction of cartilage and bone. The disease 
seems to be driven by a tissue specific inflammatory attack on peripheral, cartilaginous j oints. 
Since there is an association of RA with certain alleles of the DRB1 locus it may be hypothesized 
that one or more joint specific antigens may be recognized by HLA class II-restricted T cells, 
which in turn  mediate or perpetuate the inflammatory process ( 1 ,2 ).
Several matrix or cellular components expressed at the site of chronic joint inflammation have 
been proposed as candidate autoantigens amongst which type II collagen (CII), the major 
component of articular cartilage, the cartilage proteoglycan component aggrecan and human 
cartilage glycoprotein 39 (HC gp-39). The potential pathogenic nature of these autoantigen 
candidates in RA has been exemplified by their arthritogenic nature in animal models (3-5). 
HC gp-39 has gained interest recently as a target in RA since 1) both HC gp-39 mRNA and 
protein have been detected in synovial specimens and cartilage of RA patients but not in normal 
cartilage (6,7), 2) HC gp-39 is the predominant secretory protein of synovial fibroblasts and 
is produced by articular chondrocytes (8 ), 3) serum levels of HC gp-39 correlate with joint 
disease (9), 4) peripheral blood mononuclear cells of RA patients proliferate to HC gp-39 
derived peptides (5). Thus, multiple levels of evidence suggest that HC gp-39 is a target of the 
immune response in articular joints of RA patients.
Antigen specific immunological tolerance, a natural and powerful mechanism to avoid 
unwanted immune reactivity to inhaled or ingested antigens, has been put forward as a 
modulatory process that can be exploited therapeutically. Intervention of an antigen-specific 
immune response by the native antigen itself, or with the use of an im m unodom inant epitope, 
has been described extensively as a potent way to prevent the induction of autoimmunity ( 1 0 -
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13). In such a setting, HC gp-39 has been demonstrated to induce tolerance in a study aiming 
at the prevention of HC gp-39 induced arthritis (5). Moreover, when HC gp-39 was applied 
intranasally after clinical signs of arthritis had occurred, effective suppression of disease activity 
was noted (14).
Since in an established autoimmune disease, through intra- and intermolecular antigen- 
spreading multiple antigens are thought to be involved, T cells recognizing one of these 
autoantigens may be targeted to regulate disease. This implies that, for effective 
immunoregulation to occur, such T cells should have the potential to downregulate, by cross­
tolerance, other autoreactive T cells within their neighbourhood. Thus, the success of nasal 
tolerance induction with a candidate auto-antigen may highly depend on the capacity of such 
an antigen to induce cross-tolerance. Therefore, we were interested whether HC gp-39 can 
interfere, by the induction of cross-tolerance, in a non-HC gp-39 triggered cartilage derived 
antigen induced arthritis model in mice.
Collagen-induced arthritis (CIA) is a chronic inflammatory arthropathy considered to be an 
experimental model for RA that can be induced in susceptible strains of mice and rats by 
immunization with heterologous type II collagen (CII) (15-17). Both the generation of CII 
specific Th1-cells and high levels of complement fixing anti-CII antibodies are essential for 
expression and chronicity of this type of arthritis. The process of arthritis in these animals 
displays histopathologic features in common with hum an RA. Involvement of T cells in 
tolerance induction in CIA has been demonstrated previously (18,19). In the current study 
we have used CII-induced arthritis to compare effectiveness of treatment with the antigen used 
for arthritis induction (CII) with a non-related antigen (HC gp-39) known to be expressed in 
arthritis and other inflammatory conditions (7,8,20-22). Two treatment schedules were 
studied in this respect, one preventive scheme (application at days -15, -10, -5) and a semi- 
therapeutic protocol in which antigen was applied at days 20, 25 and 30. These two treatment 
schedules were previously shown to be effective in HC gp-39 induced arthritis (5,14). Aspects 
of these interventions were detailed with the use of X-ray and histopathological analysis. Since 
we hypothesized that the effective influence with clinical disease might be explained by 
downmodulating of Th1 cells evidenced through reduced IgG2a anti-CII concentrations, total 
IgG as well as IgG1 and IgG2a anti-CII antibody levels were monitored in order to obtain clues 
on the supposed mechanistic aspects of intervention protocols. The overall data indicate that 
intranasal application of HC gp-39 initiates immune regulatory mechanisms suppressing 
murine collagen type II induced arthritis and protecting against joint pathology.
MATERIALS a n d  M E T H O D S
Animals and immunization
DBA-1J/Bom mice were purchased from Bomholdgard, Ry, Denmark. Mice were housed in 
filter-top cages, and water and food were provided ad libitum. All mice were immunized at 
the age of 10-12 weeks. Bovine type II collagen was isolated as described previously (23). 
Collagen (2 mg/ml in 0.05 M acetic acid) was emulsified in equal volumes of CFA (4 mg/ml 
Mycobacterium Tuberculosis H37Ra, Difco Laboratories, Detroit, MI, USA). The mice were 
immunized intradermally at the base of the tail with 100 |jl of emulsion. On day 21 animals 
were boosted with an i.p. injection of 100 |j,g of CII dissolved in saline (24).
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Synthesis and purification o f HC gp-39
RecHC gp-39 was isolated from the culture supernatant of a Chinese Hamster Ovary (CHO) 
transfectant clone. HC gp-39 was purified from the supernatant as described previously (5). 
The purification procedure comprised of cation exchange chromatography on sepharose, 
immunoaffinity chromatography and gelfiltration. The purity was over 97% as determined 
by SDS-PAGE electrophoresis.
Intranasal administration o f HC gp-39
Mice were treated intranasally before (days -15, -10, -5) or after (days 20, 25 and 30) the first 
immunization with bovine type II collagen. HC gp-39 (3 - 30 |j,g as specified in the legends of 
the Figures, Organon, Oss, The Netherlands), CII (100 |j,g), ovalbumin (100 |j,g, Sigma 
Chemical Co., St Louis, MO, USA), or buffer solution were administered intranasally, divided 
into two aliquots of 10 |jl, using a PT45 micro conduit and a Hamilton syringe (5,25). Mice 
were anaesthetised lightly with Halothane. As a control, a group of mice was left untreated.
Assessment o f arthritis
Mice were carefully examined three times a week for the visual appearance of arthritis in 
peripheral joints, and scores for severity were given as previously described (24,26). Mice were 
considered arthritic when significant changes in redness and/or swelling were noted in digits 
or in other parts of the paws. At later time points ankylosis was also included in the arthritis 
score. Clinical arthritis was graded on a scale of 0 to 2 per paw, and expressed as a cumulative 
arthritis score per mouse with a maximum score of 8 .
Radiology and histology
At the end of the experiment, knee and ankle joints were isolated and used for X-ray analysis 
as a marker for bone destruction. Immediately thereafter, j oints were fixed in 4% formaldehyde 
for histology. X-ray photographs were carefully examined using a stereo microscope and bone 
destruction of a joint was scored on a scale from 0-5 ranging from no damage to complete 
destruction of the joint. For histology, joints were decalcified in 5% formic acid and were 
processed for paraffin embedding (24,26). Tissue sections (7 |j,m) were stained with 
Haematoxylin and Eosin or Safranin O. Histopathologic changes determined as infiltration 
of cells, cartilage damage and matrix proteoglycan depletion were scored on a scale ranging 
from 0-3, as described previously (24,26). Scoring was performed on decoded slides by two 
observers.
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Determination o f anti-collagen antibodies
Antibodies against bovine type II collagen were examined by using an enzyme-linked 
immunosorbent assay (ELISA). Titers of total IgG, IgG1 and IgG2a were measured. Briefly, 
plates were coated with 1 0  ju,g of bovine collagen and thereafter nonspecific bindings sites were 
blocked with 0.1 M ethanolamin (Sigma). Serial 1:2 dilutions of the sera were added followed 
by incubation with isotype specific goat anti-mouse peroxidase (Southern Biotechology 
Associates, Birmingham, AL, USA) and substrate (5-aminosalicyclic acid, Sigma). Plates were 
read at 492 nm. Titres were expressed as mean±SD dilution which gives the half maximal 
value.
CHAPTER 9
RESULTS
Intranasal administration of HC gp-39 (days 20, 25 and 30) suppresses CIA 
Intranasal application of CII on days -15, -10 and -5 suppressed expression of CIA in terms 
of disease incidence and arthritis severity (Figure 1A,B) which is in line with findings 
previously demonstrated by several authors. Application of HC gp-39 before immunization 
of the animals with type II collagen revealed to be ineffective in this respect. In contrast, 
intranasal application of HC gp-39 after immunization with CII (applied on days 20, 25 and 
30) resulted in an impressive amelioration of disease activity. Both disease incidence and 
arthritis severity were suppressed compared to either CII, ovalbumin, buffer or non-treated 
groups (Figure 2A,B). In fact, seven out of eleven animals treated with HC gp-39 following 
this protocol were fully protected from expression of disease (Figure 2C). This suppressive 
effect of late (days 20, 25 and 30) HC gp-39 administration on CIA expression was confirmed 
in a dose-finding experiment (Figure 3). A dose range of 30 (as in Figure 2) down to 3 p.g of 
HC gp-39 was administered intranasally after immunization. The 30 p.g dose of HC gp-39 
showed clear suppression of disease expression. Doses of 10 or 3 |ig HC gp-39, however, were 
less effective. Individual disease activity scores at day 30 further illustrate significantly reduced 
clinical signs of collagen arthritis following intranasal treatm ent with HC gp-39 (Figure 3B).
HC gp-39 treatment protects against joint pathology
Radiological analysis, as an indicator of bone erosion of knee as well as ankle joints, revealed 
that intranasal treatment with HC gp-39 resulted in protection against bone destruction 
whereas treatment with either CII, ovalbumin or buffer was without such a protective effect 
on bone erosions (Figure 4). This protective effect of HC gp-39 treatment on bone erosion is
Figure 1. Intranasal tolerance induction (days -15, -10, - 
5) with CII prior to CIA reduces expression of disease.
A. Effect of intranasal antigen administration on incidence 
of CIA. HC gp-39, CII, Ovalbumin or saline were applied 
intranasally on days -15, -10 and -5. One group of animals 
was left untreated. Arthritis was induced on day 0. Incidence 
of arthritis was significantly inhibited by intranasal 
application of CII, but not by intranasal application of HC 
gp-39, Ovalbumin or saline. Each data point represents the 
percentage incidence of at least 10 mice per treatment group 
with clinical signs of arthritis. B.Effect of intranasal antigen 
administration on severity of CIA. Intranasal administration 
was applied as described in A, CII application inhibited 
severity of arthritis significantly as compared to all other 
groups of mice. * P<0.05 using students t-test.
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Figure 3. Intranasal application of HC gp-39 reduces 
CIA in a dose dependent manner 
A. Effect of intranasal administration of 3, 10 or 30 |J,g 
HC gp-39 on severity of CIA. Mice were treated with 
either 30, 10 or 3 |lg HC gp-39 or saline on days 20, 25 
and 30. HC gp-39 application inhibited progression in 
a dose dependent manner as compared to saline treated 
group of mice. Data of hind paws are shown. B. 
Individual data of all mice on day 30 following arthritis 
induction. Each data point represents an arthritis score 
per hind paw of a mouse. *** P<0.005, students t-test.
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Figure 2. Intranasal application of HC gp-39 reduces 
CIA.
A. Effect of intranasal antigen administration on incidence 
of CIA. HC gp-39, CII, ovalbumin or saline were applied 
intranasally on days 20, 25 and 30. One group of animals 
was left untreated. Arthritis was induced on day 0. Each 
data point represents the mean clinical arthritis score of at 
least 10 mice per group. B. Effect of inatranasal antigen 
administration on severity of CIA. Mice were treated with 
HC gp-39, CII, ovalbumin or saline on days 20, 25 and 30 
or were left untreated. HC gp-39 application inhibited 
progression of CIA significantly as compared to all other 
groups of mice. C. Individual data of hind paw per mouse 
on day 34 following arthritis induction. Each data point 
represents an individual arthritis score per mouse. * P<0.05 
using students t-test.
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further illustrated in Figure 5. In knee joints of ovalbumin-treated mice, marked bone 
erosions were seen on the head of the femur, the patella and the tibia (Figure 5A). Erosive 
processes were not observed in knee joints of HC gp-39-treated mice. Moreover, in ankle joints 
of HC gp-39 treated mice no bone erosions were detected at all which is exemplified by the 
clear picture of tibia, fibulare (calcaneum) and tarsal bones. In contrast, mice treated with
T
II Oval umin saline none-treated 
intranasal application
Figure 4. Intranasal tolerance induction with HC gp-39 inhibits 
joint destruction in CIA.
All ankle joints (n > 20 per group) were evaluated using X-ray 
analysis on day 34 after arthritis induction. Destructive processes 
in ankle joints (erosion of bone) was scored on a scale from 0- 5:  
score 0: no changes, score 1: minor bone destruction observed as 
one enlightened spot, score2: moderate changes, 2-4 spots observed 
in one area, score 3: marked changes, 2-4 spots observed in more 
areas, score 4: severe erosions afflicting the joint, score 5: complete 
destruction of joint and/or new bone formations. Intranasal 
administration ofHC gp-39 completely inhibited joint destruction 
whereas intranasal administration of CII or ovalbumin had no effect 
as compared with saline treated mice, or mice that were left 
untreated. *** P<0.005 using students t-test.
Figure 5. HC gp-39 protects against joint destruction in CIA: X-ray analysis.
A. Marked zones of bone erosion are found in the head of the femur (arrows) and patella in the knee joint of a control, 
non-treated mouse. B. Clear protection against joint destruction: no bone erosions were found in head of the femur, 
patella or other places in the knee joint of a mouse treated with HC gp-39. C. In the hind paw of a control non-treated 
mouse complete joint destruction was observed in ankle joint and tarsal area (arrows), whereas no bone erosions 
were found in the hind paw of a HC gp-39 treated mouse (D). (fe: femur, ti: tibia, fi: fibula, pa: patella)
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ovalbumin showed an almost complete destruction of the tarsal area resulting in enlightened 
spots in X-ray photography. In line with the above-m entioned radiological findings, 
histological examination of joints of HC gp-39-treated animals showed a significant reduction 
in histopathological alterations. Numbers of joint infiltrating inflammatory cells were strongly 
decreased and cartilage pathology, as determined by cartilage erosion and loss of matrix 
proteoglycans, was significantly suppressed in the HC gp-39 treated group (Figure 6 , Table 1).
Table 1. HC gp-39 treatment ameliorates joint pathology
Ankle joints
Treatment Infiltration of Cartilage damage Proteoglycan Number of
cells depletion joints
evaluated
HC gp-39 0.4 ± 0.8* 0.±0. 0.3 ± 0.8* 22
CII 1.1 ± 1.2 0.±.70. 1.1 ± 1.4 22
Ova 0.9 ± 1.0
000.±.60. 1.0 ± 1.2 20
Buffer 1.4 ± 1.3 1.0 ± 1.1 1.5 ± 1.4 20
Control 1.3 ± 1.3 1.0 ± 1.3 1.1 ±1.4 20
Knee joints
Treatment Infiltration of Cartilage damage Proteoglycan Number of
cells depletion joints
evaluated
HC gp-39
©+1© 0.0 ± 0.0* 0.1 ± 0.5* 14
CII 0.7 ± 1.2 0.8 ± 1.3 0.8 ± 1.3 14
Ova 1.2 ± 1.4 1.0 ± 1.3 1.3 ± 1.4 12
Buffer 1.6 ± 1.2 1.5 ± 1.5 2.0 ± 1.3 12
Control 1.0 ± 1.5 1.0 ± 1.5 1.0 ± 1.5 12
Joint pathology was examined in knee and ankle joint at the end of the experiment (day 34). Histology was
performed on whole joints as described in M&M section. Scoring was performed by two independent
observers on decoded slides. Data represent the mean±SD of at least 12 joints. Five sections, spaced 70 |lM, of a
joint were scored and a the mean value was used for calculation of the mean score per group. *P=<0.05, Mann-
Whitney U-test, compared to control.
HC gp-39 treatment reduces levels o f anti-CII antibodies
Since it is known that CII-specific, complement-fixing, antibodies are needed for collagen- 
induced arthritis to develop, we investigated levels of these antibodies. Anti-CII total IgG, IgG1 
and IgG2a isotypes were determined in sera of animals that were treated with either HC gp-
39, CII or ovalbumin prior to or after the first immunization with collagen. As expected, in 
sera of CII pre-treated (days -15, -10 and -5) animals, significantly lower levels of anti-CII 
antibodies (total IgG, IgG1 and IgG2a) were detected. In contrast, pre-treatment with HC gp- 
39 had no effect on levels of anti-CII when compared to control (OVA-pretreated) mice (Figure 
7A). Analysis of anti-CII antibody titres in sera of animals treated after immunization (days
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Figure 6 . Effect of HC gp-39 treatment on inflammation and cartilage pathology.
A,B. Knee joint sections of a normal mouse, Haematoxilin & Eosin staining (A) and Safranin O staining (B). Note 
the fully stained cartilage layers indicating no proteoglycan loss (inB). C,D. HC gp-39 treated animals. Mild synovial 
inflammation can be seen in figure 6c. No loss of cartilage proteoglycans due to HC gp-39 treatment. E,F. Severe joint 
inflammation in the ovalbumin treated animals. Cartilage destruction and chondrocyte death are indicated by arrows. 
Fully destained cartilage layers reflected total loss of matrix proteoglycans (F).
20, 25 and 30) revealed significantly lower levels of total IgG and IgG2a in the HC gp-39 treated 
group (Figure 7B), suggesting a downmodulation of Th1 type cells. In contrast, treatment 
with CII after immunization did not result in significantly lower levels of anti-CII antibodies 
when compared to control (ovalbumin-treated) mice. The combined data implicate that HC 
gp-39 suppresses CIA by a mechanism of bystander suppression.
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Figure 7. Effective intranasal tolerance induction 
with HC gp-39 is associated with a reduction in anti- 
CII antibody levels.
A. Effect of intranasal antigen administration prior 
to CIA on CII-antibody formation. Administration 
of CII on days -15, -10 and -5 showed a complete 
inhibition of both IgG1 and IgG2a type anti CII- 
antibody formation, whereas administration of HC 
gp-39 showed no effect as compared with 
ovalbumine administration. B. Effect of intranasal 
antigen administration following CII arthritis 
induction on CII-antibody formation. Admini­
stration of HC gp-39 on day 20, 25 and 30 showed 
a marked and significant reduction of IgG total and 
IgG2a type antibody formation. Administration of 
CII showed no effect on antibody formation. 
*P<0.05 using students t-test.
D ISC U SSIO N
Here we demonstrate for the first time that murine type II collagen arthritis is efficiently 
suppressed by intranasal administration of a non-related hum an cartilage antigen e.g. HC gp- 
39 using a semi-therapeutic protocol. Both arthritis incidence and severity were significantly 
suppressed. Histological analysis of knee and ankle joints proved the absence of an abundant 
inflammatory process: almost no infiltrating cells and no proliferating synovial tissue were 
observed. Most interestingly, bone erosions and cartilage destruction were completely 
prevented by HC gp-39 treatment. The disease modifying capacity of HC gp-39 is in sharp 
contrast with the data on intranasal administration of the disease inducing antigen, type II 
collagen, where no influence on the course of CIA and ongoing joint destruction was found. 
In previous studies using CII, a reduction of arthritis severity was seen (27,28). However, 
effective tolerance induction was only achieved by oral administration of peptides, in stead of 
whole protein, with high dosages ( 1 0 0  |j,g peptide) given every other day over a period of 2 0  
days, starting at day 24 after immunization with CII (27). In our study, we applied 100 |j,g of 
native bovine collagen at days 20, 25 and 30 after immunization and this could explain 
differences in efficacy of the treatment. On the other hand, intranasal application of CII prior 
to immunization of the animals suppressed both disease incidence and severity of CIA. This 
is in line with previous findings using CII or collagen peptides (18,19,23,24).
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Nasal application of HC gp-39 before immunization with CII did not influence the onset or 
course of the arthritis. The lack of efficacy of preventive HC gp-39 treatment could be due to 
the fact that regulating T cells induced by the nasal application of HC gp-39 gradually lose 
their potential to modulate (29). At time of onset of arthritis, from day 23 onwards (Figure 
1A), most of these T cells may have become apoptotic or anergic in the absence of repetitive 
antigen re-stimulation in this four-week time interval (30). Thus, the window of time between 
the last intranasal application (day 5 before immunization) and the expression of clinical disease 
(around day 23) may have been too large. This is different for CII tolerance induction, since 
an effect of the induced regulatory anti-CII T cells both on priming and boosting with CII at 
days 0 and 21 might be expected. On the other hand, it has been demonstrated that induction 
of bystander suppression with other non-related antigens can be achieved in an early treatment 
regimen. Nasal administration of heat shock protein 60 (HSP-60), prior to immunization, 
suppresses both CIA and another experimental arthritis model, avridine-induced arthritis 
(31,32). In these cases, reduced anti-collagen IgG2a isotype antibodies were found due to cross­
tolerance induction with HSP-60. It has been shown that IgG2a isotype mediates CIA 
expression, since this isotype fixes to complement and complement activation is required for 
the onset of CIA (33). In our study intranasal application of CII, but not of HC gp-39, before 
immunization with CII reduced IgG2a anti-CII antibody levels implicating that such an effect 
may be crucial in defining the final outcome of an intervention, namely either the control or 
lack of suppression of CIA.
In contrast to HC gp-39 treatment before immunization, treatment in a semi-therapeutic 
scheme caused a marked reduction of collagen arthritis. This may have been caused by an effect 
of regulatory T cells on anti-CII antibody responses or be the result of a direct or indirect 
suppression of the inflammatory process in the joints, by the local release of suppressive 
cytokines from infiltrating T cells. Whatever the precise molecular mechanism may be, it is 
clear that levels of both total IgG’s and IgG2a CII specific antibodies were markedly reduced 
as a result of the semi-therapeutic nasal application of HC gp-39, strongly pointing to an 
effective inhibition of antigen-specific Th1 cells. Since IgG2a CII antibodies are essential in 
disease expression in CIA (33) this finding may largely explain downmodulation of arthritis 
following HC gp-39 treatment. Research aiming at the definition of factors or mechanisms 
involved is currently in progress.
Cross tolerance as a way to modulate an immunological process has received major attention 
(34-36). Three mechanisms for tolerance induction have been proposed: clonal deletion, 
induction of anergy and T cell-mediated suppression. Deletion or anergy induction can be 
induced by high doses of antigen, whereas application of a low dose of antigen may lead to T 
cell-mediated suppression (13,37). Both competitive effects of regulatory T cells on antigen 
presenting cells (APC’s) and production of regulatory cytokines, such as interleukin-4 (IL-4), 
IL-10 and transform ing growth factor beta (TGF0) have been proposed as potential 
mechanisms of T cell-mediated suppression (38,39). Recently, it was shown that active cellular 
suppression was mediated via secretion of suppressive cytokines such as TGF0, IL-4 and IL-
10 following antigen-specific triggering (40). These cytokines downregulate disease inducing 
Th1 responses by either inhibiting IL-12 mediated Th1 cell proliferation or by a direct 
suppressive effect on the production of Th1 cytokines, such as IFN-y, IL-2 and TN Fa (41,42) 
which may the result in an inhibition of IgG2a antibody responses as seen in our model. IL-
4, IL-10 and TGF0 are powerful inhibitors of IL-12 production, which itself can promote onset 
of collagen arthritis (43,44). Moreover, tolerance induction can be abrogated by IL-12, since
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anti-IL-12 treatment enhances oral tolerance in OVA-TCR-transgenic mice and is associated 
both with increased TGF0 secretion and T cell apoptosis (45). More recently, it was 
demonstrated that IL-4 plays a crucial role in tolerance induction towards CII, since anti-IL- 
4 treatment abrogated oral tolerance induction through reduction of anti-CII IgG2a specific 
antibodies (46). Furthermore, systemic IL-4 administration enhanced oral tolerance in 
experimental allergic encephalomyelytis (EAE) and it was shown that IL-4 was a differentiation 
factor for TGF0 secreting Th3 cells (47). It remains to be seen which of these cytokines plays 
a dominant role in suppression of CIA following nasal application of HC gp-39 and how this 
can be related to the crucial finding that downmodulation of IgG2a anti-CII levels is of major 
importance both in antigen-specific disease regulation and in a cross-tolerance setting. At the 
present, we put forward the involvement of regulatory, HC gp-39 specific T cells in the 
suppression of CIA following nasal HC gp-39 application. Involvement of regulatory T cells 
in nasal tolerance induction with HC gp-39 has been suggested earlier: application of HC gp- 
39 prior to systemic immunization completely inhibited a HC gp-39 specific DTH response 
in Balb/c mice (5,14,25).
Although most patients with RA present scant evidence of a collagen type II specific T cell 
response (48), clinical trials aiming at tolerance induction with this antigen have been initiated 
and the first results of such trials have been published recently. Oral administration of low 
doses chicken type II collagen demonstrated some positive effects on disease activity, whereas 
high doses were ineffective (49,50). These data were in line with findings in animal studies of 
orally applied CII where only low doses result in protection, probably due to the observed 
bystander suppression.
In contrast to the apparent lack of T cell responses to CII, reactivity to epitopes of HC gp-39 
has been found in over 50% of patients with RA (5), identifying this antigen as an interesting 
candidate for specific forms of tolerance induction. Now, in this study we demonstrate for the 
first time that HC gp-39, when administered in a semi-therapeutic protocol, ameliorates 
murine collagen arthritis through the induction of bystander suppression. Thus, the combined 
data provide a strong case for HC gp-39 based immunotherapy in RA, which is to be proven 
in future clinical trials.
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ABSTRACT
Interleukin-12 (IL-12) can promote Th1 responses and early administration of IL-12 during 
immunization was shown to enhance expression of autoimmune collagen-induced arthritis 
(CIA). We now studied the impact of IL-12 at the stage of disease expression and during 
established CIA in DBA-1 mice. Accelerated onset and enhanced severity was provoked when
i.p. injections of 100 ng mIL-12 were given arround time of arthritis onset. Moreover, onset 
of CIA could be ameliorated with anti-mIL-12 antibodies, indicating that IL-12 is a pivotal 
mediator in expression of CIA. In addition, the effect of anti-mIL-12 treatment was analyzed 
in established CIA. Continued treatment did not suppress established arthritis. In stead, these 
mice showed an impressive excerbation of arthritis shortly after cessation of anti-mIL-12 
treatm ent, indicative of inpairm ent of endogenous control. Exaggerated disease was 
characterized by massive granulocyte influx and enhanced expression of IL-10 and TNFa 
mRNA in the synovial tissue. Subsequently, we treated established collagen arthritis with rmIL- 
12 for 7 days. Profound suppression of arthritis score was noted, including reduced influx of 
cells and dimished cartilage damage. Ten-fold enhanced levels of IL-10 were detected in sera 
of mIL-12 treated mice and upregulated mRNA levels of IL-10, IFN-y and IL-12 were 
measured in synovial tissue. Finally, the anti-inflammatory effect of IL-12 on CIA could be 
reversed by co-administration of anti-IL-10 antibodies. This study indicates that IL-12 has a 
stimulatory role in early arthritis expression, whereas it has a suppressive role in the established 
phase of collagen arthritis.
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IN T R O D U C T IO N
IL-12 is a pleiotropic cytokine that is produced by antigen-presenting cells, macrophages and 
B cells and it promotes the growth of activated T cells and NK cells (1-4). IL-12 selectively 
generates the development of naive T cells into Th1 cells and stimulates IFN-y secretion by 
differentiated Th1 cells (5,6,7). IL-12 is efficiently induced in macrophages upon stimulation 
with LPS, several bacteria and intracellular parasites (8-10). In LPS induced lethal shock and 
generalized Shwartzman reaction, IL-12 plays a crucial role through the major induction of 
IFN-y and TN Fa (11,12). In general, IL-12 is considered as a principal protective factor in 
bacterial infections, where it bridges innate resistance and antigen specific immunity (13). On 
the other hand, IL-12 may unmask Th1 dependent autoimmune reactions and may be a crucial 
intermediate in the often suggested link between bacterial infections and expression of 
autoimmune diseases (14). On the contrary, it controls excessive tissue pathology in allergy 
and parasitic infections by suppression of the Th2 response (15). Production of IL-12 by 
activated macrophages is enhanced by IFN-y and suppressed by IL-4 and IL-10 (16). More 
recently, it was demonstrated that IL-12 itself is an strong inducer of IL-10 production of T 
cells and macrophages in vitro, potentially providing an im portant negative feedback 
mechanism to prevent excessive activation and tissue pathology (17-21).
Collagen-induced arthritis (CIA) is a widely accepted experimental model of polyarthritis. It 
can be induced in susceptible strains of mice and rats by immunization with heterologous type
II collagen (CII), the major component of articular cartilage, and displays histopathological 
features in common with hum an rheumatoid arthritis (RA) (22-24). The arthritis is dependent 
on the generation of a combination of anti-CII Th1 cellular immunity and the production of
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anti-CII antibodies and full expression is best achieved upon immunization with CII in 
complete Freund’s Adjuvant. The antibodies are essential elements in the onset of the arthritis. 
Complement activating antibodies bind to CII at the cartilage surface, with signs of acute 
inflammation, mild tissue damage and further release of CII from the cartilage. Chronicity is 
than sustained by a T cell reaction in the synovial tissue. The monokines IL-1 and TNF enhance 
the autoimmune response to CII and exacerbate the arthritis (25). Furthermore, neutralization 
of IL-1 with anti-IL-1 antibodies or IL-1Ra even suppressed fully established arthritis and 
ameliorated cartilage pathology, whereas TN Fa neutralization was less effective at that late, 
destructive stage (26-28). Recently, we demonstrated that expression of CIA is under stringent 
control of IL-4 and IL-10, in particular. Treatment with anti-IL-4/anti-IL-10, shortly before 
onset of CIA, accellerated the disease expression. Moreover, IL-4/IL-10 treatment of established 
CIA resulted in clear suppression of the arthritis and prevented cartilage destruction (29). 
First studies with IL-12 in collagen arthritis were focused on early treatment and skewing of 
CII autoimmunity. IL-12 can replace mycobacteria in the immunization protocol and causes 
severe arthritis in DBA/1 mice when coadministered for 5 days with CII in incomplete Freund’s 
Adjuvant (30). A strongly enhanced anti-CII immunity was found. In contrast, high doses of 
IL-12 given to mice immunized with CII in complete Freund’s adjuvant were shown to inhibit 
development of arthritis and this was associated with reduced anti-CII antibody levels (31). 
In the present study, we focused on the potential role of IL-12 at the onset of arthritis, around 
day 28 after primary and boost immunization with CII at days 0 and 21. At that stage the mice 
already display anti-CII T cell im munity and high anti-CII antibody titers. Studies include in 
vivo treatment with either rmIL-12 or neutralizing anti-IL-12 antibodies from day 28 and we 
are the first to demonstrate that such IL-12 treatment can accelerate arthritis expression, 
whereas anti-IL-12 antibodies were shown to prevent arthritis onset. The most striking 
observation was the fact that anti-IL-12 treatment was without effect when started in fully 
established CIA at day 35, yet caused impressive exacerbation shortly after cessation of anti- 
IL-12 dosing, indicative of impairment of endogenous control. Further studies with late IL- 
12 treatment and neutralization with anti-IL-10 revealed impressive IL-12 mediated IL-10 
generation and suggest that IL-12 has a stimulatory role in arthritis onset, yet a controling role 
in the established stage of collagen arthritis. This would urge for subtle tuning of IL-12 directed 
therapy in hum an arthritis.
MATERIALS a n d  M E T H O D S
Animals
Male DBA-1 Lac/J mice were obtained from Jackson Laboratories (Bar Harbor, ME). Male 
DBA-1/Bom mice were purchased from Bomholdgard, Denmark. The mice were housed in 
filter top cages, and water and food were provided ad libitum. The mice were immunized at 
the age of 9-10 weeks.
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Materials
Complete Freund’s adjuvant and Mycobacterium tuberculosis (strain H37Ra) were obtained 
from Difco Laboratories, Detroit, USA. LPS (E. Coli, 0111:84), Ethidiumbromide, rat Ig’s, 
sheep Ig’s, and bovine serum albumin were purchased from Sigma Chemicals, St Louis, USA. 
Taq DNA Polymerase, 100 bp DNA marker, TRIzol Reagent, and Agarose were obtained from
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Life Technologies, Breda, The Netherlands. Goat anti-murine Ig’s-peroxidase (PO), goat anti­
murine IgG1-PO, goat anti-murine IgG2a-PO were obtained from Southern Biotechnology 
Associates Inc., Birmingham, AL, USA. GAPDH, IL-1ß, IL-1Ra, IL-4, IL-10, IL-12, IFN-y, 
TGFß and TN Fa primers were purchased from Eurogentec, Seraing, Belgium. Recombinant 
murine IL-12 (3 x 106  U/mg) and purified sheep anti-murine IL-12 IgG were kindly provided 
by Dr. S. Wolf, Genetics Instistute Inc., Cambridge, MA, USA. Murine IL-10 ELISA kits were 
obtained from R&D Systems Europe Ltd, Abingdon, England. Cytoscreen murine IFN-y ELISA 
was purchased from Biosource, Camarillo, CA, USA. Hybridoma cells (JES5-2A5) producing 
rat anti-murine IL-10 were obtained from ATCC, Rockville, MA, USA.
Collagen preparation
Articular cartilage was obtained from meta-carpophalangeal joints of 1-2 years old cows. Bovine 
type II collagen was prepared according to Miller & Rhodes (26). Collagen was resolved in
0.05 M acetic acid (10 mg/ml) and stored at -70°C.
Immunization
Bovine type II collagen was diluted with 0.05 M acetic acid to a concentration of 2 mg/ml and 
was emulsified in equal volumes of complete Freund’s adjuvant (2 mg/ml MT H37Ra). The 
mice were immunized intradermally at the base of the tail with 1 0 0  |jl emulsion ( 1 0 0  |j,g 
collagen). At day 21 the animals were boosted with an i.p. injection of 100 |j,g collagen type II, 
dissolved in phosphate buffered saline.
Acceleration o f collagen-induced arthritis
When DBA-1 Lac/J mice were immunized with collagen type II and boosted at day 21 a gradual 
onset of collagen arthritis was noted from day 28. At this time point mice were visually scored 
for having collagen-induced arthritis. In general, arthritis incidence ranged from 10-30 % of 
these animals. Mice without clear macroscopic signs of arthritis were selected at this stage and 
the onset of arthritis was accelerated by a single i.p. injection of 40 |j,g of LPS (27,32). This 
resulted in onset of CIA within three days and at day 35 full blown expression of arthritis was 
noted in paws of more than 95% of the animals. The histopathology in knee and ankle joints 
was comparable in accelerated CIA and classic CIA. As described previously, administration 
of 40 |j,g LPS to non-immunized DBA-1 Lac/J mice, or mice immunized with a non- 
arthritogenic antigen did not result in any macroscopical or histological abnormalities (33). 
Immunization of DBA-1/Bom mice resulted in high disease expression of 80-90 % arround 
day 28. Therefore, LPS acceleration was not nessesary in these animals.
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Assessment o f arthritis
Mice were examined for visual appearance of arthritis in peripheral joints and scores for severity 
were given (arthritis score) as previously described (26-29). Mice were considered arthritic, 
when significant changes in redness and/or swelling were noted in digits or in other parts of 
the paws. At later time points ankylosis was also included in the arthritis score. Clinical severity 
of arthritis was graded on a scale of 0  to 2  for each paw, according to changes in redness and 
swelling; 0: no changes; 0.5: significant; 1.0: moderate; 1.5: marked; 2.0: maximal swelling and 
redness and later on ankylosis. Arthritis score (mean±SD) was expressed as cumulative value 
for all paws, with a maximum of 8 . More than 90% of the animals which expressed CIA in a 
particular ankle joint, expressed arthritis in the knee joint of the same leg.
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Treatment o f CIA with mIL-12, anti-mIL-12 or anti-mIL-10 antibodies 
To evaluate the effect of mIL-12 on onset of CIA, DBA-1 Lac/J mice without signs of arthritis 
at day 28 were treated for 5 days with 100 ng of mIL-12 or bovine serum albumin as control. 
The role of endogenous IL-12 during LPS acceleration of DBA-1 Lac/J mice was studied by 
anti-mIL-12 treatment. 200 |j,g of purified sheep anti-murine IL-12 antibodies (34) or sheep 
Ig’s were injected i.p., starting 2h before LPS injection at days indicated in the results. DBA-1 
Bom mice with established CIA at day 35 were selected and divided in groups of at least 10 
mice with similar arthritis score. Thereafter, mice were treated daily with 100 ng of mIL-12, 
starting at day 35 upto day 42. Anti-mIL-12 treatment of DBA-1 Bom mice with full blown 
CIA was given i.p. at days indicated in the results. To investigate the effect whether IL-10 was 
involved in IL-12 mediated suppression of full blown CIA, mIL-12 (100 ng/day) and anti-mIL-
10 (0.75 mg JES5-2A5 (29,35) were injected. As control we injected 0.75 mg rat Ig’s and 100 
ng BSA i.p.
RNA isolation
Mice were killed by cervical dislocation, immediately followed by dissection of the patella with 
adjacent synovium (36,37). Two synovium biopsies with a diameter of 3 m m  were punched 
out of each patella, using a biopsy punch (Stiefel, Wachtersbach, Germany): one from the lateral 
and one from the medial side. Six patella specimens per experimental group were taken and 
3 lateral and 3 medial biopsies were pooled, to yield 2 samples per group. The synovium samples 
were immediately frozen into liquid nitrogen. Synovium biopsies were ground to powder using 
a micro-dismembrator II (B.Braun, Melsungen, Germany). Total RNA was extracted in 1 ml 
TRIzol reagent, an improved single-step RNA isolation method based on the method described 
by Chomczynski and Sacchi (38,37).
PCR amplification
One microgram of synovial RNA was used for RT-PCR. Messenger RNA was reverse 
transcribed to cDNA using oligodT primers and 1/20 of the cDNA was used in one PCR 
amplification. PCR was performed at a final concentration of 200 |J,M dNTP’s, 0.1 |J,M of each 
primer, and 1 unit Taq-polymerase (Life-Technologies) in standard PCR buffer. The mixture 
was overlaid with mineral oil and amplified in a thermocycler (Omnigene, Hybaid Ltd, UK). 
Message for GAPDH, IL-1, IL-1Ra, IL-4, IL-10, IL-12, IFN-y, TGF0 and TN Fa was amplified 
using primers described elsewhere (27,39). Samples of 5 |jl were taken from the reaction tubes 
after a certain number of cycles. PCR products were separated on 1.6 % agarose and stained 
with ethidiumbromide. GAPDH levels were very consistent in all samples, not warranting any 
further correction of mRNA values for the cytokine of interest.
Blood analysis
Mice were bled after ether anaesthesia and blood was collected in 2 ml EDTA-tubes, mixed 
well and placed on 4°C. Thereafter the levels of white blood cells (WBC), RBC, large 
unidentified cells, hemoglobulin and a differentation of the WBC was determined on a 
cytometric analyzer (Bayer/Technicon H2, Mijdrecht, The Netherlands).
Determination o f anti-collagen antibodies
To investigate whether treatment of CIA with mIL-12 or anti-mIL-12 changed collagen type
11 specific antibody subtypes, we determined subtype antibodies titres. Antibodies against
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bovine type II collagen were determined with an enzyme-linked im m unosorbent assay 
(ELISA). The titres of either total Ig’s, IgG1, IgG2a were measured. Briefly, ELISA plates (NUNC 
maxisorb) were coated with 10 |j,g bovine type II collagen. Thereafter, non-specific bindings 
sites were blocked with 1% BSA solution. Serial 1/10 dilutions of the immune sera were added 
followed by an incubation with isotype-specific goat anti-mouse-peroxidase ( 1 :1 0 0 0 ) and 
substrate (5-aminosalicylic acid). Plates were read at 492 nm.
Histology
Mice were killed by ether anaesthesia. Thereafter, ankle and knee joints were removed and 
fixed for 4 days in 4% formaldehyde. After decalcification in 5% formic acid the specimens 
were processed for paraffin embedding (26,27,36). Tissue sections (7 |j,m) were stained with 
Haematoxylin & Eosin or Safranin O. Histopathological changes were scored using to the 
following parameters. Infiltration of cells was scored on a scale of 0-3, depending on the amount 
of inflammatory cells in the synovial cavity and synovial tissues. Proteoglycan depletion was 
determined using Safranin O staining. The loss of proteoglycans was scored on a scale of 0-3, 
ranging from full stained cartilage to destained cartilage or complete loss of articular cartilage. 
A characteristic parameter in CIA is the progressive loss of articular cartilage. This destruction 
was separately graded on a scale of 0-3, ranging from the appearance of dead chondrocytes 
(empty lacunae) to complete loss of the articular cartilage. Histopathological changes in the 
knee joints were scored in the patella/femur region on 5 semi-serial sections of the j oint, spaced 
70 |J,M apart. Scoring was performed on decoded slides by two observers, as described earlier 
(26,27,36).
Statistical analysis
Differences between experimental groups were tested using the Wilcoxon rank test, unless 
stated otherwise.
RESULTS
Role o f IL-12 during the onset o f CIA
DBA-1 Lac/J mice develop gradual onset of collagen-induced arthritis after immunization with 
type II collagen in CFA, ranging from 30% up to 90% at day 70. Early expression of CIA can 
be enhanced with a single i.p. injection of 40 |j,g LPS at the time of onset at day 28 (Figure 1A). 
To investigate the involvement of IL-12 in this acceleration, mice without signs of CIA were 
selected at day 28 and challenged with LPS. Treatment with 200 |j,g purified sheep anti-mIL- 
12 antibodies at days 28, 30 and 32, starting shortly after LPS injection, highly reduced CIA 
expression (Figure 1A). Anti-mIL-12 treatment suppressed LPS accelerated CIA expression 
to the level of onset of CIA in non-treated DBA-1 Lac/J mice. To further underline the 
accelerating role of IL-12, daily treatment with 100 ng mIL-12 was given from day 28 upto day
32. Enhanced disease incidence was evident within a few days (Figure 1B). In addition, we 
studied whether endogenous IL-12 is involved in onset of CIA. Since onset of arthritis is rather 
variable in DBA-1 Lac/J mice, DBA-1 Bom mice were used, which normally show high arthritis 
incidence after CII immunization ( 80% incidence at day 38; Figure 2A). Treatment with 200 
|J.g of purified sheep anti-mIL-12 Ig’s at days 28, 30 and 32 suppressed both disease incidence 
and arthritis score of CIA (Figure 2A,B). Subsequent studies were all performed with DBA-1 
Bom mice.
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Figure 1. Role of IL-12 during onset of accelerated and 
classic CIA in DBA-1 Lac/J mice. (A) Immunized DBA- 
1 Lac/J mice without signs of CIA at day 28 were divided 
in three separate groups of at least 10 mice. One group 
of mice were not treated and arthritis onset was 
monitored. The other groups were either treated with 
200 |ag sheep Ig’s or with 200 |ag sheep anti-mIL-12 
antibodies followed by LPS acceleration. (B) Immunized 
DBA-1 Lac/J mice without signs of CIA were selected and 
divided in two separate groups of 10 mice. Mice were 
treated with either 100 ng mIL-12 or 100 ng BSA for 5 
consecutive days. The data represents the mean 
incidence of disease of two identical experiments.
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Figure 2. Effect of anti-mIL-12 treatment on onset of 
CIA in DBA-1 Bom mice. Mice without expression of 
CIA were selected at day 28 after immunization with CII, 
and divided in two separate groups. Mice were treated 
with either 200 |ag sheep Ig’s or 200 |ag anti-mIL-12 
antibodies at days indicated by arrows. (A) Incidence of 
CIA is expressed. (B) Arthritis score is expressed. The 
data represents the mean incidence or the mean±SD 
arthritis score of two experiments with at least 10 mice 
per group. *P<0.05, Wilcoxon rank test, compared to 
control group.
Role o f IL-12 in established CIA
To investigate involvement of IL-12 in established arthritis, treatment with neutralizing anti­
mIL-12 antibodies was started at day 35 and repeated at days 37 and 39. Unexpectedly, no 
suppression of arthritis severity was found. In stead, these mice showed an impressive 
exacerbation of arthritis, starting a few days after cessation of anti-mIL-12 treatment and 
suggesting that endogenous control of arthritis was impaired by anti-mIL-12 treatment. This 
experiment was repeated and synchronized data is shown in Figure 3. In a third experiment 
the degree of exacerbation was less. As can be seen from Table 1 the severity of the arthritis 
was already high in this group, probably explaining the lack of exacerbation.
The exacerbation was confirmed with histology (Figure 4). The num ber of inflammatory cells, 
but in particular, the relative num ber of granulocytes, was markedly increased. Cartilage
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Figure 3. Exacerbation of CIA after anti-mIL-12 treatment. 
DBA-1 Bom mice with established CIA were selected at day 
35 and divided in two separate groups of at least 9 mice per 
group with roughly the same mean arthritis score. Anti-mIL- 
12 (200 |J,g) or control Ig’s were injected i.p. as indicated by 
arrows. Data are expressed as mean±SD percentage of the 
control (sheep Ig’s) arthritis score of two experiments (I and
II, see table 1). *P<0.05, Wilcoxon rank test, compared to 
control group.
Table 1. Exacerbation of CIA after anti-mIL-12 treatment.
Arthritis score PMN influx in knee joints
Exp. Group Day 35 Day 46 Day 52 PMN@
I Control 1.8±0.8 2.0±0.9 1.9±1.1 3/18
anti-mIL-12 1.8±0.9 2.8±1.2 3.5±1.3 (185%)# 13/18
II Control 1.9± 1.2 2.8±1.4 2.6±1.1 6/26
anti-mIL-12 2.0±1.3 3.8±1.4 4.2±1.0 (179%) 20/26
III Control 4.7±1.2 4.2±0.9 3.6±0.7 14/18
anti-mIL-12 4.6± 1.1 4.4±1.0 4.4±0.9 (121%) 15/18
Mice with established CIA were selected at day 35 and divided in separate groups of at least 9 mice with the 
same arthritis score. Three repeat experiments were performed. Sheep anti-mIL-12 antibodies (200 |J,g) or 
control sheep Ig’s were injected at days 35, 37 and 39. In total three identical experiments were performed. 
#Arthritis score expressed as percentage of the control at day 52. @The number of knee joints is expressed in 
which marked influx of PMN’s were found in synovial tissues or joint cavity. More than 90% of the animals 
expressed arthritis in both knee and ankle joint of the same leg.
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damage was not significantly higher (Table 2). Further proof of exaggerated disease was 
provided by enhanced IL -ip and TNFa mRNA levels in the synovial tissue, whereas mRNA 
levels of IL-4, IL-10, IFN-y and TGFp were unchanged (Table 3).
Treatment o f established CIA with rmIL-12
Since neutralization of endogenous IL-12 caused a marked exacerbation of arthritis, we 
wondered whether late treatment might have a therapeutic effect. DBA-1 Bom mice with 
established CIA at day 35 were treated for 7 days with 100 ng rmIL-12. This resulted in gradual 
suppression of arthritis, reaching significance at day 40 (Figure 5). Histology taken at day 42 
confirmed this suppression, including a clear reduction in numbers of synovial infiltrate and 
granulocytes. Intriguingly, apart from suppression of cellular infiltrate, amelioration of 
cartilage proteoglycan loss and cartilage surface destruction was noted (Figure 6 , Table 2).
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Figure 4. Influx of granulocytes in arthritic knee joints after anti-mIL-12 treatment of established CIA. (A) Arthritic 
knee joint (day 52) of a mouse treated with sheep Ig’s. Histological scores; 1.0 for infiltrate, 0.3 for cells in the cavity. 
(B) Knee joint of a mouse treated with sheep anti-mIL-12 antibodies. Note the enhanced joint inflammation 
(predominantly granulocytes) after neutralization of IL-12. Histological scores; 2.0 for infiltrate, 1.5 for cells in the 
cavity. P= patella, F= femur, JS= joint space, C= cartilage, S= synovium. H&E staining, original manification 200x
Table 2. Effect of anti-mIL-12 or mIL-12 treatment on knee joint pathology.
Infiltrate Cells in Cartilage Proteoglycan
joint cavity damage depletion
Control@ 1.2±0.4 0.5±0.3 1.8±0.7 1.6±0.6
Anti-mIL12@ 2.1±0.5* 1.3±0.4* 2.4±0.9 2.1±0.5
Control# 1.8±1.0 1.1±0.8 2.0±1.3 2.2±1.4
mIL-12# 0.±0.
©
0.±.00. 1.9±0.9 1.4±1.2
@Anti-mIL-12 (200 jag) treatment was started at day 28 (see Figure 3) and was repeated at days 30 and 32. As 
control sheep Ig’s was injected. Histology was taken at day 52 after the first immunization with collagen.
#Mice were treated for 7 days with 100 ng mIL-12 started at day 35 (see Figure 5). As control we injected 100 
ng of bovine serum albumin. Histology was performed at day 42 after immunization with collagen. Histology 
was scored on a scale ranging from 0 to 3 as indicated in M & M section.
*P<0.05, Wilcoxon rank test. Values represents the mean±SD of two identical experiments with at least 9 mice 
per group.
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Table 3. Synovial mRNA levels after treatment with anti-mIL-12 or mIL-12
Control# snt Control@ mIL-12@
day 52 day 52 day 42 day 42
Cytokine PCR cycles$ ▲* PCR cycles$ ▲*
IL-1 ß 8 9 1 9 9 0
IL-1Ra 8 6 -2 9 9 0
IL-4 2 2 0 2 4 2
IL-10 4 4 0 2 8 6
IL-12 2 0 -2 0 6 6
IFN-y 4 4 0 2 9 7
TGFß 4 4 0 4 6 2
TNFa 4 6 2 4 4 0
Synovial cytokine mRNA levels were determined by RT-PCR technology. Synovium biopsies were taken at the 
end of the experiments. Synovium samples of 6 mice per group were pooled. Values are the mean of 2 
experiments in groups with CIA. The PCR measurements of a particular cytokine were routinely repeated 3 
times. The variations in the 2 repeated experiments never exceeded more than 2 cycles.
#Cytokine mRNA expression at day 52 of CIA. Mice were injected 3 times with sheep Ig’s or with 200 |J,g sheep 
anti-mIL-12 at days 35, 37 and 39.
@Cytokine expression at day 42 in arthritic control and mIL-12 treated groups. Murine IL-12 100 ng was given 
from day 35 upto day 42.
$Number PCR cycles in which gene product of interest was first detectable as compared to normal synovium. 
*▲ refers to the difference between respective control arthritis and anti-mIL-12/mIL-12 treated. IL- 
1=interleukin-1; IL-1Ra=interleukin-1 receptor antagonist; IFN-y=interferon gamma; TGFP= transforming 
growth factor beta; TNFa= tumor necrosis factor alpha.
Figure 5. Suppression of established CIA after IL-12 
treatment. Arthritic DBA-1 Bom mice were divided in two 
separate groups of at least 10 mice at day 35. Murine IL-12 
(100 ng) was injected i.p. once a day for 7 days. As control 
100 ng BSA was used. Data represents the mean±SD arthritis 
score of two experiments. *P<0.05, Wilcoxon ranktest 
compared to control group.
To obtain insight in the mechanism of the IL-12 mediated suppression, mRNA levels were 
measured in synovial specimens. Levels o f IL-1^, IL-1Ra and TN Fa were similar, IL-4 and 
TGFP were slightly enhanced, whereas IL-10 and IFN-y were greatly enhanced in tissue of IL- 
12 treated as compared to control mice. O f interest, IL-12 treatment also induced IL-12 
upregulation (Table 3, Figure 7).
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Figure 6 . Therapeutic effect of IL-12 treatment on joint pathology during established CIA. (A) Arthritic knee joint 
(day 42) of the control (100 ng BSA) group. Note the severe joint inflammation at this time point of CIA. Histological 
scores; 2.5 for infiltrate, 1.5 for cells in the cavity. (B) Knee joint of a mouse treated for 7 days with 100 ng mIL-12. 
Clear suppression of inflammation and disappearance of granulocytes was found. Histological scores; 0.5 for infiltrate, 
0 for cells in the cavity. For details see Figure 4.
Dominant role o f IL-10 in IL-12 mediated suppression
Plasma levels of IL-10 and INF-y were analyzed at the end of the 7 days IL-12 treatment (Figure 
8 ). Both parameters were markedly enhanced. To further underline the potential involvement 
of IL-10 upregulation in the IL-12 mediated suppression, a final experiment was performed 
in which animals were treated with IL-12 as well as anti-mIL-10 antibodies (Figure 9). That 
study again confirmed the clear suppression of established arthritis with IL-12 treatm ent and 
furthermore made it clear that concomitant anti-mIL-10 treatment completely prevented the 
IL-12 effect. Histology of these groups showed suppression of inflammation only in the IL-12 
treated mice (data not shown).
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Figure 8 . Plasma levels of IL-10 and IFN-y after 
IL-12 treatment. Mice with full blown CIA were 
treated for 7 days with either control (BSA) or mIL-
12, started at day 35 (see Figure 5). Mice were bled 
at day 42 and plasma levels of IL-10 and IFN-y were 
determined by ELISA. Values are expressed as 
mean±SD cytokine level of 6 mice per group of two 
experiments. *P<0.05, Wilcoxon rank test compa­
red to control.
Figure 9. Abrogation of the suppressive effect of 
IL-12 treatment on established CIA by co­
administration of anti-mIL-10 antibodies. DBA-1 
Bom mice with established CIA were selected at day 
33 and divided in four separate groups of 10 mice. 
Control mice recieved i.p. daily BSA (100 ng) and 
rat Ig’s (0.75 mg) as indicated by arrows. IL-12 group 
was injected with 100 ng mIL-12 and with rat Ig’s as 
indicated by arrows. The mIL-12/anti-IL-10 group 
recieved mIL-12 and anti-mIL-10 (0.75 mg). Anti­
mIL-10 group was injected with BSA and anti-mIL- 
10. *P<0.05, Wilcoxon rank test compared to 
control.
Anti-collagen type II antibody titres and circulating leucocytes
Involvement of shifts in anti-collagen type II antibody titres in exacerbations or suppressions 
of CIA seems unlikely. Anti-CII antibody levels are already high at day 35 of CIA and neither 
mIL-12 nor anti-mIL-12 treatment caused major changes in the levels of anti-CII IgG’s, IgG1 
or IgG2a (data not shown). Since it is known that high levels of IL-12 (1 |j,g/day) may have an 
impact on the bone marrow (41), differential counts of circulating leucocytes were performed. 
No major suppression in numbers of granulocytes, mononuclear cells or lymphocytes were 
found (data not shown).
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IL-12 is an intriguing cytokine, playing an im portant role in early innate resistance to bacterial 
infections and the subsequent antigen specific adaptive immunity. This is due to activation of 
NK cells and selective generation of Th1 responses. Likewise, IL-12 is an im portant defense 
mechanism against uncontroled tum or growth. As a dark side of this protective response, 
excessive IL-12 generation may unmask latent autoimmune disease. It was elegantly shown in
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the model of experimental allergic encephalomyelitis that the lack of encephalogenicity of 
antigen (MBP) specific T cells from nonsusceptible mice could be restored upon exposure to 
IL-12 (14) and similar observations have been made in a range of autoimmune models (see 
below). The present study further identifies the potential of IL-12 to enhance arthritis 
expression in collagen arthritis prone mice, but it also shows that IL-12 is a potent inducer of 
IL-10 and a downregulator of the arthritic process in late stages of the disease.
Collagen induced arthritis is an autoimmune model driven by the combination of cellular and 
humoral immunity against cartilage collagen type II (CII). Upon immunization with CII in 
Freunds complete adjuvant, the cytokine pattern in the lymphoid organs showed a dominant 
Th1 pattern (42). In line with this, IL-12 administered during immunization with CII in IFA 
strongly enhanced Th1 responses, resulting in severe collagen arthritis (30). However, high 
doses of IL-12 were shown to suppress disease severity, associated with a marked reduction in 
CII specific antibody levels (31). Further analysis in susceptible and resistant mouse strains 
underlined the critical importance of high antibody levels. IL-12 was shown to enhance cellular 
but not humoral CII specific Th1 responses in C57Bl and B10.Q mice and failed to induce 
arthritis (43). The critical importance of antibodies in disease expression is compatible with 
our earlier observations of strong IL-1 dependence of both collagen arthritis and murine 
immune complex arthritis (26,27,44).
In the present study we further analysed the role of IL-12 in the expression of joint 
inflammation, starting at day 28 after a first and booster immunization. Anti-CII antibody 
levels were measured in various experiments, not revealing significant changes and making it 
unlikely that antibody shifts determined the arthritis outcome. We showed for the first time 
that late IL-12 treatment can still accelerate arthritis expression, whereas anti-IL-12 antibodies, 
given shortly before onset, prevented both LPS induced and classic onset of arthritis. This is 
probably related to IL-12 mediated IFN-y production and generation of TNF and IL-1, 
mediators known to be of crucial importance in CIA onset (27,45).
In other models of autoimmune inflammation such as experimental allergic encephalomyelitis 
(EAE), diabetes in nonobese diabetic mice (NOD), experimental colitis and 
glomerulonephritis, IL-12 played a potentiating role. In an adoptive transfer model of EAE, 
IL-12 or anti-IL-12 treatment of T cells in vitro was shown to modulate subsequent disease 
expression (46). Likewise, early onset and severity of diabetis in NOD mice was markedly 
enhanced by in vivo IL-12 treatment, associated with massive influx of Th1 cells in islets (47). 
Furthermore, treatment of experimental colitis in mice with anti-IL-12 antibodies abrogated 
the disease and improved the histopathological aspects of the disease (48). Recent studies 
suggest that expression of colitis in this model is due to loss of tolerance to resident intestinal 
flora and this state can be restored with anti-IL-12 or IL-10 treatment (49). Finally, the 
expression of autoimmune disease in MRL/lpr mice was linked to high capacity of this strain 
to produce IL-12 and greater responsiveness of its macrophages to IL-12 mediated NO 
production (50).
The above set of data illustrates that IL-12 is a potentiating factor in a number of autoimmune 
diseases, including arthritis, and suggests the potential utility of anti-IL-12 antibodies in 
patients. However, our present data on effects in fully established arthritis warrant great care 
with clinical application. It suggests a dual role of IL-12 in early and late arthritis, with dominant 
IL-12 mediated regulation of IL-10 production in late arthritis and a potential risk of 
exacerbation of arthritis upon IL-12 blocking. We showed impressive upregulation of IL-10 
in serum and synovial tissue after late IL-12 treatment, and the concomitant amelioration of
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arthritis is in line with earlier observations with IL-10 treatment (29,51). Moreover, the IL-12 
effect could be abrogated with anti-IL-10 treatment. Recent in vitro studies confirm the strong 
capacity of IL-12 to induce IL-10 production by both T cells and monocytes (17-21). 
Furthermore, IL-12 inhibits the IL-4 and IL-10 production in allergen-specific T cells, but this 
effect was not noted anymore in already activated T cells (17). IL-12 does not suppress a Th2 
cell recall response (52). Intriguingly, IL-12 exacerbates rather than suppresses Th2 dependent 
pathology in IFN-y knockout mice, in the absence of endogenous IFN-y (53).
Our data shows that IL-12 enhances onset of arthritis, probably related to enhanced IFN-y 
and NO production and subsequent generation of TNF and IL-1. In late disease, IL-12 
upregulates itself as well as IL-10 and IFN-y, without significant effects on IL-1 and TNF. 
Suppression of arthritis is probably due to IL-10, although it can not be excluded that IFN-y 
plays a role in this as well. Earlier studies in arthritis models showed variable effects of IFN-y, 
with a tendency to show suppression in established disease. It is known that repeated high dose 
IL-12 (1 |j,g/day) treatment may have unwanted side effects on bone marrow and lymph nodes. 
We have not seen such effects using daily dosing with 100 ng. Leucocyte counts in the blood 
were normal and the only change was some upregulation of large unidentified cells, probably 
reflecting lymphoblasts.
The present study confirms a role of IL-12 in arthritis onset, but furthermore identifies a 
regulatory role in late disease. It is now well accepted that TNF and IL-1, in particular, are key 
therapeutic targets in the treatment of hum an RA (54). Trials with anti-TNF provide great 
relief of symptoms, yet data on protection against ongoing cartilage destruction are under 
investigation. Trials with IL-1Ra are ongoing (55) and it is promising to see first data showing 
protection against joint erosions. In addition, new trials in RA patients are in progress with 
IL-4 and IL-10, focusing on the expected benefit of IL-1/TNF inhibition and additional 
upregulation of cytokine and enzyme inhibitors, as well as im m unom odulation of RA 
orchestrating, but yet unidentified Th1 responses. IL-12 would be a challenging target, with 
expected protection against onset or acute exacerbation of chronic arthritis upon IL-12 
blocking. IL-12 has been detected in synovial fluid cells of RA patients (56). Moreover, recent 
studies in a murine arthritis, caused by B. Burgdorferri, showed a reduction in severity of arthritis 
with anti-IL-12 treatment (57).
Analysis of immune mediated tissue injury in atherosclerotic plaques demonstrated that the 
degree of destruction is dependent on the critical balance of IL-12 and IL-10 (58). The present 
study urges great care with IL-12 elimination in established arthritis, linked to potential 
impairment of IL-10 mediated control. It is tempting to speculate that a combination 
treatment of anti-IL-12, with suppletion of IL-10, may provide optimal impact, but further 
insight in the regulation of the IL-10/IL-12 balance in various stages of the disease is highly 
warranted.
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ABSTRACT
The goal of the present study was to investigate the role of endogenous IL-12 in murine 
streptococcal cell wall (SCW) arthritis. C57black/6 mice were injected with rat anti-murine 
IL-12 (C17.8), shortly before induction of arthritis by intraarticular injection of 25 |j,g SCW 
fragments into the right knee joint. Joint swelling and chondrocyte synthetic function was 
analysed several days after induction of SCW arthritis. Local cytokine profile was determined, 
protein by using ELISA and mRNA by RT-PCR technology. To confirm the findings at later 
time points, tissue chamber model of inflammation was used. Histology was performed to 
examine cell influx and cartilage damage. Suppression of joint swelling was noted at days 2 
and 4, whereas no suppressive effect of anti-IL-12 was found at day 1. Severe inhibition of 
chondrocyte proteoglycan (PG) synthesis was seen at day 1 in both arthritic control and anti- 
IL-12 treated mice. However, chondrocyte function was restored at day 4 of arthritis in the 
anti-IL-12 injected animals, but not in the arthritic controls. Moreover, cell influx in synovial 
tissue and joint cavity was reduced by anti-IL-12 treatment. Neutralization of IL-12 reduced 
the local levels of IL-10, IL-12 and IFN-y, when examined shortly after induction of SCW 
arthritis, whereas TN Fa levels were not affected. In contrast, IL-10 and IL-1Ra protein and 
mRNA levels were strongly upregulated in synovial tissues after IL-12 blockade. Enhancement 
of IL-10 and IL-1Ra by anti-IL12 was confirmed in a tissue chamber model with SCW induced 
inflammation. The present study indicates that IL-12 is a pro-inflammatory cytokine during 
onset of SCW arthritis. Balances of pro- and anti-inflammatory cytokines were strongly 
improved by anti-IL-12 treatment.
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IN T R O D U C T IO N
Interleukin-12, originally described as cytotoxic lymphocyte maturation factor and natural 
killer cell stimulatory factor is a 70 kDa heterodimeric cytokine consisting of two subunits of 
35 kDa and 40 kDa. It is produced by phagocytic cells, dendritic cells, B lymphocytes and NK 
cells upon stimulation with LPS, bacteria, parasites (1-4). IL-12 generates the development of 
naive T cells into Th1 cells and stimulates IFN-y secretion by differentiated Th1 cells (5,6). 
Through major induction of IFN-y and TNFa, IL-12 plays a crucial role in LPS lethal shock 
and generalized Shwartzman reaction (7,8). During bacterial infections, IL-12 is considered 
to be a principal protective cytokine, where it bridges innate resistance and antigen specific 
immunity (9). Recently, it was demonstrated that IL-12 deficient mice are unable to control 
bacterial infections with Leishmania major and were defective in IFN-y production and Th1 
responses (10,11). On the contrary, IL-12 may unm ask Th1-dependent auto-im m une 
responses and may be a crucial intermediate in the often-suggested link between bacterial 
infections and expression of auto-immune diseases (12). For instance arthritis has been 
associated with bacterial infections of the throat (rheumatic fever), the gastrointestinal tract 
(reactive arthritis), inflammatory bowel disease like M. Crohn, and Lyme disease. In all of these 
cases IL-12, induced by the bacterial organisms, may be the pivotal cytokine involved in the 
onset of arthritis. Rheumatoid arthritis (RA) is associated with Th1 immune response, 
however typical Th1 cytokines, like IL-2, IFN-y and TNF0 were hardly detected in synovial 
fluid or tissues (13). Recently, IL-12 was detected in synovia of rheumatoid arthritis (RA) 
patients, and marcophage like cells seems to be the main producers (14).
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Several bacterial arthritis models have been described and beside adjuvant arthritis (AA), 
induced by M. Tuberculosis, streptococcal cell wall (SCW) arthritis is one of the important 
experimental animal models. Chronic arthritis can be induced in susceptible rat strains by an 
intraperitoneal injection of a sterile solution of bacterial cells or cell wall fragments from the 
group A streptococci (15). A reactivation model of local SCW arthritis, induced by intraarticular 
injection of SCW into a rat ankle joint, can be achieved by intravenous rechallenge with SCW 
fragments (16). SCW arthritis can also be induced in mice after immunization with SCW 
fragments in complete Freund’s adjuvant. After intraarticular injection of SCW fragments into 
the knee joint a chronic erosive arthritis will occur. In contrast, one single injection of SCW 
fragments into a knee joint of a naive mouse leads to an acute joint inflammation (17). It has 
been shown that TN Fa and IL-1 play different roles in the latter SCW arthritis model. While 
T N Fa mediates only joint swelling, IL-1 is crucial regarding cartilage destruction and 
inflammatory cell influx (18). Furthermore, it was demonstrated that endogenous IL-10 
controls the severity of SCW arthritis, since anti-IL-10 treatment aggravated SCW arthritis 
(19).
In the present study, we investigated whether IL-12, produced by synovial macrophages after 
injection of bacterial cell wall fragments, is involved in the onset and severity of SCW arthritis. 
Therefore we injected anti-murine IL-12 antibodies before intraarticular application of SCW 
fragments. Joint swelling was monitored and joint pathology was examined by histology. 
Furthermore, local cytokine profile was determined by ELISA and RT-PCR technology. Due 
to the fact that synovial cytokine levels were only detectable in the first 24h of SCW arthritis, 
we further analyzed the effect of endogenous IL-12 blockade in a tissue chamber model of SCW 
inflammation. This study indicates that blockade of IL-12 during onset of SCW arthritis 
suppresses secundary joint swelling, cell influx and leads to restoration of chondrocyte PG 
synthesis by upregulation of IL-10 and IL-1Ra levels.
MATERIALS a n d  M E T H O D S
Animals
Male C57/Bl6 mice were obtained from our university breeding facilities in Nijmegen. The 
mice were housed in filter top cages, and water and food were provided ad libitum. The mice 
were used at the age of 1 0 - 1 2  weeks.
Materials
Ethidiumbromide, rat Ig’s, and bovine serum albumin were purchased from Sigma Chemicals, 
St Louis, USA. DNEM medium, RPMI 1640 medium, FCS, Taq DNA Polymerase, 100 bp DNA 
marker, TRIzol Reagent, and Agarose were obtained from Life Technologies, Breda, The 
Netherlands. GAPDH, IL-10, IL-10, IL-12, IFN-y and TN Fa primers were purchased from 
Eurogentec, Seraing, Belgium. Murine IL-1Ra capture (MAP480) and detection (BAF480) 
antibodies and recombinant murine IL-1Ra were obtained from R&D systems, Abingdon, UK. 
IL-10 (CMC9102) and IFN-y (CMC4034) ELISA cytosets were obtained from Biosourche, 
Camarillo, CA, USA. Anti-mIL-12 antibodies (capture 80-3891-01, detection 80-3892-01) were 
purchased from Genzyme, Cambridge, MA, USA. Murine IL-12 was kindly provided by Dr.
S. Wolf, Genetic Institute Inc, Cambridge, MA, USA.
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Anti-IL-12 antibodies
Hybridoma cells producing rat anti-murine IL-12 antibodies (C17.8) were kindly provided 
by G. Trinchieri, Wistar Institute, Philidelphia, USA. Hybridoma cells (3 x 106) were injected 
in nude Balb/C mice and after three weeks ascites fluid was collected. Thereafter Ig’s were 
isolated using a protein-G column. Anti-murine IL-12 antibodies (0.5mg) were injected in a 
volume of 0.2 ml PBS
SCW  preparation and induction o f SCW  arthritis
Streptococcus pyogenes T12 organisms were cultured overnight in Todd-Hewitt broth. Cell walls 
were prepared as described previously (17). The resulting 10.000 x g supernatant was used 
throughout the experiments. These preparations contained 11% muramic acid. Unilateral 
arthritis was induced by intraarticular injection of 25 |j,g SCW (rhamnose content) in 5 |jl 
phosphate buffered saline (PBS) into the right knee joint of naive mice. As a control, PBS was 
injected into the left knee joint.
Anti-IL-12 treatment
Two hours before induction of SCW arthritis, mice were injected with either 0.5 mg purified 
rat anti-murine IL-12. As previously described, this dose revealed to be effective in vivo (7,20). 
As control the same amount of normal rat Ig’s was injected. For time-course experiments, mice 
were injected at -2h, day 1 and day 2 after the induction of SCW arthritis. To neutralized IL-
12 during SCW inflammation in the tissue chambers, mice were injected with anti-IL-12 2h 
before injection of SCW fragments into the tissue chambers.
Measurement o f joint inflammation
SCW arthritis was quantified by the 99mTc-uptake method (21). This method measures by 
external gamma counting the accumulation of a small radioisotope at the site of inflammation 
due to local increased blood flow and tissue swelling. The severity of inflammation is expressed 
as the ratio of the 99mTc-uptake in the right (inflamed) over the left (control) knee joint. All 
values exceeding 1 .1 0  were assigned as inflammation.
Chondrocyte proteoglycan synthesis determination
Patellae with minimal surrounding tissue, were placed in RPMI 1640 medium with glutamax, 
gentmicin (50|j,g/ml) and 35S-sulfate (0.74 MBq/ml). After 3h incubation at 37°C in a CO2 
incubator, patellea were washed in saline 3 times, fixed in 4% formaldehyde and subsequently 
decalcified in 5% formic acid for 4h. Patellae were punched out of the adjacent tissue, dissolved 
in 0.5 ml Luma Solve at 65°C (Ominlabo) and after addition of 10 ml Lipoluma (Omnilabo) 
the 35S content was measured by liquid scintilation counting. Values are presented as 
percentage 35S incorporation of the left control joint.
Cytokine production in a mouse tissue chamber model o f inflammation
Autoclaved sterile Teflon (TeflonR-PFA, kind gift of Novartis, Basel, Switzerland) tissue 
chambers (20 m m  x 8  m m  diameter perforated by 135 regularly spaced 1 m m  holes) were 
implanted subcutaneously under aseptic conditions through a small incision into the backs 
of mice (41). The incisions were closed by wound clips and the chambers were tested for sterility 
after 7 days by culturing a 10 |jl sample on LB agar for 24h at 37°C. Thereafter SCW 
inflammation was induced by injection of 100 |jl SCW fragments (4 mg/ml rhamnose
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content). At days 1 and 2 after induction of inflammation samples of tissue chambers fluid 
(±200 |jl) were taken. The samples were centrifugated for 5 minutes at 1000g and stored at 
-80° C until cytokine determination.
Cytokine measurements
To determine the levels of IL-10, IL-10, IL-12, IFN-y or TN Fa in patellae washouts, patellae 
were isolated from inflamed knee j oints as previously described [18,19]. Patellae were cultured 
in RPMI 1640 medium (200 |jl/patella) for 1 hour at RT. There after supernatant was harvested 
and centrifugated for 5 minutes at 1000g. IL-10 and TN Fa were determined by RIA (22). IL- 
1Ra, IL-10, IL-12 and IFN-y levels were measured by ELISA. The sensitivty of the ELISA for 
IL-1Ra, IL-10, IL-12 , IFN-y and the RIA for IL-10 and TN Fa is 80, 40, 20 10, 20 and 40 pg/ml, 
respectively. The same assays were used for determination of cytokine levels in tissue chamber 
fluid samples
RNA isolation
Mice were killed by cervical dislocation, immediately followed by dissection of the patella with 
adjacent synovium (23,30). From 6  patella specimens synovium biopsies were taken. Two 
biopsies with a diameter of 3 m m  were punched out, using a biopsy punch (Stiefel, 
Wachtersbach, Germany): one from the lateral and one from the medial side. Six patella 
specimens per experimental group were taken and 3 lateral and 3 medial biopsies were pooled, 
to yield 2 samples per group. The synovium samples were immediately frozen into liquid 
nitrogen. Synovium biopsies were ground to powder using a micro-dismembrator II (B.Braun, 
Melsungen, Germany). Total RNA was extracted in 1 ml TRIzol reagent, an improved single­
step RNA isolation method based on the method described by Chomczynski and Sacchi [24].
PCR amplification
One microgram of synovial RNA was used for RT-PCR. Messenger RNA was reverse 
transcribed to cDNA using oligodT primers and 1/20 of the cDNA was used in one PCR 
amplification. PCR was performed at a final concentration of 200 |J,M dNTP’s, 0.1 |J,M of each 
primer, and 1 unit Taq-polymerase in standard PCR buffer. The mixture was overlaid with 
mineral oil and amplified in a thermocycler (Omnigene, Hybaid Ltd, UK). Message for 
GAPDH, IL-10, IL-10, IL-12, IFN-y and TN Fa was amplified using the primers as previously 
described [25]. Samples of 5 |jl were taken from the reaction tubes after a certain number of 
cycles. PCR products were separated on 1.6 % agarose and stained with ethidiumbromide. 
The results are presented as differences in PCR cycles between mRNA isolated from inflamed 
synovium compared to normal synovium. GAPDH levels were very consistent in all samples, 
not warranting any further correction of mRNA values for IL-10, IL-10, IL-12, IFN-y and 
TNFa.
Histology
Mice were sacrificed by ether anaesthesia. Thereafter, whole knee joints were removed and 
fixed for 4 days in 4% formaldehyde. After decalcification in 5% formic acid the specimens 
were processed for paraffin embedding. Tissue sections (7 |j,m) were stained with Haematoxylin 
& Eosin or Safranin O. Histopathological changes were scored using to the following 
parameters. Infiltration of cells was scored on a scale of 0-3, depending on the amount of
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inflammatory cells in the synovial cavity and synovial tissues. Proteoglycan depletion was 
determined using Safranin O staining. The loss of proteoglycans was scored on a scale of 0-3, 
ranging from full stained cartilage to destained cartilage or complete loss of articular cartilage. 
Histopathological changes in the knee joints were scored in the patella/femur region on 5 semi­
serial sections of the joint, spaced 70 |J,M apart. Scoring was performed on decoded slides by 
two observers, as described earlier [18,19,30,49].
Statistical analysis
Differences between experimental groups were tested using the Mann-W hitney U-test, unless 
stated otherwise.
RESULTS
Murine streptococcal cell wall (SCW)-induced arthritis
One single injection of SCW fragments into a mouse knee joint leads to an acute inflammation, 
characterized by joint swelling and inhibition of chondrocyte proteoglycan (PG) synthesis in 
patellar cartilage. Significant knee joint swelling was found up to day 7 after injection of SCW 
fragments. Marked inhibition of chondrocyte PG synthesis was observed at days 1, 2 and 4, 
whereas at day 7 an overshoot of chondrocyte PG synthesis was noted (Figure 1A). To examine 
the cytokine pattern during the first stage of this type of experimental arthritis we analyzed 
synovial tissue wash-outs (Figure 1B). TN Fa and IL-10 levels were increased shortly after 
injection of SCW fragments. At 90 minutes the highest levels (450±40 pg/ml) of TN Fa were 
found, whereas the maximum IL-10 levels were found at 4h (2520±280 pg/ml). IL-12 levels 
were detectable at 1.5, 4, 24 and 48 hours after induction of arthritis, with the peak at 4h (160±30 
pg/ml). Protein levels of IFN-y reached a maximum at 4h, 50±15 pg/ml. As described 
previously, massive influx of polymorphonuclear cells (PM N’s) in the joint cavity and synovial 
membrane was seen at days 1 and 2. Lateron, at days 4 and 7 macrophage-like cells were noted 
in the synovial tissue. The maximum influx of inflammatory cells was seen at days 2 and 4 after 
the induction of SCW arthritis (18,19).
184
Table 1. Joint pathology after neutralization of endogenous IL-12.
Days of arthritis Treatment Cell influx Cell influx Matrix PG
synovial tissue jointCavity Depletion
Day 2 Control (Ig’s) 0 .8 ±0 .2 1.8±0.4 1 .0 ±0 .2
Day 2 Anti-IL-12 0.4±0.3 0.7±0.3* 0.9±0.3
Day 4 Control (Ig’s) 1.3±0.3 1.9±0.4 1.7±0.4
Day 4 Anti-IL-12 1.0±0.3 0.6±0.3* 1.2±0.3
Mice were injected with either rat Ig’s (0.5 mg) or anti-IL-12 (0.5 mg) 2h before induction of an unilateral
arthritis by intra-articular injection of 25 |lg SCW fragments into the right knee joint. Histology was taken at
days 2 and 4 of SCW arthritis and performed as described in Materials and Methods. Data represent the
mean±SD of two identical experiments, each experiment consisted of at least 7 mice per group. *P<0.05,
Mann-Whitney U-test compared to control.
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Figure 1. SCW arthritis, joint 
swelling, chondrocyte proteoglycan 
(PG) synthesis, and cytokine profile. A. 
SCW arthritis was induced by injection 
of 25 |J,g SCW fragments. Joint swelling 
was measured by 99mTc-uptake 
method and is expressed as right/left 
ratio. A ratio >1.10 is considered as 
inflammation. Inhibition of 
chondrocyte PG synthesis was 
determined by 35S-sulphate 
incorporation. The data represent the 
mean±SD of at least 7 mice per group.
Cytokine levels were determined 
either by RIA or ELISA in patellae 
washouts at several time points. The 
data represent the mean cytokine level 
of washouts of 6 patellae per time 
point.
Reduction o f SCW  arthritis by blocking endogenous IL-12 
To investigate the effect of neutralization of endogenous IL-12 on SCW arthritis, we injected 
rat anti-murine IL-12 antibodies 2h before injection of SCW fragments. At day 1 no reduction 
of joint swelling was found. In contrast, marked suppression of joint swelling was seen at days 
2 and 4 (Figure 2A). Severe inhibition of chondrocyte PG synthesis was noted at day 1 in the 
control arthritis, treated with rat Ig’s. Blocking of IL-12 had no significant effect on chondrocyte 
PG synthesis at day 1. In line with the reduction of joint swelling at days 2 and 4, anti-IL-12
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Figure 2. Effect of anti-IL-12 treatment on 
joint swelling and chondrocyte PG synthesis. A. 
Mice were injected 2h before induction of 
arthritis with either 0.5 mg rat anti-murine IL- 
12 or rat Ig’s. At days 1, 2, and 4 joint swelling 
was determined by 99mTC-uptake and 
expressed as R/L ratio. The data represent the 
mean±SD of at least 7 mice per group. B. 
Chondrocyte PG synthesis was measured by 
35S-sulphate incorporation at days 1, 2, and 4 
after induction of arthritis. The data represent 
mean±SD percentage chondrocyte PG synthesis 
of the left control patella. *P<0.05, Mann­
Whitney U-test, compared to rat Ig’s group.
treatment enhanced the chondrocyte PG synthesis (Figure 2B). At day 4, the chondrocyte PG 
synthesis reached values found in normal cartilage (left joint), whereas in the arthritic control 
group (rat Ig’s) still 30% inhibition was seen. Histology showed that anti-IL-12 treatment 
significantly reduced the num ber of inflammatory cells in the joint cavity at day 2 of SCW 
arthritis (Figure 3A/C, Table 1). Infiltration of synovial membrane with inflammatory cells 
was reduced by IL-12 blocking although this did not differ significantly from the control group. 
No significant effect of anti-IL-12 was seen on cartilage proteoglycan (PG) depletion as depicted 
in Figure 3B/D. Marked loss of PG was found in both control and anti-IL-12 groups (Table 1).
Kinetics o f anti-IL-12 induced suppression o f SCW  arthritis
To examine whether IL-12 is only crucial at the onset of SCW arthritis or is involved as well 
at later stages of this type of joint inflammation we injected anti-IL-12 at several time-points. 
As shown above anti-IL-12 treatment before induction of SCW arthritis suppressed both joint 
swelling and inhibition of chondrocyte PG synthesis (Figure 4A/B). W hen anti-IL-12 treatment 
was delayed until day 1 of arthritis we found nearly the same effects on joint swelling and 
chondrocyte function as treatment prior to induction of arthritis. No suppressive effect on 
joint swelling or inhibition of chondrocyte PG synthesis was observed anymore when anti-IL-
12  was given at day 2 .
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Figure 3. Effect of IL-12 blockade on cell influx and cartilage damage in the knee joint. A. Arthritic knee joint of 
the rat Ig’s treated control group. Note the marked joint inflammation and cell influx in the joint cavity. B. Section 
of the control group stained for matrix proteoglycan. Note the loss of matrix PG in the cartilage layers (arrows). C. 
Knee joint of a mouse treated with anti-IL-12 antibodies. Strong reduction of cell influx can be seen in synovial tissue 
and joint cavity. D. Section of anti-IL-12 treated knee joint stained for PG loss. No reduction of matrix PG depletion 
was seen after IL-12 blockade. p= patella, f= femur, c= cartilage, js= joint space, s= synovium. A/C Haematoxilin & 
Eosin staining, B/D Safranin O staining.
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Figure 4. Kinetics of IL-12 neutralization on joint 
swelling and chondrocyte PG synthesis. A. Mice were 
treated with anti-IL-12 at either -2h, day 1 or day 2 after 
induction of SCW arthritis. As control we injected at the 
same time points rat Ig’s. Joint swelling was determined 
at day 3. The data represent the mean±SD joint swelling 
of at least 7 mice per group. B. Chondrocyte PG synthesis 
measured at day 4. Mice were treated with either anti- 
IL-12 or rat Ig’s as indicated above. The data are 
expressed as mean±SD percentage of chondrocyte PG 
synthesis found in left control patella of at least 7 patellae 
per group. *P< 0.05, Mann-Whitney U-test, compared 
to rat Ig’s
Figure 5. Synovial cytokine levels after IL-12 
neutralization. Mice were injected either with anti-IL-12 
or rat Ig’s before induction of arthritis. After either 90 
minutes (TNFa) or 4 hours (all other cytokines), patellae 
were isolated and cytokine levels were determined in 
washouts. A, TNFa and IL-1p. B, IFN-y and IL-12. C, 
IL-10 and IL-1Ra. The data represent mean±SD cytokine 
level in at least 6 patellae washouts. *P<0.05, Mann­
Whitney U-test, compared to rat Ig’s group.
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Effect o f IL-12 blockade during SCW  arthritis on cytokine pattern
Analysis of local cytokine production at 1.5 and 4h after induction of arthritis revealed that 
TN Fa levels were not changed after anti-IL-12 treatment, whereas IL-1^, IL-12 and IFN-y levels 
were significantly reduced (Figure 5A/B). Of high interest, IL-10 and IL-1Ra levels were 
markedly enhanced due to IL-12 elimination (Figure 5C). RT-PCR analysis of synovium 
biopsies showed that mRNA levels of TNFa, IL-1^, IL-1Ra, IL-10, IL-12 and IFN-y were 
upregulated at days 1 and 2 of SCW induced arthritis, when compared to normal (non­
inflamed) synovium (Figure 6 ). Anti-IL-12 treatment slightly decreased mRNA levels for IL- 
1^, but marked reduction was found of mRNA levels for IFN-y, IL-12 and TNFa. This was 
mainly noted at day 2 after treatment with anti-IL-12. In line with cytokine levels in synovium
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Figure 6. RT-PCR analysis of synovial tissue mRNA levels for TNFa (A), IL-lp (B), IFN-y (C), IL-12 (D), IL-10 
(E), IL-1Ra (F) after treatment with either anti-IL-12 or rat Ig’s. Synovium biopsies of six mice per group were pooled 
and RNA was extracted. Expressed is the number of PCR cycles in which gene product of interest was first detectable 
compared with normal synovium. Values are the mean of two experiments with SCW arthritis. The PCR measurements 
of a particular cytokine was routinely repeated three times. The variations never exceeded more than two cycles. The 
absolute difference in mRNA levels were calculated using the difference in PCR cycles between arthritic synovium 
and non-inflamed synovium (2 cycles mean 22 more mRNA, 4 cycles = 24). From these values ratio’s for IL-1Ra/IL- 
lp  (G) and IL-10/TNFa (H) were calculated, using delta PCR cycles found in F/B and E/A.
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washouts, both IL-1Ra and IL-10 mRNA levels were increased at day 1 and 2 of SCW arthritis 
after blocking endogenous IL-12. When ratio’s of relative mRNA levels were calculated a strong 
shift in IL-1Ra/IL-10 and IL-10/TNFa balances was found (Figure 6G/H).
Neutralization o f IL-12 during SCW  inflammation in a tissue chamber model resulted in 
enhanced levels o f IL-10 and IL-1Ra
Since we can not detect large amounts of cytokines in patella washouts at days 1 and 2 after 
induction of SCW, we analyzed the impact of IL-12 blockade on cytokine levels in a tissue 
chamber model. High levels (ng/ml) of various cytokines could be measured after injection
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Figure 7. Effect of anti-IL-12 treatment on cytokine levels in tissue-chamber model. Tissue-chambers were implanted 
s.c. 7 days before injection (i.p.) of either anti-IL-12 or rat Ig’s. Two hours later, 100 |^g SCW fragments were injected. 
At days 1 and 2 100 |^l tissue-chamber fluid was extracted. Levels of TNFa (A), IL-1 P (B), IFN-y (C), IL-12 (D), IL- 
10 (E) and IL-1Ra (F) were determined by RIA or ELISA. The data are expressed as mean±SD cytokine level of six 
tissue-chambers per group. *P<0.05, Mann-Whitney U-test, compared to rat Ig’s.
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Table 2. Effect o f anti-IL-12 treatment on IL-lRa/IL-10 and IL-10/TNFa ratios.
Day of SCW arthritis Treatment Protein level#
IL-1Ra/IL-10 IL-10/TNFa
Day 1 Control (Ig’s) 0.64 0.38
Day 1 Anti-IL-12 2.27 0.60
Day 2 Control (Ig’s) 0.60 0.25
Day 2 Anti-IL-12 3.55 0.95
Cytokine ratios were calculated after treatment with either rat Ig’s or anti-IL-12. #For protein ratios we used levels
of cytokine found in the tisssue chamber model of inflammation (see Figure 7).
of SCW fragments in a tissue chamber (Figure 7). Anti-IL-12 treatment of mice bearing such 
tissue chambers showed that neutralization of IL-12 reduced IL-10, IFN-y and IL-12 levels, 
whereas TN Fa levels were not changed (Figure 7B,C,D,A). In line with mRNA and protein 
levels in synovial tissue, IL-10 and IL-1Ra levels were upregulated after anti-IL-12 treatment 
(Figure 7E/F). Table 2 showed that ratio’s of either mRNA or protein for IL-1Ra/IL-10 and 
IL-10/TNFa were increased due to anti-IL-12 treatment. This indicates that the balance of 
anti (e.g.IL-1Ra, IL-10) and pro-inflammatory (e.g. IL-10, TNFa) cytokines is clearly improved 
after elimination of endogenous IL-12, also at later time points.
D ISC U SSIO N
Streptococcal cell wall arthritis is an experimental model of arthritis in which macrophages 
play an im portant role. It has been shown that bacterial cell wall fragments (peptidoglycan) 
induced production of IL-12 by macrophages in vitro (26). Here we showed that endogenous 
IL-12 is involved in the persistence of SCW induced arthritis. Suppression of joint swelling 
was found at days 2 and 4 and not at day 1 after intraarticular injection of SCW fragments. 
This indicates that IL-12 is not involved in joint swelling seen at the initial stage. As shown 
previously, TN Fa is the major cytokine regarding acute joint swelling in SCW arthritis (18,27). 
The lack of effect at day 1 is in line with the fact that shortly after onset of SCW TN Fa levels 
were not affected by anti-IL-12 treatment. Moreover, TN Fa levels were not influenced by anti- 
IL-12 treatment at later time points both in a tissue-chamber model of inflammation and at 
synovial mRNA level. The pivotal role of TN Fa in the early joint swelling was corroborated 
by elegant studies of SCW arthritis in TN Fa deficient mice (28). The major role of TN Fa in 
early joint swelling was also noted in murine collagen-induced arthritis (29,30). The suppressive 
effect of anti-IL-12 on joint swelling in sub-acute stages of arthritis could be explained on the 
one hand by the reduced levels of IFN-y, IFN-y itself being involved in joint swelling and on 
the other hand reduction of NO (31) In respect to j oint swelling, endogenous IL-12 is involved 
between 24h-48h after onset of SCW arthritis, but appears again less dominant at later stages, 
since anti-IL-12 treatment started at day 2 was ineffective.
Inhibition of chondrocyte proteoglycan (PG) synthesis in the arthritic cartilage is a common 
feature seen in experimental arthritis models and IL-1 is the pivotal cytokine in this inhibition 
(32). In the present study it was shown that elimination of IL-12 during onset results in
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restoration of chondrocyte function at days 2 and 4 of SCW arthritis. IL-10 levels were reduced 
by anti-IL-12 treatment, but significant levels were still found in synovial tissue washouts. At 
days 1 and 2 reduction of IL-1 activity was also observed in tissue chamber fluid after IL-12 
blockade. This was in line with findings in tumor-bearing mice treated with anti-IL-12 
antibodies in which decreased IL-10 levels were reported (33). Recently, it was demonstrated 
that chondrocyte PG synthesis induced by IL-1 was mediated by nitric oxide (NO) since NOS2 
deficient mice revealed to be resistant for IL-1 induced chondocyte PG synthesis (34,35). 
Cytokine induced NO synthesis by macrophages, synoviocytes and chondrocytes is strongly 
enhanced by IFN-y (36,37). IL-12 is a potent inducer of IFN-y production and we showed that 
anti-IL-12 treatment resulted in markedly decreased IFN-y levels in the synovial tissue 
washouts. Furthermore, synergistic effects on inhibition of chondrocyte PG synthesis between 
IL-1 and several other cytokines, such as TNFa, IFN-y were demonstrated (38). Recently, it 
was demonstrated that there is a direct role of IL-12 in NO production (39). Although we could 
not measure NO in the 1 hour culture supernatants, it seems likely that NO production is 
decreased by anti-IL-12 treatment. The combination of IL-1 suppression, IFN-y reduction and 
direct decrement of NO is probably responsible for the reduced the inhibition of chondrocyte 
PG synthesis.
Blockade of IL-1 activity by application of IL-1Ra completely prevents inhibition of 
chondrocyte PG synthesis during SCW arthritis as described previously (18). Apart from 
reduction of the cytokines IL-1, IFN-y and NO the restoration of chondrocyte PG synthesis 
could be the result of enhancement of IL-1Ra and IL-10 levels by anti-IL-12. IL-12 exposure 
to mononuclear cells (MNC) reduced the IL-1Ra production by these cells in vitro (40). 
Administration of IL-10 during SCW arthritis revealed to enhance chondrocyte function 
whereas anti-IL-10 aggravated inhibition of PG synthesis at days 2 and 4 after injection of SCW 
(19). IL-10 is an inhibitor of IL-1 and NO production and it upregulates IL-1Ra production 
in several cell types. Reduction of IL-10, IL-12 and IFN-y by IL-12 blockade was not only found 
shortly after onset of SCW arthritis, but also at later stages (days 1 and 2). The latter was 
examined in a tissue-chamber model of inflammation. As shown previously, high levels of 
several cytokines could be detected in the fluid what can be easily isolated from the chamber 
(41).
Histology showed that neutralization of IL-12 reduced the num ber of inflammatory cells in 
joint tissues. Recently, it has been reported that overexpression of IL-12 with an adenoviral 
vector leads to upregulation of pro-inflammatory chemokines, including M IP-1a, MIP-2 and 
MCP-1 (42). These chemokines direct leukocyte migration into inflamed tissue and blockade 
of IL-12 may lead to decreased expression. Furthermore, it was shown that IL-10 downregulated 
ICAM expression and anti-IL-10 treatment of CIA enhanced expression of M IP-1a and MIP- 
2 (43,44). Therefore, the reduced number of inflammatory cells in the joint might also be 
explained by markedly elevated IL-10 and decreased IL-12 levels in the anti-IL-12 treated 
animals. Finally, IL-1 itself induces production of pro-inflam m atory chemokines and 
expression of adhesion molecules (45). A shift in the balance of IL-1Ra/IL-10 was noted after 
IL-12 elimination, and this may also contribute to reduced cell influx.
Recently, three pathways of IL-12 production by either macrophages or dendritic cells have 
been described (46). Direct stimulation by bacterial agents, triggering by T cell dependent 
immune responses and activation by the matrix glycosaminoglycan hyaluran (47). The latter 
is mediated by binding of low molecular fragments of matrix proteoglycans to adhesion surface 
molecule CD44 and these PG fragments are abundantly present in an inflamed joint. Since 
IL-12 promotes Th1 responses, it may be possible that IL-12 generates a local immune response
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in the joint towards cartilage autoantigens like CII, gp-39 and aggrecan (48). In other models 
of autoimmune inflammation such as collagen-induced arthritis (CIA), experimental colitis, 
diabetes in nonobese diabetic mice (NOD) and experimental allergic encephalomyelitis 
(EAE), an essential role of IL-12 was observed (49,50,51,52). Elimination of IL-12 in these 
animal models by anti-IL-12 treatment leads to suppression or prevention of disease expression. 
We recently found that intra-articular IL-12 gene transfer with an adenoviral vector aggravates 
SCW arthritis and local IL-12 expression can promote conversion of an acute SCW arthritis 
to a chronic destructive arthritic process (manuscript in preparation). This suggests that IL-
12 not only plays a role in the onset of arthritis but could also determine the chronicity of the 
disease. W hether generation of joint specific Th1 response occurred in these animals is still 
under investigation. The present study indicates that IL-12 is a primary pro-inflammatory 
cytokine during onset of bacterial induced arthritis and blockade of IL-12 ameliorates joint 
inflammation, leads to restoration of chondrocyte function, and reduces influx of leukocytes. 
Anti-IL-12 treatment could be efficacious in the treatment of patients with arthritis.
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SUMMARY
Apart of the persistent joint inflammation, cartilage and bone destruction are the hallmarks 
of chronic rheumatoid arthritis (RA). Mediators like IL-1 and TN Fa are considered as master 
cytokines in the process of hum an RA and concomitant destruction. One of the aims in this 
thesis was to investigate whether blockade of either IL-1 or TN Fa leads to a tissue protective 
therapy. In chapter 2, we demonstrated that elimination of TN Fa during onset of murine 
collagen-induced (CIA) arthritis resulted in amelioration of disease activity. However, no 
protection was noted against cartilage damage after anti-TNFa treatment. Moreover, when 
anti-TNFa treatment was given to animals with full blown CIA no suppression of disease 
activity at all was found. In contrast, anti-IL-1 therapy by anti-IL-1a,0 or continuous 
administration of IL-1Ra markedly suppressed disease activity and cartilage destruction in 
established arthritis. IL-10 is the pivotal mediator regarding arthritis mediated cartilage 
destruction, since anti-IL-10 exposure alone induced strong suppression. Dose-finding study 
with IL-1Ra, administrated systemically with osmotic pumps, showed that very high levels of 
IL-1Ra were needed to achieve optimal suppression of disease activity and cartilage damage 
in established CIA. The relatively low dose of IL-1Ra used in hum an studies could explain the 
marginal suppression of disease activity in RA. However, still amelioration of radiological 
progression was noted with these low doses IL-1Ra.
The tissue protective effect of IL-1 neutralization was further corroborated in chapter 3. Here 
we showed that IL-1 blockade reduced both cartilage and bone destruction. Generalized 
cartilage destruction was monitored by measurement of cartilage oligomeric matrix protein 
(COMP). Strong correlation was noted between serum COMP levels and disease activity. This 
was in line with findings in adjuvant (AA) and pristane induced arthritis (PIA) in rats. Although 
COMP can be produced by inflamed synovial tissue, elevated levels were only found after 
cartilage destruction occurred. Anti-IL-1 treatment of established CIA markedly reduced serum 
COMP levels, whereas TN Fa blockade did not suppress COMP levels although disease activity 
was ameliorated. Moreover, acute phase proteins, such as IL-6 were decreased in both anti- 
IL-1 and sTNFbp (PEG-sTNF-RI(p55)) treated groups. The reduced COMP levels correlated 
with cartilage destruction determ ined by histology. In addition, VDIPEN neoepitope 
expression was almost absent in the anti-IL-1 treated animals, whereas in the sTNFbp treated 
animals strong expression of the neoepitope was visible. VDIPEN neoepitope is a marker of 
matrix metalloproteinase (MMP)-mediated cleavage of aggrecan, the major proteoglycan of 
articular cartilage and it has been demonstrated that VDIPEN expression correlates with severe 
cartilage destruction. Furthermore, we investigated whether blockade of TN Fa or IL-1 during 
CIA resulted in a protective outcome on bone destruction which is a major target in the 
treatment of RA. Both X-ray analysis and histology revealed that elimination of IL-1 and not 
TNFa, showed strong suppression of bone destruction.
The different role of TN Fa and IL-1 in arthritis was further analyzed in chapter 4. Using acute 
murine streptococcal cell wall (SCW) arthritis we examined the profiles of TN Fa and IL-1 
release in arthritis. Maximal TN Fa levels were reached after 90 minutes after induction of SCW 
arthritis, whereas IL-1 peak levels were reached at 6 hours. This may indicate a cascade in which 
TN Fa induces IL-1 production as claimed in hum an RA, but anti-TNFa treatment did not 
decrease IL-1 levels at 6h time-point. We further demonstrated that TN Fa was the pivotal 
cytokine regarding joint swelling. Both anti-TNFa antibodies as well as sTNFbp exposure 
completely suppressed j oint swelling at day 2 of SCW arthritis. In contrast, IL-1 blockade during
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onset of SCW arthritis did not reduce joint swelling. Inhibition of cartilage chondrocyte 
proteoglycan (PG) synthesis due to the inflammatory process in the joint was unaffected by 
blockade of TNFa, whereas IL-1 neutralization completely restored the chondrocyte synthetic 
capacity. This indicated the pivotal role of IL-1 with respect to inhibition of matrix components. 
Moreover, histology taken at day 7 after induction of SCW arthritis showed that anti-IL-1 
treatment reduced cartilage PG depletion and cell influx. Combination of anti-TNFa and anti- 
IL-1 suppresses both inflammation and cartilage damage, but the impact on the both 
parameters did not exceed the effects of either anti-TNF or anti-IL-1 treatment.
The distinct roles of TN Fa and IL-1 in both acute and relapsing chronic SCW arthritis was 
further demonstrated in chapter 5. Here we used TN Fa and IL-10 deficient mice to analyze 
the different roles of TN Fa and IL-1 on two models of SCW arthritis. Induction of acute SCW 
in TNF-/- or IL-10-/- mice corroborated the findings in chapter 4. In addition, we found that 
joint swelling and cell influx could be restored in TNF deficient animals by the expression of 
membrane bound TNFa. No differences were seen compared to wild type animals in these 
membrane TN Fa knockin (mTNFki) mice indicating the predominant role of membrane 
expressed TN Fa over soluble TN Fa in arthritis.
In chronic relapsing SCW arthritis we determined that TN Fa deficiency results in reduced 
joint swelling at later stages but no protective role of TN Fa on joint pathology was noted. In 
strong contrast, IL-10 deficiency revealed that joint swelling was only mild suppressed after 
reactivation of arthritis but influx of inflammatory cells and joint pathology was markedly 
reduced in these knockout mice. To conclude the findings in chapters 3 to 5, we found clear 
distinct roles of TNF and IL-1 in arthritis. Membrane bound TN Fa accounts for joint swelling 
in experimentally induced arthritis, whereas IL-1 is the key mediator in cell influx, cartilage 
and bone destruction.
Regulatory cytokines, such as IL-4, IL-10 or TGF0 downmodulate IL-1 and TN Fa levels directly 
or via induction of suppressive T cells. In chapter 6 we demonstrated that the onset of collagen 
type II arthritis is under stringent control of IL-4 and IL-10. Administration of anti-IL-4 and 
anti-IL-10 accelerated both onset and disease activity when applied just before expected disease 
expression. In addition, systemical treatment of established CIA with IL-10 reduced arthritis 
severity, while low dose IL-4 alone was ineffective. However, combined IL-4/IL-10 treatment 
ameliorated disease activity and protected against cartilage destruction. Moreover, levels of 
mRNA for TN Fa and IL-1 were highly decreased in both synovial tissue and in the articular 
cartilage. Opposite effects were noted for mRNA levels for IL-1Ra after IL-4/IL-10 treatment, 
suggesting that the mechanism of protection may be related to suppressed IL-1 and TNFa, 
with concomitant upregulation of the IL-1/IL-1Ra balance.
In order to enhance the anti-inflam m atory effect of IL-10, com bination studies with 
corticosteroids and IL-10 were performed. Synergistic suppression of CIA was noted with low 
dose prednisolone and IL-10 as described in chapter 7. In line with suppression of disease 
activity, cartilage destruction was reduced. Serum COMP levels, as marker for severe cartilage 
destruction was markedly decreased to levels found in non-arthritic animals after exposure 
with IL-10 and low dose prednisolone confirming decreased cartilage involvement. Of high 
interest, treatment of CIA with prednisolone/IL-10 reduced IL-10 and enhanced IL-10 
production by synovium tissue. In addition mRNA levels were decreased for IL-10 and 
enhanced for IL-10 and IL-1Ra by combined treatment.
In chapter 8 we investigated the potential tissue protective effect of systemic IL-4 in CIA.
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Treatment of CIA with high doses IL-4, up to 1 |j,g/day, resulted in suppression of disease 
activity. Although IL-4 (1 |j,g/day) had a moderate effect on severity, it strongly reduced cartilage 
pathology, as determined by histology and serum COMP levels. In addition, radiological 
analysis revealed that bone destruction was prevented by systemic IL-4 treatment. Furthermore, 
elevated serum IL-1Ra levels were found after IL-4 exposure. Synergistic effects were found 
with low dose prednisolone and low dose IL-4. This study demonstrates that systemic IL-4 
treatment ameliorates CIA and protects against cartilage and bone destruction. Improved anti­
inflammatory effects were seen with combined IL-4/ prednisolone treatment. This indicates 
that systemic IL-4/prednisolone treatment may provide a cartilage and bone protective 
therapy for hum an rheumatoid arthritis.
Generation of suppressive mediators such as IL-4, IL-10 or TGF0 by tolerance induction with 
disease inducing antigens might be a downregulatory mechanism for experimental arthritis. 
In chapter 9 we demonstrated for the first time that intranasal tolerance induction with human 
cartilage gp-39 (HC gp-39) ameliorates clinical, histological and radiological signs of collagen- 
induced arthritis. Administration of HC gp-39 in a semi-therapeutical way suppressed disease 
activity and joint pathology by induction of cross tolerance or bystander suppression. This 
mechanism is based on the generation of regulatory T cells, which suppressed the disease 
inducing immune response. We found that the humoral response to collagen was decreased 
in animals that were treated with HC gp-39. To summarize the data in chapters 6 to 9, arthritis 
can be downregulated by direct treatment with modulatory cytokines such as IL-4 and IL-10 
alone or in combination with corticosteroids, or via induction of bystander suppression.
Interleukin-12 (IL-12) is a pro-inflam m atory cytokine produced by phagocytic cells, 
macrophages, natural killer cells and dendritic cells in response to bacteria, viruses and 
intracellular parasites. During bacterial infections, IL-12 is considered to be a principal 
protective cytokine, where it bridges innate resistance and antigen specific immunity. 
Furthermore IL-12 promotes generation of Th1 immune responses.
In chapter 10 we studied the impact of IL-12 at the stage of disease onset and during the 
established stage of murine CIA. Accelerated onset and enhanced disease severity were found 
when i.p. injections of 100 ng of murine IL-12 were given around the day of onset. Disease 
expression was prevented by blocking endogenous IL-12 with anti-murine IL-12, indicating 
the pivotal role of IL-12 in onset of CIA. In addition, we studied the effect of anti-IL-12 
treatment on established CIA. Anti-IL-12 administration did not suppress established CIA. 
Instead, impressive exacerbation of the disease was noted shortly after cessation of the anti- 
IL-12 treatment. This observation leads to treatment of established CIA with IL-12. Treatment 
for 7 days with 100 ng recombinant mIL-12 suppressed disease activity of CIA. Further analysis 
revealed a tenfold increased serum IL-10 level in animals treated with IL-12. Finally, the anti­
inflam m atory effect o f systemic IL-12 treatm ent could be abolished by anti-IL-10 
administration. Here we demonstrated that IL-12 has a stimulatory role in early arthritis, 
whereas it has a suppressive role in the established phase of CIA.
In chapter 11 the role of endogenous IL-12 was investigated in a bacterial cell wall induced 
(SCW) arthritis model. Suppression of joint swelling with anti-IL-12 was noted at days 2 and 
4, whereas no suppressive effect was found at day 1. Severe inhibition of chondrocyte 
proteoglycan (PG) synthesis was seen at day 1 in both arthritic control and anti-IL-12 treated 
mice. However, chondrocyte function was restored at day 4 of arthritis in the anti-IL-12 injected 
animals, but not in the arthritic controls. Moreover, cell influx in synovial tissue and j oint cavity
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was reduced by anti-IL-12 treatment. Neutralization of IL-12 reduced the local levels of IL-
10, IL-12 and IFN-y, when examined shortly after induction of SCW arthritis, whereas TN Fa 
levels were not affected. In contrast, IL-10 and IL-1Ra protein and mRNA levels were strongly 
upregulated in synovial tissues after IL-12 blockade. Enhancement of IL-10 and IL-1Ra by anti- 
IL-12 was confirmed in a tissue chamber model with SCW induced inflammation. This study 
indicates that IL-12 is a pro-inflammatory cytokine during onset of SCW arthritis. Balances 
of pro- and anti-inflammatory cytokines were strongly improved by anti-IL-12 treatment. To 
conclude the findings in chapters 10 and 11, IL-12 exert an dual role in early and late stages 
of experimental arthritis. Before onset of arthritis a clear pro-inflammatory role was found, 
whereas in ongoing arthritis an anti-inflammatory role was noted.
In this thesis we demonstrated that arthritis can be downmodulated by targeting different 
cytokines. Firstly, elimination of TNFa, but in particular IL-1 suppresses disease activity and 
joint pathology. Secondly, reduction of the master cytokines TN Fa and IL-1 can be achieved 
by treatment with the regulatory cytokines IL-4 and IL-10 resulting in suppression of arthritis 
and concomitant tissue destruction. Finally, both reduction of onset of arthritis and severity 
can be obtained by indirect inhibition of pro-inflammatory cytokines, such as TN Fa and IL-
1, through elimination of the inflammation-promoting cytokine IL-12.
FINAL REMARKS
Targeting of cytokines is one of the most promising new therapies for treatment of rheumatoid 
arthritis (RA). As mentioned previously, neutralization of TN Fa and IL-1 is under current 
investigation in RA and the results of anti-TNFa are looking promising, regarding disease 
activity (1,2). W hether TN Fa blockade leads to a tissue protective therapy in RA remains still 
unknown. However, the first data on tissue destruction, determined as serum cartilage 
oligomeric matrix protein (COMP) indicated that TNF a  elimination did not alter the cartilage 
destruction. Radiological analysis has to reveal whether bone destruction was affected by anti- 
TN Fa treatment. It was claimed that TN Fa is the driving force for synovial IL-1 production 
but in this thesis we clearly showed that this is not the case in murine arthritis models. In 
addition, there was no cascade T N F a^IL -1  found in humans. Strong evidence was obtained 
from studies in TN Fa knockout mice as well as in anti-TNFa studies in RA patients, where 
still high IL-10 expression was found in the synovial tissues (3,4).
Blockade of IL-1 by IL-1Ra administration ameliorated the progressive joint destruction, 
although the inflammatory process was not significantly reduced (5,6). High doses of IL-1Ra 
have to be tested to see whether the inflammatory component of RA could be suppressed. One 
disadvantage of IL-1Ra is the short half-life in vivo and therefore slow-release forms of IL-1Ra 
were developed to circumvent these problems. Another possibility to achieve high levels of 
IL-1Ra is local overexpression of IL-1Ra by the use of gene transfer (7,8). This is a new intriguing 
endeavour for treating RA and the first attempts in humans have taken place. It is to early to 
conclude whether IL-1 blockade by IL-1Ra gene transfer protects against j oint destruction in 
hum an RA, but studies in animals revealed that this is the case (9). Other IL-1 inhibitors, such 
as soluble IL-1 receptor type II (sIL-1RII) and human anti-IL-10 antibodies have to be screened 
in the near future. As suggested previously, optimal suppression of disease severity and joint
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destruction will be achieved with combination therapy of TNFa/IL-1 inhibitors. 
Downregulation of TNF/IL-1 activity can indirectly be induced by adm inistration of 
m odulatory cytokines, such as IL-4 and/or IL-10 alone or in com bination with 
glucocorticosteroids. Until today there are no clinical trials performed in RA patients with IL-
4. The first IL-10 trials in RA did not show impressive anti-inflammatory effects, although in 
other diseases like Crohn s disease it was disease modifying. Combination therapy of IL-4/IL- 
10 did suppress experimental arthritis models, such as CIA and SCW arthritis (10,11). In the 
near future clinical trials in RA will be started with systemic IL-4/IL-10 administration to 
elucidate the potential anti-inflammatory and tissue protective effects of IL-4 and IL-10. 
W hether these latter cytokines will reach levels in the joint that will affect the inflammatory 
process remains unknown. Local gene transfer into murine knee joints with adenoviral 
constructs containing IL-4 or IL-10 demonstrated that high levels of these cytokines could be 
reached for several days. Furthermore, it was shown that local IL-10 overexpression suppressed 
CIA in the injected knee joint. Of high interest, the ipsilateral paw was protected from onset 
of CIA (12). In line with systemic high dose IL-4 treatment of CIA, local overexpression of IL- 
4 by adenoviral vectors showed impressive protection against cartilage and bone destruction 
in CIA, although the inflammation was not suppressed (13,14). At the moment we are trying 
to unravel the mechanisms behind the tissue protective effect of IL-4. We demonstrated already 
that IL-4 suppresses synovial mRNA levels for IL-12 and IL-17. In addition, we found a 
complete absence of osteoclasts in the inflamed synovium and therefore we now investigate 
the role of IL-4 in osteoclast differentiation and osteoclastogenesis. Osteoprotegerin ligand 
(OPGL) is a member of the TNF family and is an essential factor of osteoclast formation (15). 
The role of IL-4 in the regulation of OPGL expression is under current investigation. 
Adenoviral vectors deliver gene constructs temporally and the first attempts to transfect a 
severely inflamed joint were not successful in producing high levels of cytokines. Other viral 
vectors, containing RGD fragments are being developed at the mom ent to transfect inflamed 
synovium. The transfection is mediated by intergrins, which are highly expressed in the 
inflamed synovium. The first attemps showed that there was increased transfection of 
synovium by these vectors (17).
The high scientific interest of im m unomodulation studies in animal models will soon provide 
further insight in the therapeutic applicability of tolerance induction, be it in an antigen specific 
way or using the principle of bystander suppression. Apart from HC gp-39, other cartilage 
antigens will be used for suppression of inflammation by Th2 of Th3 cells which locally produce 
suppressive cytokines, such as IL-4, IL-10 or TGF0 (16). To enhance tolerance induction, 
cartilage antigens were combined w ith the latter cytokines (18). Even oral or nasal 
administration of IL-4, IL-10 or TGF0 alone seems to be effective in downmodulation of 
arthritis. It might be expected that im m unodom inant epitopes of possible autoantigens 
together with IL-4 or TGF0 will be screened for their anti-inflammatory capacity.
Whether IL-12, IL-17 or IL-18 will be a target for interventions in human RA has to be unraveled 
in the future. IL-12 is an intruiging cytokine that exerts a dual role in inflammation, pro- 
inflam m atory before onset and anti-inflam m atory in established disease. However, 
administration of high levels of IL-12 to cancer patients leads to serious side effects and it may 
also unmask latent immune responses (19). The first new drugs that are interfering with IL- 
12 signaling and IL-12-mediated Th1 differentation have been developed (20). Since IL-17 
displays IL-1 like activities it may also contribute to joint destruction (21). The first in vitro 
blocking studies with anti-human IL-17 showed reduction of several pro-inflammatory
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cytokines and M M P’s of RA synovial tissue. Thus, it is likely that IL-17 inhibitors will soon be 
available for screening in RA models. IL-18 is a novel cytokine that plays an im portant role in 
the Th1 response, primarily by its ability to induce IFN-y production. IL-18 is related to the 
IL-1 family in terms of structure and function (22). Since IL-18 is a promoter of Th1 responses, 
as well as a direct pro-inflammatory cytokine, targeting IL-18 in RA is a sensible strategy. IL- 
18 binding protein (IL-18BP) is under present investigation in several models of autoimmune 
diseases. However, reduced Th1 response by decreased level of IFN-y can lead to enhanced 
infections, such as Mycobacteria or Salmonella.
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SAMENVATTING
Reumatoïde artritis (RA) is een systeem ziekte waarvan het ontstaan nog steeds onbekend is 
en die gekenmerkt wordt door chronische ontstekingen van verschillende gewrichten. 
Opvallend is de symmetrische expressie van de ziekte aan handen, polsen en voeten. RA komt 
voor bij ongeveer 1-2% van de volwassen bevolking en voornamelijk bij vrouwen. Het 
ziekteverloop van RA wordt gekarakteriseerd door actieve en rustige perioden. Progressieve 
destructie door de chronische ontsteking van gewrichtsstructuren, zoals kraakbeen en bot 
vormt een van de kenmerken van RA. Nadere analyse van de ontstoken gewrichten wijst uit 
dat er verschillende celtypen te vinden zijn, zoals macrofagen, plasmacellen en lymfocyten. 
Naast immuuncomplexen en fibrose is er een sterke verdikking van het synoviale membraan 
te zien. De ziekte wordt gezien als een auto-immuunziekte waarbij er een afweerreactie tegen 
lichaamseigen stoffen optreedt. Echter deze stoffen (auto-antigenen) zijn nog steeds niet 
ontdekt. Wel wordt er gedacht aan kraakbeen bestanddelen als auto-antigeen omdat al langer 
bekend is dat wanneer het kraakbeen verloren is gegaan of chirurgisch verwijderd is de 
ziekteactiviteit sterk afneemt. Bovendien kan er met een aantal kraakbeencomponenten, 
experimentele artritis in muizen worden opgewekt. Dit is het geval voor type II collageen, 
proteoglycanen, HC gp-39 en cartilage oligomeric matrix proteïne (COMP). Collageen 
geïnduceerde artritis (CIA) is een geaccepteerd model voor RA dat veel overeenkomsten 
vertoont met deze ziekte. CIA kan worden opgewekt in bepaalde muizenstammen die gevoelig 
zijn voor auto-im m uun ziektes. De ziekte begint in een teen waarna de gehele poot ontstoken 
raakt. Vervolgens zijn ook de andere poten snel aangedaan en ontstaat er een polyartritis. 
Antilichamen en specifieke T lymfocyten spelen een belangrijke rol in het ontstaan van CIA. 
Naast kraakbeencomponenten wordt er gedacht aan bacteriële fragmenten als oorzaak van RA. 
Zo is er een relatie gevonden tussen bacteriële infecties en artritis. Het is bekend dat bij de 
ziekte van Crohn en bij jejunum  bypass operaties er een verhoogde kans bestaat op reactieve 
artritis. Tevens is het mogelijk om artritis op te wekken in ratten en muizen m et behulp van 
bacteriën of bacterie fragmenten. Streptokokken cel wand (SCW)fragmenten veroorzaken een 
chronische artritis wanneer er een immuunrespons wordt opgewekt in ratten. In dit model 
spelen T cellen en macrofagen een belangrijke rol. Mogelijke kruisreactiviteit tegen kraakbeen 
componenten kan een van de oorzaken van chronische artritis zijn, omdat er een grote 
overeenkomst bestaat tussen kraakbeenmatrix en bacterie-celwanden. 
Ontstekingsmediatoren, die geproduceerd worden door de geïnfiltreerde cellen en/of het 
synoviale membraan, zijn factoren die zelf een pro-inflammatoir (ontsteking stimulerend) 
effect kunnen hebben of andere cellen aanzetten tot productie van deze stoffen. Cytokines zijn 
stoffen die zowel pro- als anti-inflammatoir (ontsteking remmend) kunnen zijn en door 
verschillende celtypen gemaakt worden. Tot de pro-inflam m atoire cytokines behoren 
interleukine-1 (IL-1), IL-2, IL-6, IL-8, IL-12, IL-15, IL-17, IL-18, interferon-y (IFN-y) en tumor 
necrosis factor a  (TNFa). Anti-inflammatoire cytokines zijn IL-1 receptor antagonist (IL-1Ra), 
IL-4, IL-10, en transforming growth factor 0 (TGF0). Bot en kraakbeen destructie zijn de 
belangrijkste oorzaken van de invaliditeit die kenmerkend is voor RA. IL-1 en TN Fa zijn twee 
pro-inflammatoire cytokines die verantwoordelijk worden geacht voor het ontstaan van 
chronische gewrichts reuma en de daarbij behorende destructie.
Een van de vraagstellingen van dit proefschrift is welke van de twee cytokines, IL-1 of TNFa, 
verantwoordelijk is voor ontsteking en/of destructie. In hoofdstuk 2 blijkt dat neutraliseren
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van TN Fa tijdens het ontstaan van collageen artritis (CIA) in muizen de ziekte activiteit 
vermindert. Dit in tegenstelling tot een reeds bestaande CIA waar het blokken van TNFa 
activiteit geen invloed op de ziekte heeft. Echter wanneer ernstige CIA wordt behandeld met 
anti-IL-1 antilichamen of de natuurlijke remmer van IL-1, namelijk IL-1 receptor antagonist 
(IL-1Ra), wordt de artritis expressie sterk onderdrukt. Dit heeft tot gevolg dat de schade aan 
het gewricht beperkt blijft. Ook blijkt dat de bèta vorm van IL-1 (IL-1ß) een belangrijke rol 
speelt in zowel chroniciteit van een ontsteking als in gewrichtsdestructie. De beschermende 
werking van een anti-IL-1 behandeling op kraakbeen en bot is nader onderzocht in hoofdstuk
3. Kraakbeenschade kan bepaald worden door afbraakproducten van het kraakbeen, zoals 
COMP, in het bloed te meten. In hoofdstuk 3 tonen we aan dat COMP spiegels sterk correleren 
met kraakbeenschade tengevolge van een ernstige ontsteking. Hoewel anti-TNFa de ernst van 
de CIA onderdrukte, is er geen verlaging van de COMP spiegels in het serum gevonden. Sterke 
reductie van serum COMP wordt gevonden door de muizen te behandelen met IL-1 remmers. 
Bovendien laten wij zien dat de boterosie wordt verminderd door anti-IL-1. Anti-TNFa heeft 
geen beschermend effect op de botdestructie die bepaald is met röntgen analyse. In een ander 
ontstekingsmodel, opgewekt in muizen met bacterie-celwanden is tevens de rol van IL-1 als 
van TN Fa onderzocht. H oofdstuk 4 laat zien dat gewrichtszwelling in dit artritis model geheel 
geblokkeerd kan worden met een anti-TNFa behandeling. IL-1 eliminatie heeft in dit model 
geen effect op de ontsteking, maar herstelt de m atrix productie van kraakbeencellen 
(chondrocyten) volledig. In dit hoofdstuk wordt tevens aangetoond dat er geen cascade bestaat 
waarin TN Fa productie essentieel is voor de IL-1 productie. Combinatie therapie met zowel 
anti-TNFa als anti-IL-1 laat zien dat celinfiltratie en kraakbeenschade verminderd wordt. 
Hieruit blijkt dat blokkade van beide cytokines resulteert in zowel een anti-inflammatoire als 
een kraakbeen en bot beschermende therapie. De verschillende functies van TN Fa en IL-lß 
worden verder onderbouwd door gebruik te maken van muizen die geen TN Fa of IL-1ß 
kunnen produceren. H oofdstuk 5 onderschrijft de eerdere bevindingen uit hoofdstuk 4 door 
gebruik te maken van deze TN Fa en IL-1ß knockout muizen. Membraan gebonden TNFa 
(mTNFa) blijkt in staat de functies van oplosbaar TN Fa in een ontsteking te kunnen 
overnemen. Dit is onderzocht in TN Fa deficiënte muizen waarin de membraan gebonden 
TN Fa vorm tot expressie is gebracht. Deze m TN Fa knockin muizen vertonen geen verschillen 
met de controle muizen wanneer er een streptokokken artritis wordt opgewekt. In een 
chronisch artritis model, geïnduceerd met bacteriële celwand fragmenten in IL-1ß knockout 
muizen blijkt dat IL-1ß belangrijk is voor zowel celinfiltratie als destructie van kraakbeen.
De productie van TN Fa en IL-1 kan door andere cytokines, zoals IL-4, IL-10 en TGFß negatief 
gereguleerd worden. Deze cytokines remmen de productie rechtstreeks of via inductie van 
regulatoire T cellen. In hoofdstuk 6 hebben we aangetoond dat IL-4 en IL-10 een remmende 
werking uitoefenen op het ontstaan van CIA. W anneer anti-IL-4 en anti-IL-10 antistoffen 
worden ingespoten vlak voor de verwachte opkomst van CIA zien we sterke toename van het 
aantal dieren met artritis. In de lijn der verwachtingen, systemische IL-4/IL-10 injecties verlagen 
de ziekte activiteit van reeds bestaande CIA. Bovendien wordt de mate van kraakbeen erosie 
verminderd door de behandeling met IL-4/IL-10. Analyse van synoviaalweefsel toont aan dat 
mRNA spiegels voor TN Fa en IL-1 drastisch verlaagd worden. Doordat de mRNA spiegel van 
IL-1Ra (de natuurlijke remmer voor IL-1) is opgereguleerd, verandert de balans IL-1/IL-1Ra 
ten gunste van het IL-1Ra.
IL-10 zelf heeft een mindere anti-inflammatoire werking dan de combinatie IL-4/IL-10. In
hoofdstuk 7 hebben we de remmende werking van IL-10 verhoogd door het te combineren 
met lage doseringen corticosteroïden, die zelf geen anti-inflammatoire werking hebben. 
Synergistische effecten van IL-10 en prednisolon zijn er gevonden op het gebied van artritis 
expressie, serum COMP gehalte en kraakbeenschade. De lokale productie van IL-1ß is 
verlaagd en die van IL-10 verhoogd na behandeling met IL-10/prednisolon. Ook zijn de 
synoviale mRNA spiegels voor IL-10 en IL-1Ra verhoogd. Dit is een aanwijzing dat de balans 
tussen pro- en anti-inflammatoire cytokines gunstig beïnvloed wordt door IL-10/prednisolon 
behandeling. Het effect van systemische behandeling van CIA met hoge doseringen IL-4 is in 
hoofdstuk 8 bestudeerd. Dagelijkse injecties met IL-4 resulteren in een matige onderdrukking 
van de artritis. Echter bij nadere analyse van de gewrichten blijkt dat zowel de schade aan het 
kraakbeen als aan het bot sterk verminderd is. Dit wordt bevestigd door verlaagde COMP 
spiegels in het serum en door afname van boterosies op röntgen foto’s. Door IL-4 te 
combineren met lage dosering prednisolon wordt de anti-inflammatoire werking van IL-4 sterk 
verbeterd. Deze waarnemingen geven aan dat systemische IL-4/prednisolon behandeling van 
RA kan leiden tot een therapie waarbij het kraakbeen en bot beschermd worden. Anders dan 
systemische injectie van IL-4 en/of IL-10 kunnen deze cytokines geproduceerd worden door 
suppressieve T lymfocyten. Deze specifieke T cellen worden aangemaakt wanneer men 
tolerantie opwekt tegen een bepaald antigeen of eiwit. Tolerantie houdt in dat er geen 
immuunrespons optreedt wanneer men met een eiwit immuniseert als dat van tevoren in een 
oplosbare vorm is toegediend. Tolerantie inductie kan zowel oraal als nasaal geschieden waarbij 
de cytokines direct gegenereerd worden of door de suppressieve T cellen wanneer deze in 
aanraking komen met het betreffende eiwit. In hoofdstuk 9 hebben we voor het eerst 
aangetoond dat tolerantie inductie met een menselijk kraakbeeneiwit (HC gp-39) het ontstaan 
en de ernst van collageen artritis kan onderdrukken. Daarnaast is er een aanzienlijke 
vermindering van de gewrichtsdestructie gevonden in dieren die behandeld zijn met HC gp-
39. HC gp-39 wordt vlak voor de verwachte opkomst van de artritis nasaal toegediend. Een 
sterke afname van de hoeveelheid antilichamen gericht tegen het collageen type II in de HC 
gp-39 behandelde dieren kan een van de redenen zijn waardoor artritis onderdrukt wordt.
Interleukine-12 is een pro-inflammatoir cytokine dat geproduceerd wordt door macrofagen 
en andere celtypen wanneer deze cellen in aanraking komen met bacteriën, virussen of 
parasieten. IL-12 speelt een belangrijke rol bij de eerste afweerreactie bij infecties, waarbij het 
de initiële respons en de latere im m uun respons stuurt. IL-12 is een krachtige stimulator van 
interferon-y (IFN-y) productie. IFN-y zelf stimuleert de productie van TN Fa en IL-1 door 
andere cellen. Door IL-12 te neutraliseren hebben we in hoofdstuk 10 aangetoond dat dit 
cytokine een belangrijke rol speelt in het ontstaan van artritis. Extra IL-12 injecties voor de 
opkomst van CIA versnelt de artritis expressie wat de pro-inflammatoire rol van IL-12 opnieuw 
bevestigt. Echter, wanneer anti-IL-12 wordt toegediend aan muizen die al artritis hebben zien 
we een sterke toename van de ontsteking. De dubbele rol van IL-12 in CIA wordt nog eens 
bevestigd door IL-12 injecties in dieren met een bestaande artritis. Door IL-12 toediening wordt 
de ziekte activiteit sterk verminderd. De anti-inflammatoire werking van IL-12 kan worden 
opgeheven door anti-IL-10 antilichamen wat er op wijst dat IL-12 een sterke stimulator is van 
IL-10 productie.
In hoofdstuk 11 hebben we de rol van IL-12 onderzocht in een bacterie celwand (SCW) artritis. 
Door gebruik te maken van anti-IL-12 antilichamen hebben we het aanwezige IL-12
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geneutraliseerd voor de inductie van SCW artritis. Reductie van gewrichtszwelling is gevonden 
op dag 2 na inductie van SCW artritis, dit in tegenstelling tot dag 1. De aanmaak van 
kraakbeenmatrix door de kraakbeencellen (chondrocyten) is door de artritis sterk verminderd. 
Op dag 1 na inductie van SCW artritis is deze remming niet beïnvloed door het wegvangen 
van IL-12. Echter op dag 4 van de artritis is de chondrocyt functie sterk hersteld wat niet 
optreedt in de controle groep. Daarnaast is er een reductie gevonden van het aantal 
ontstekingscellen in het gewricht na anti-IL-12 behandeling. Analyse van de lokale cytokine 
productie kort na de inductie van SCW artritis toont aan dat spiegels van IL-1ß, IL-12 en IFN- 
Y sterk verlaagd zijn, dit in tegenstelling to t TN Fa. Dit laatste verklaart waarom  de 
gewrichtszwelling op dag 1 niet verlaagd is. Tevens zijn de spiegels voor IL-10 en IL-1Ra 
verhoogd door neutralisatie van IL-12. Deze studie demonstreert de sterke pro-inflammatoire 
rol van IL-12 in bacteriële artritis. Anti-IL-12 behandeling resulteert in een sterk verbeterde 
balans tussen pro- en anti-inflammatoire cytokines.
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